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ABSTRACT 
Plasmodium falciparum is responsible for ninety percent of malaria infections in sub-
Saharan Africa, and the majority of malaria-related deaths, with antimalarial drugs failing at 
an alarming rate. To combat this deadly disease, not only are novel target-specific 
antimalarial drugs needed, but also a high-throughput method for the screening of 
compounds to replace standard methodologies. 
A total of 112 novel compounds from three chemical classes were assessed for antimalarial 
activity against the chloroquine-sensitive 3D7 strain of P. falciparum using the [3H]-
hypoxanthine incorporation assay, and their haemolytic activity against healthy red blood 
cells determined. Lead compounds were examined for their effects on parasite morphology 
and parasitic development; as well as their pharmacological interactions when combined 
with standard antimalarial drugs. Antimalarial mechanisms of action were examined using 
the β-haematin inhibitory activity, 2,2-diphenyl-1-picrylhydrazyl (DPPH•) free-radical 
scavenging, and ferrous iron chelating activity assays. Using the DNA probe 
dihydroethidium, flow cytometry as a high-throughput drug screening method was 
validated against the [3H]-hypoxanthine incorporation assay and assessed for its ability to 
determine the stage-specific activity of the compounds. 
Of the three classes of compounds, the metronidazole-thiosemicarbazone analogues were 
the most active, 75% of the compounds inhibited parasite growth at IC50 values below 10 
µM, whilst also exhibiting no haemolytic activity. The most active of which, 4-(2-
Chlorobenzyl)-1-(4-(2-(1-(2-hydroxyethyl)-5-nitro-1H-imidazol-2-yl)vinyl)benzylidene)-thio-
semi-carbazide (compound Y-3) (IC50 value: 2.83 ± 0.20 µM) was also a potent inhibitor of 
β-haematin formation (IC50 value: 19.08 ± 2.37 µM), proving to be more active than 
chloroquine (IC50 value: 29.64 ± 3.35 µM). Similarly, metronidazole-thiosemicarbazones 
analogues were potent scavengers of the free-radical of DPPH•, with the activity of 1-(4-(2-
(1-(2-Hydroxyethyl)-5-nitro-1H-imidazol-2-yl)vinyl)benzylidene)-4-benzyl-4-methyl-thio-
semi-carbazide (compound Y-8) (IC50 value: 21.98 ± 0.56 µM), comparable to that of the 
standard, ascorbic acid (IC50 value: 19.31 ± 2.62 µM). When combined with quinine and 
dihydroartemisinin, compound Y-3 produced an additive pharmacological interaction. 
Seventy one percent of the chloroquinoline-chalcones tested had IC50 values below 100 
µM, with (E)-3-(2-chloro-7-methylquinoline-3yl)-1-(pyridine-2yl)prop-2-en-1-one 
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(compound F-13) the most active (IC50 value: 31.31 ± 0.87 µM). None of the compounds 
displayed any notable activity in the antimalarial mechanisms of action tested for, whilst 
also resulting in no red blood cell toxicity. When combined with quinine, compound F-13 
exhibited an additive interaction. 
The nucleoside phosphonates, phosphonic acids and purine/pyrimidine derivatives 
exhibited disappointing antimalarial activity, with only 21% of the compounds inhibiting 
parasite growth with IC50 values below 100 µM, with compound DR-4850 (currently under 
patent) the most potent (IC50 value: 13.35 ± 0.38 µM). None of the compounds resulted in 
any red blood cell lysis, with the exception of compound DR-4914B (currently under patent) 
(50.20 ± 3.35% haemolysis at 100 µM). Some nucleoside derivatives were potent inhibitors 
of β-haematin formation, with Hexadecyloxypropyl uridin-5’-yl 2-([3R,4R]-3,4-
dihydroxypyrrolidin-1-N-yl)ethylphosphonate (compound DR-4137) (IC50 value: 8.29 ± 1.11 
µM) 3.6-fold more active than chloroquine, although this did not appear to be the primary 
antimalarial mechanism of action of this class of compounds. Combination studies with 
quinine produced an additive interaction, whilst combination studies with the nucleoside 
transporter inhibitor dipyridamole produced additive-antagonistic interactions.  
In conclusion, this study examined a wide variety of compounds and identified lead 
compounds, which following structural modifications may produce potent antimalarial 
drugs.  
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CHAPTER 1: INTRODUCTION 
1.1 The global distribution and impact of malaria 
Malaria continues to be one of the greatest infectious diseases ever known, placing 
approximately half of the worlds’ population, in over 100 countries, at risk of infection 
(Figure 1.1) (www.rollbackmalaria.org, 2011; WHO, 2011).  
 
Figure 1.1: The global distribution and disease control status of malaria 
(www.rollbackmalaria.org, 2009). 
 
The World Health Organisation (WHO) estimated the number of malaria cases to be 216 
million in 2010 (WHO, 2011). Africa bears the greatest burden of malaria infections with 
transmission reported in all sub-Saharan African countries (except Lesotho) (National 
Department of Health, 2010). Preventative programmes have proven to be highly 
successful in reducing transmission in South Africa. Once endemic to eastern and low lying 
northern districts of the country, malaria is now limited to areas of Limpopo, Mpumalanga 
and northern Kwazulu Natal, with occasional cases reported along the Molopo and Orange 
rivers in the North West and Northern Cape provinces (National Department of Health, 
2009).  In spite of control methods being instituted, a general upward trend in mortality 
and morbidity on the African continent has been observed since the 1970’s. This is possibly 
due to the increased resistance of the mosquito vector to insecticides, as well as the 
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widespread and improper use of antimalarials (Sanchez et al., 2010; WHO, 2010b). Coupled 
with the enormous humanitarian burden of the disease, is the economic cost of malaria 
which has resulted in a loss of approximately 12 billion dollars, or 1.3% of the gross 
domestic product of the African continent per year (www.rollbackmalaria.org, 2008). 
1.2 Malaria life cycle and transmission 
1.2.1 The mosquito vector and liver stages 
Malaria is an infectious disease caused by four species of the Plasmodium parasite, namely: 
Plasmodium falciparum, P. malariae, P. ovale and P. vivax (National Department of Health, 
2009). Of the four species, P. falciparum accounts for over 90% of infections in sub-Saharan 
Africa and the majority of deaths (White, 2004; Kaur et al., 2009). Malaria is transmitted to 
the human host via the bite of an infected female of the Anopheles mosquito. The 
Anopheline family contains all species known to transmit malaria, with at least three 
species responsible for malaria transmission in Southern Africa (National Department of 
Health, 2009).  The parasite has a complex life cycle which takes place in the mosquito 
vector and both the liver and red blood cells of the human host (Figure 1.2) (Bozdech et al., 
2003; WHO, 2010a). 
1.2.1.1 The mosquito vector 
The sexual phase of the parasite’s life cycle is initiated when the female Anopheles 
mosquito ingests a blood meal from an infected person, during which the mosquito ingests 
both female and male gametocytes (macrogametocytes and microgametocytes, 
respectively) (Figure 1.2A) (Khan et al., 2005; National Department of Health, 2009). In the 
midgut of the mosquito the microgametocyte emerges from the red blood cell and 
produces flagella, allowing each microgametocyte to seek out and fertilise a 
macrogametocyte, forming a zygote or ookinete (Figure 1.2B) (Khan et al., 2005). Once 
attached to the midgut, the oocyst produces thousands of daughter cells, known as 
sporozoites, which when released migrate to the salivary glands of the mosquito (Figure 
1.2C) (Greenwood et al., 2008; National Department of Health, 2009; WHO, 2010a). The 
sexual phase within the mosquito takes between 1-3 weeks and is dependent on the 
species of Plasmodia carried by the mosquito, as well as the humidity and temperature of 
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the external environment (Greenwood et al., 2008; National Department of Health, 2009; 
WHO, 2010a). 
A
B
CD
E
F
G
H
I
 
Figure 1.2: The developmental stages of the malaria parasite, and potential targets for 
immune system attack (adapted from Greenwood et al., 2008).  
Abbreviation: interferon-γ. 
 
1.2.1.2 The liver stage 
The sporozoites, housed within the salivary glands of the mosquito, are released into the 
human host by the infected mosquito during its next blood meal (Figure 1.2C). Upon 
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entering the host the sporozoites migrate to the liver, where they invade hepatocytes 
(Figure 1.2D) (National Department of Health, 2009; WHO, 2010a). In the hepatocyte, the 
parasite multiplies over 6-21 days, whereupon the ruptured hepatocytes release thousands 
of merozoites into the blood stream, ending the asymptomatic stage of the disease known 
as exo-erythrocytic schizogony (National Department of Health, 2009; WHO, 2010a). 
1.2.1.3 The asexual erythrocytic stage of P. falciparum 
Antimalarial drugs target all stages of parasitic development; however the majority of the 
antimalarials in existence target the intra-erythrocytic stages, thereby reducing the clinical 
symptoms of the disease (Olliaro, 2001). 
The asexual stage begins with merozoite invasion of the red blood cell (Figure 1.2E). 
Merozoites, although small in size, contain all the organelles needed to exit the ruptured 
host red blood cell, attach to and invade a healthy red blood cell, and resume the asexual 
life cycle (Bannister et al., 2000; Hanssen et al., 2010). Invasion occurs rapidly (within 
approximately 60 seconds), to decrease the risk of attack by the host’s immune system 
(Cowman et al., 2006). Following invasion, dense granules released from merozoite 
organelles, re-locate to the membrane of the parasitophorous vacuole and release their 
contents, thereby increasing the surface area of the membrane and possibly initiating the 
progression of the life cycle into the ring-stage (Figure 1.2F) (Bannister et al., 2000; Hanssen 
et al., 2010). 
Thereafter, the parasite appears in the red blood cell as a ring-shaped form with a nucleus, 
apicoplast, mitochondrion, endoplasmic reticulum, golgi apparatus and ribosomes 
contained in its cytoplasm (Bannister et al., 2000; van Dooren et al., 2005; Hanssen et al., 
2010). The ring-stage lasts for approximately 20 hours post invasion, with little change in 
parasite morphology and low metabolic activity observed during this time (Spielmann et al., 
2006). However, survival of the parasite and progression into the later stages is dependent 
on modifications carried out in this stage. In a screening of ring-stage specific genes it was 
found that most genes code for exported proteins involved in host cell modification. One 
such protein, the ring-infected erythrocyte surface antigen, is inserted into the red blood 
cell membrane, allowing it to maintain its biconcave shape and circulate through peripheral 
blood vessels (Mills et al., 2007). Other proteins encoded include: membrane proteins, 
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which localise to the parasitophorous vacuole membrane and may play a role in parasite 
and host cell interactions; as well as proteins transported to the red blood cell membrane 
which affect host cell permeability (Spielmann et al., 2003, 2006).  Facilitating the sorting, 
storage and transport of the various parasite proteins to the red blood cell membrane are 
structures known as Maurer’s clefts (Cooke et al., 2004; Spycher et al., 2006; Tilley et al., 
2011). Transition from the ring- to trophozoite-stage is marked by the appearance of new 
permeation pathways, proteins responsible for the cytoadherence of infected red blood 
cells to microvasculature, as well as haemoglobin ingestion and breakdown (Spycher et al., 
2006; Coppens et al., 2010; Hanssen et al., 2010). 
In contrast to the low metabolic activity of the ring-stage, parasitic metabolic processes 
peak in the trophozoite-stage (Figure 1.2G), one of which is host cell haemoglobin 
degradation (Figure 1.3) (Bozdech et al., 2003; Hanssen et al., 2010). 
 
Figure 1.3: Haemoglobin digestion within the food vacuole of the malaria parasite (Skinner-
Adams et al., 2009). Where: Hb = haemoglobin; PfM1AAP and PfM17LAP = 
Plasmodium falciparum M1-family alanyl aminopeptidase and M17-family 
leucyl aminopeptidase, respectively.  
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During the blood phase the parasite digests up to 80% of all haemoglobin present in the red 
blood cell (Egan, 2008).  The process of haemoglobin digestion occurs when portions of 
haemoglobin-containing erythrocyte cytosol enter the parasite via cytostomes (Hanssen et 
al., 2010; Tilley et al., 2011), which are double-membraned invaginations of the parasite 
plasma and parasitophorous vacuolar membranes (Lazarus et al., 2008; Hanssen et al., 
2010). Following internalisation of the haemoglobin, haemoglobin-containing vesicles bud 
off from the cytostome and fuse to the food vacuole (Figure 1.3i) (Sullivan, 2002; Lazarus et 
al., 2008; Tilley et al., 2011).  The food vacuole is a highly acidic compartment with a pH of 
approximately 5, and contains various parasitic proteases responsible for haemoglobin 
degradation (Figure 1.3ii-iv) (Banerjee et al., 2002; Egan, 2008; Skinner-Adams et al., 2009). 
The products of the digestion process include haem or Fe(II)-protoporphyrin-IX and 
peptides (Chemaly et al., 2007; Egan, 2008). The host derived peptides are broken down 
further into small dipeptides (Figure 1.3iv) and then transported into the parasite cytosol, 
possibly by an ATP-dependant membrane transporter (Figure 1.3v). Whereupon they are 
further digested into amino acids (Figure 1.3vi), and used for parasite protein synthesis 
(Skinner-Adams et al., 2009).  
The haem released by haemoglobin catabolism is highly toxic to the parasite and may move 
from the food vacuole into the parasite cytoplasm where it undergoes redox reactions to 
form reactive oxygen species (ROS). The iron present in haem is also capable of reacting 
with oxygen to form ROS via the Fenton reaction (Figure 1.4). Intracellular ROS attack 
parasitic macromolecules such as DNA and proteins, and cause lipid peroxidation (Müller, 
2004; Zhan et al., 2006). The toxic haem must, therefore, be detoxified by the parasite via 
biomineralisation to form the inert polymer, haemozoin, or degraded by glutathione (GSH) 
(Figure 1.4) (Müller, 2004; Garavito et al., 2007). In addition, the parasite is also under 
constant oxidative stress from ROS produced by the hosts’ immune system (Müller, 2004). 
In this manner, intracellular ROS levels are controlled via enzymatic and non-enzymatic 
parasitic defence systems (Müller, 2004; Rasoloson et al., 2004). The first line of enzymatic 
defence is a family of copper/zinc, iron and manganese metalloproteins, known as the 
superoxide dismutases (SODs) (Müller, 2004; Rasoloson et al., 2004). SODs catalyse the 
reaction which forms hydrogen peroxide and oxygen from superoxide anions (Figure 1.4). 
The reduction of hydrogen peroxide to water and oxygen is catalysed by the second 
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enzymatic defence system, the peroxidases. The latter include haem-peroxidase catalase, 
GSH-dependant peroxidises and thioredoxin-dependant peroxidises (Müller, 2004).  
Degraded by glutathione
 
Figure 1.4: Sources of reactive oxygen species and anti-oxidant systems in P. falciparum 
(adapted from Müller, 2004).  Abbreviations: FP IX, ferriprotoporphyrin-IX 
(haem); HbO-Fe2+, oxy-haemoglobin containing haem; MetHb-Fe3+, 
methaemoglobin containing haem; SOD, superoxide dismutase. 
 
In order to cope with the increased protein synthesis and metabolic processes of the 
trophozoite- and schizont-stages, various internal changes occur in the parasite. Notably an 
increase in the number of ribosomes, enlargement of the endoplasmic reticulum and Golgi 
apparatus and lengthening of the mitochondrion and apicoplast (Bannister et al., 2000; 
Hanssen et al., 2010). The apicoplast, an important target in drug development, houses 
various metabolic processes such as an isoprenoid and a type II fatty acid synthetic 
pathway, which utilise products of glycolysis imported from the parasite cytosol (Coppens 
et al., 2010; Lim and McFadden, 2010). Enzymes involved in the haem biosynthesis 
pathway and iron-sulphur cluster biosynthesis have also been localised to the apicoplast 
(Becker et al., 2004; Lim et al., 2010).  The close association between the mitochondrion 
and apicoplast during asexual development facilitates the transfer of metabolites between 
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the two organelles (van Dooren et al., 2005; Lim et al., 2010).  The mitochondrion of P. 
falciparum contains enzymes involved in electron transport, the citric acid cycle as well as 
ubiquinone biosynthesis (Becker et al., 2004; Hyde, 2005). Another key enzyme of the 
folate pathway, dihydropteroate synthase (DHPS), has been hypothesised to be located in 
the mitochondrion, apicoplast and nucleus (Hyde, 2005; Müller et al., 2010).  
The folate pathway is crucial for parasite growth. It involves the conversion of GTP, ρ-
aminobenzoic acid (ρABA) and ι-glutamate into cofactors necessary for various metabolic 
pathways, such as DNA synthesis and amino acid catabolism (Hyde, 2005; Chango and 
Abdennebi-Najar, 2011). P. falciparum is incapable of de novo purine synthesis and requires 
specialised purine transporters located on the parasite plasma membrane, as well as a 
unique set of purine salvage enzymes to scavenge the host-derived purines (Section 5.1) (El 
Bissati et al., 2006; Downie et al., 2008).  In contrast to purine salvage, the parasite relies 
on de novo salvage of pyrimidines (Section 5.1) (Hyde, 2007; Jana and Paliwal, 2007). 
As the parasite moves from the late trophozoite- into the schizont-stage (Figure 1.2H), the 
rate of DNA synthesis becomes exponential in anticipation for nuclear division (de Rojas et 
al., 1985).  Ingestion of host-derived haemoglobin continues well into the schizont-stage, 
until virtually all of the available haemoglobin has been digested, forming a large compact 
haemozoin crystal (Bannister et al., 2000; Hanssen et al., 2010).  Similarly, the expression 
and export of parasite proteins continues into the schizont-stage. Proteins exported to the 
red blood cell membrane distort the membrane so that an increase in ‘knobs’ are visualised 
at the surface (Figure 1.5). Some proteins, such as the ring-infected erythrocyte surface 
antigen, are produced in the late schizont-stage and stored in apical organelles following 
merozoite formation (Bannister et al., 2000; Marti et al., 2005). The nucleus of P. 
falciparum completes approximately 4 divisions, with the peak in DNA synthesis between 
33-45 hours indicating that each newly synthesised DNA molecule is used as a template for 
the next (de Rojas et al., 1985; Bannister et al., 2000).  From the 4 divisions, approximately 
16-20 individual nuclei may be formed, although as many as 32 may be formed (Bannister 
et al., 2000; Hanssen et al., 2010).  Accompanying nuclear division is multiplication of the 
mitochondrion and apicoplast, as well as proliferation of the endoplasmic reticulum and 
ribosomes. As the maturation of the merozoites proceeds, the apical organelles are 
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assembled and a nucleus, mitochondrion and apicoplast move into each merozoite from 
the schizont cytoplasm (Figure 1.5) (Bannister et al., 2000; Hanssen et al., 2010).   
Merozoite buds
Apicoplast
Mitochondrion
Apical organelle
Knobs
RBC membrane
Mitotic spindle
Nucleus
Pigment crystal
 
Figure 1.5: Internal structure of a P. falciparum late schizont, depicting parasite and red 
blood cell structure (Bannister et al., 2000). 
 
The merozoites are then separated by a constriction ring and primary rupture of red blood 
cell membrane occurs, releasing parasitophorous vacuole membrane-associated 
merozoites. Following which, a secondary rupture of the parasitophorous vacuolar 
membrane, probably due to protease activity, releases the invasive merozoites (Figure 1.2I)  
which will infect new red blood cells, thereby repeating the life cycle (Figure 1.2E) (Marti et 
al., 2005; Soni et al., 2005; Hanssen et al., 2010). 
1.2.1.4 The sexual erythrocytic stage of P. falciparum 
Some asexual-staged parasites may also differentiate into gametocytes (Figure 1.2A), a 
process taking about 12 days in P. falciparum. A number of conditions are known to induce 
gametocytogenesis; certain antimalarial drugs, such as chloroquine and young red blood 
cells in circulation. Commitment to gametocytogenesis appears to occur in the late 
schizont- or early ring-stage in the generation preceeding gametocyte formation, indicating 
some form of signalling pathway must be involved in gametocytogenesis (Gardiner et al., 
   
10 
 
2005). Gametocytes do not contribute to the symptoms of the disease; however they do 
persist in the blood stream for weeks, contributing to the spread of the disease as well as 
antimalarial drug resistance (Wirth, 2002; National Department of Health, 2009; WHO, 
2010b). 
1.3 Antimalarial prophylaxis and treatment  
The WHO aims to reduce the number of malaria cases by 75% by 2015 (WHO, 2011). The 
control of malaria falls into two classes, prevention and treatment (WHO, 2011). The 
prevention of malaria has a further two divisions, personal protection methods and 
prophylaxis. Personal protection methods include reducing exposure to the mosquito 
vector, such as mosquito repellents applied to the skin, insecticide impregnated bed nets 
and the spraying of dwellings with insecticides. However, insecticides come with their own 
health risks, and the mosquito has rapidly developed resistance to insecticides, as is the 
case with pyrethroid and dichlorodiphenyltrichloroethane (DDT) resistance in parts of 
Western and Eastern Africa (Abdalla et al., 2008; WHO, 2011). Insecticide resistance was 
also observed in South Africa in the late 1990’s/early 2000’s, with the worst outbreak of 
malaria in South Africa in 50 years attributed to the resistance of the Anopheles fenestus 
vector to pyrethroid insecticides used to spray dwellings (Coetzee & Fontenille, 2004). The 
addition of prophylaxis to personal protection methods is usually recommended in high risk 
populations such as pregnant women, children, the elderly as well as immune-
compromised individuals (National Department of Health, 2009). The choice of prophylaxis 
must be tailored to the geographical region, as well as to the individual (National 
Department of Health, 2009). 
Subsequent to the failure of preventative measures, the correct and timeous treatment of 
malaria is vital. The symptoms of malaria generally present within 10-21 days following an 
infection and are often non-specific and easily confused with other diseases such as 
influenza, hepatitis and tick bite fever (National Department of Health, 2010). Diagnosis of 
malaria can therefore not only rely on a clinical assessment, a blood test should be carried 
out to confirm the diagnosis and percentage parasitaemia, as well the species of malaria,  
so that an appropriate therapeutic regimen can be implemented (National Department of 
Health, 2010). Rapid diagnostic tests are also available for P. falciparum and P. vivax 
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detection, and are based on their ability to detect parasite antigens such as histidine-rich 
protein 2 or parasitic lactate dehydrogenase (National Department of Health, 2010).  
If promptly detected and appropriately treated, fatality due to uncomplicated P. falciparum 
infection is low. However, if not, there is a rapid progression into severe malaria and at this 
stage the risk of mortality approaches 100% (WHO, 2010b). Progression from 
uncomplicated into severe malaria is characterised by a high parasitaemia (3-4% or higher), 
respiratory distress, lactic acidosis, haemoglobinuria, anaemia, convulsions and coma with 
resultant organ failure (National Department of Health, 2010; WHO, 2010b).  The cause of 
the clinical features of severe malaria appears to be partly mediated by the release of 
inflammatory cytokines by the immune system that, when uncontrolled, induce pathology 
in both the host and parasite; as well as the sequestering of parasites in vital organs such as 
the brain, resulting in the obstruction of blood flow (Clark and Cowden, 2003; Alonso, 2006; 
Sauerwein, 2009).   
The treatment of P. falciparum malaria relies on the use of two or more antimalarial 
agents, with differing modes of action, in order to combat the risk of treatment failure and 
drug resistance (WHO, 2010b). Currently, artemether-lumefantrine is the first-line and 
most widely used treatment for uncomplicated P. falciparum malaria in most countries, 
including South Africa, with a combination of quinine and either doxycycline or clindamycin 
recommended as a second line treatment (Rosenthal, 2009; National Department of 
Health, 2010; Vinetz et al., 2011). In the case of pregnant women, quinine and clindamycin 
is used as the first line treatment, with artemether-lumefantrine recommended only in the 
second and third trimesters due to insufficient safety information (Rosenthal, 2009; 
National Department of Health, 2010; Vinetz et al., 2011).  
For severe P. falciparum malaria, intravenous quinine is the treatment of choice in South 
Africa. Parenteral artesunate is recommended by the WHO as the treatment of choice for 
severe P. falciparum malaria, partially due to the fact that it does not require cardiac 
monitoring or a slow infusion like quinine, but is currently the second-line treatment in 
South Africa (National Department of Health, 2010; WHO, 2010b). Both treatments should 
be administered for a minimum of 24 hours, following which, a full course of quinine plus 
doxycycline/clindamycin or artemether-lumefantrine should be given to ensure total 
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parasite clearance (National Department of Health, 2010; WHO, 2010b). For mixed P. 
falciparum infections, treatment follows that of P. falciparum infections, with the addition 
of primaquine to clear tissue schizontocides (National Department of Health, 2010).  
Compounds used for the prophylaxis and treatment of malaria can be classified into 5 
groups based on similar mechanisms of action and include: the quinolines, antifolates, 
napthoquinones, antibacterials and artemisinin-type compounds (Olliaro, 2001). These 
compounds target various stages of the parasitic life cycle such as: the asexual blood stage 
(blood schizontocides), the liver or exo-erythrocytic stage (tissue schizontocides), the sexual 
blood stage (gametocytocides) and the developmental stages within the mosquito vector 
(sporontocides) (Vangapandu et al., 2007; Rosenthal, 2009). With blood schizontocides 
acting to combat the clinical symptoms of malaria, tissue schizontocides acting to combat 
development of infection past the liver stage, gametocytocides inhibiting transmission from 
the host to the mosquito and sporontocides acting to inhibit transmission from the 
mosquito to the host (Vangapandu et al., 2007).    
1.3.1 Quinolines 
Chloroquine, amodiaquine, quinine, mefloquine and lumefantrine (Figure 1.6) are blood 
schizontocides, and exhibit no gametocytocidal effects against mature gametocytes. 
Chloroquine may even increase infectivity in mature gametocytes (Butcher, 1997; WHO, 
2010b). Primaquine exhibits little blood schizontocidal activity and is used primarily as a 
tissue schizontocide, sporontocide and gametocytocidal agent. It is reportedly active 
against mature gametocytes, whilst also accelerating gametocyte clearance (Butcher, 1997; 
Vangapandu et al., 2007; WHO, 2010b).   
The quinolines are a large family of antimalarial drugs comprising the 4-aminoquinolines; 
chloroquine and amodiaquine, the aryl amino alcohols; quinine, mefloquine and 
lumefantrine and the 8-aminoquinoline primaquine (Figure 1.6) (Olliaro, 2001; Biagini et al., 
2003; Vangapandu et al., 2007). The 4-aminoquinolines and aryl amino alcohols are both 
weak bases; however, the 4-aminoquinolines are hydrophilic at neutral pH, whereas the 
aryl amino alcohols are lipophilic at neutral pH. They exhibit similar antimalarial 
mechanisms of action, albeit different interactions with their targets (Olliaro, 2001). The 
predominant antimalarial mechanism of action for these two groups appears to be 
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interference in the haem detoxification process, resulting in inhibition of haemozoin 
formation (Olliaro, 2001; Biagini et al., 2003; Vangapandu et al., 2007). 
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Figure 1.6: Chemical structures of the quinoline family of antimalarials (WHO, 2010b). 
 
Other mechanisms of action which have been proposed include: intercalation in to parasitic 
DNA thereby inhibiting DNA replication, inhibition of protein synthesis; as well as inhibition 
of lipase and aspartic proteases within the food vacuole. However, these effects may only 
be achieved at high drug concentrations (Olliaro, 2001). It has been shown that chloroquine 
is also capable of depleting GSH, a major anti-oxidant defence system of the parasite, 
resulting in parasite death due to oxidative stress (Müller, 2004). The 8-aminoquinoline, 
primaquine, does not appear to play a role in inhibiting the formation of haemozoin, as is 
the case with the other quinolines. In contrast, its mechanism of action appears to lie in its 
ability to act as a pro-oxidant, generating reactive oxygen species within the red blood cell 
which attack parasite macromolecules (Vangapandu et al., 2007; Basso et al., 2011).  
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1.3.1.1 Efficacy and side effects 
Chloroquine has been rendered virtually obsolete against P. falciparum due to widespread 
resistance (White, 2004; Jana and Paliwal, 2007; Vangapandu et al., 2007). Whilst 
amodiaquine usage was initially discouraged due to side effects such as hepatotoxicity and 
agranulocytosis, it has been reconsidered as a possible antimalarial since the emergence of 
chloroquine resistance. However, cross resistance in chloroquine-resistant P. falciparum 
strains may occur (Biagini et al., 2003; Kerb et al., 2009; WHO, 2010b).  
Mefloquine remains mostly effective against P. falciparum, including strains resistant to 
chloroquine and sulphadoxine-pyrimethamine, and is used as a prophylactic agent in South 
Africa. It should be taken weekly, starting one week before exposure, during exposure, and 
for four weeks afterwards (National Department of Health, 2009). However, mefloquine 
resistance has emerged in areas where it is widely used, such as South-East Asia, and in 
such areas it is no longer recommended for prophylaxis or in treatment regimens 
(Rosenthal, 2009; WHO, 2010b).  
Mefloquine usage may result in various adverse effects such as neuropsychiatric 
disturbances, and is also known to interfere with the metabolism of anti-epileptics. It is 
therefore contraindicated for use in persons suffering from central nervous system 
disorders or epilepsy (Rosenthal, 2009; Rossiter, 2010). The concomitant use of mefloquine 
and chloroquine is contraindicated, with chloroquine not only used as an antimalarial 
agent, but also to manage conditions such as rheumatoid arthritis and systemic lupus 
erythematosus (Rosenthal, 2009; Rossiter, 2010). In addition, quinine and mefloquine are 
also contraindicated.  In both cases, serious adverse effects such as cardio- and 
neurotoxicity are observed, with quinine also possibly inhibiting mefloquine metabolism 
(National Department of Health, 2009; Rossiter, 2010). 
 Quinine remains effective against P. falciparum; however, cases of quinine resistance have 
been reported in South-East Asia (Rosenthal, 2009; National Department of Health, 2010). 
A common side effect of quinine, affecting up to 70% of patients, is cinchonism (tinnitus, 
hearing impairment, headache, nausea, giddiness, blurred vision); whilst less common but 
serious side effects include hypoglycaemia and cardiac arrhythmias (National Department 
of Health, 2010; Rossiter, 2010; WHO, 2010b). Due to its pro-oxidant properties, 
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primaquine can cause haemolysis and haemolytic anaemia in patients’ deficient in glucose-
6-phosphate dehydrogenase (Kerb et al., 2009; WHO, 2010b).             
1.3.2 Antifolates 
Antifolates (Figure 1.7) act as blood and tissue schizontocides and are active against all 
asexual and early intra-hepatic stages of the parasite; but appear to have no 
gametocytocidal activity (Butcher, 1997; Vangapandu et al., 2007). Pyrimethamine, 
proguanil and chlorproguanil act as sporontocides by reducing oocyst numbers in the 
mosquito vector, either through direct damage to the oocyst or inhibition of development 
(Butcher, 1997; WHO, 2010b).  
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Figure 1.7: Chemical structures of the antifolates (O’ Neill and Posner, 2004; WHO, 2010b). 
 
The antifolates have comprised of some of the most extensively used antimalarial drugs 
(Olliaro 2001). They can be classified into two classes, depending on which enzyme of the 
folate pathway they inhibit (Olliaro, 2001).  
The type-1 antifolates; dapsone and sulphadoxine, inhibit dihydropteroate synthase 
(DHPS), thereby preventing de novo folate synthesis (Rosenthal, 2009; WHO, 2010b). 
Whereas the type-2 antifolates, pyrimethamine, proguanil and chlorproguanil are 
competitive inhibitors of dihydrofolate reductase (DHFR), a key enzyme involved in folate 
salvage, as well as nucleotide and methionine biosynthesis (Vangapandu et al., 2007; 
Rosenthal, 2009). Type 1 and 2 antifolates are used in combination therapies, 
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predominantly with each other; with one inhibitor synergisticically potentiating the activity 
of another, resulting in a sequential blockade of the folate pathway (Nzila, 2006; Rosenthal, 
2009).  
1.3.2.1 Combination therapies 
Sulphadoxine in combination with pyrimethamine (SP) was one of the most widely used 
antimalarial therapies following the emergence of chloroquine-resistance. However, 
resistance to SP has rapidly emerged, such that the combination is no longer recommended 
for use in many countries, including South Africa (Rosenthal, 2009; National Department of 
Health, 2010). In addition, side effects of SP, Stevens-Johnson syndrome, epidermal 
necrolysis and erythema multiforme, have curatailed its use as a chemoprophlactic agent, 
even in areas where resistance has not yet developed (Rosenthal, 2009). The combination 
of dapsone and chlorproguanil (Lapdap®), metabolised in the liver to its active component 
chlorcycloguanil, was formulated as an alternative to SP (Nzila, 2006; Fanello et al., 2008; 
Rosenthal, 2009). However, SP cross resistance as well as concerns about drug safety, 
particularly in glucose-6-phosphate dehydrogenase deficient patients has resulted in this 
combination no longer being used (Kremsner and Krishna, 2004; Rosenthal, 2009; WHO, 
2010b).  
Prophylaxis with a single folate antagonist is no longer recommended due to antimalarial 
drug resistance, such that proguanil and its active metabolite, cycloguanil, are no longer 
used as monotherapy or in combination with chloroquine (Rosenthal, 2009; WHO, 2010b).  
Proguanil is now used in combination with atovaquone in both prophylaxis and treatment 
regimens, and is highly effective and well tolerated. However, the regimen is very costly 
(Kremsner and Krishna, 2004; Rosenthal, 2009; WHO, 2010b). Currently the regimen is only 
registered for prophylactic use in South Africa, with a daily dose taken one day prior to 
exposure, during exposure, and for seven days after returning from a malaria area (National 
Department of Health, 2009; Rossiter, 2010). This regimen has the best safety profile of all 
antimalarial prophylactics, together with improved compliance due to the shorter dose 
regimen (National Department of Health, 2009; Rossiter, 2010). Tetracyclines, opiods, 
paracetamol, laxatives, rifampicin and antidiarrhoeal agents are contraindicated for use 
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with atovaquone-proguanil as they decrease the plasma concentration of atovaquone 
(Rossiter, 2010).  
1.3.3 Napthoquinones  
Atovaquone (Figure 1.8) is a tissue schizontocide, sporontocide and blood schizontocide 
(Rosenthal, 2009; WHO, 2010b). It is a broad spectrum antiplasmodial drug acting to inhibit 
the electron transport chain of P. falciparum, resulting in the disruption of the regeneration 
of ubiquonone which is the electron acceptor for dihydroorotate dehydrogenase, a key 
enzyme of pyrimidine biosynthesis (WHO, 2010b; Hughes et al., 2011; Vinetz et al., 2011). It 
is not used as monotherapy due to the rapid spread of resistance, and as such it is used in 
combination with proguanil (Rosenthal, 2009; WHO, 2010b). Atovaquone is generally well 
tolerated and is also used to treat pneumonia caused by Pneumocystis jirovecii, an 
opportunistic infection commonly seen in human immunodeficiency virus (HIV) positive 
persons, as well as Toxoplasma gondii, the causative agent of toxoplasmosis (Rosenthal, 
2009; Hughes et al., 2011).   
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Figure 1.8: Chemical structure of atovaquone, a napthoquinone (WHO, 2010b). 
 
1.3.4 Antibacterials 
Doxycycline and clindamycin (Figure 1.9) are slow-acting blood schizontocides, with no 
gametocytocidal activity (Dahl et al., 2006; Rosenthal, 2009). Doxycycline belongs to the 
tetracycline group of antibiotics and is commonly used with a fast acting antimalarial as its 
antimalarial activity only occurs after one asexual cycle or approximately 48 hours (Dahl et 
al., 2006; Greenwood et al., 2008; Vinetz et al., 2011). Its mechanism of action appears to 
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lie in its ability to inhibit protein translation in the apicoplast, thereby inhibiting protein 
synthesis (Rosenthal, 2009; Vinetz et al., 2011). Clindamycin acts as a translation blocker in 
bacteria and appears to target rRNA of the apicoplast in Plasmodium and, in a manner 
similar to doxycycline, results in parasite death only in the second asexual cycle of blood 
stages of the parasite (Goodman et al., 2007; Vinetz et al., 2011).  
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Figure 1.9: Chemical structures of doxycycline and clindamycin (WHO, 2010b). 
 
1.3.4.1 Indications and side effects 
Doxycycline is recommended by the centres for disease control and prevention as a 
prophylactic agent and is currently used as a chemoprophylactic agent in South Africa. It is 
the recommended prophylactic agent for HIV-positive persons on antiretrovirals, as no drug 
interactions with antiretroviral regimens have been noted (National Department of Health, 
2009; Vinetz et al., 2011). Doxycycline should be taken daily, starting one day before 
exposure, during exposure, and for four weeks afterwards (National Department of Health, 
2009). In addition, it is also used in combination with quinine for the treatment of P. 
falciparum malaria (Rosenthal, 2009; National Department of Health, 2009). However, 
doxycycline is contraindicated in pregnant or lactating women and children under the age 
of eight, as it interferes with bone growth and may cause raised intracranial pressure 
(National Department of Health, 2009; WHO, 2010b; Vinetz et al., 2011).  
Clindamycin is safe for use in pregnant women and children, and in these cases is combined 
with quinine to treat P. falciparum malaria. Side effects of clindamycin include mainly 
gastrointestinal disturbances; however, some fatal cases of pseudomembranous colitis 
have been reported (WHO, 2010b). 
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1.3.5 Artemisinin and its derivatives (endoperoxides) 
The artemisinins (Figure 1.10) act as blood schizontocides against all asexual stages and 
also exhibit gametocytocidal activity against young gametocytes, making them invaluable 
antimalarial drugs (Rosenthal, 2009; WHO, 2010b). 
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Figure 1.10: Chemical structures of artemisinin and its semi-synthetic derivatives  
   (WHO, 2010b). 
 
Artemisinin is an extract of Artemisia annua (sweet wormwood) and has been used in China 
as an anti-pyretic agent for over a thousand years, and was first available for commercial 
use in the 1980’s (Meshnick, 2002). Since the discovery of the potent antimalarial effects of 
artemisinin, various semi-synthetic derivatives have been made available for use namely; 
dihydroartemisinin, artemether and artesunate (Olliaro, 2001). The original theories of the 
antimalarial mechanism of action of artemisinin and its derivatives were that cleavage of 
the endoperoxide bridge by free intraparasitic haem, as a result of haemoglobin digestion, 
generated free-radicals which alkylated proteins and damaged membranes; and that 
artemisinin inhibited haemozoin formation via the formation of adducts with haem (Pandey 
et al., 1999; Meshnick, 2002; Biagini et al., 2003). 
However, these mechanisms of action were questioned when localisation studies showed 
that artemisinin accumulated outside of the food vacuole. In addition, artemisinin and its 
derivatives are active against the early ring-stage of the parasite, where no haemoglobin 
digestion occurs (Krishna et al., 2008). The most recent hypothesis is that artemisinin 
inhibits a calcium-dependant ATPase of P. falciparum (PfATP6), which has been localised to 
the endoplasmic reticulum (Krishna et al., 2010; Vangapandu et al., 2007).  Calcium 
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signalling is vital in all stages of the parasitic life cycle and is involved in regulation of 
invasion of the red blood cell, motility and intracellular development (Krishna et al., 2010).  
Artemisinin has now largely been replaced by its derivatives dihydroartemisinin, 
artemether and artesunate (WHO, 2010b). The WHO states that artemisinin derivatives 
should never be used as monotherapy, in order to reduce the risk of widespread 
antimalarial drug resistance (WHO, 2010b), with limited cases of resistance to artemisinin 
and its derivatives recently reported on the Thailand-Cambodia border, and in Myanmar 
and Vietnam (WHO, 2010b; WHO, 2011). The choice of ACT depends on the tolerability of 
the combination, as well as levels of resistance to the partner drug (WHO, 2010b). 
However, as is the case with all ACTs, the short half-life of the artemisinin derivative leaves 
the partner drug and its metabolites vulnerable to the development of resistance 
(Kremsner and Krishna, 2004; Kerb et al., 2009). 
1.3.5.1 Combination therapies and side effects 
Artemisinin and its derivatives appear to be generally well tolerated (Kerb et al., 2009). 
Some Type I hypersensitivity reactions have been reported, as well as some neurotoxicity in 
animal trials; however neurotoxicity was not noted in human trials (Kerb et al., 2009; WHO, 
2010b). In patients co-infected with HIV there is an increased risk that artemisinin may 
decrease the efficacy of HIV medication; whilst also increasing the risk of drug reactions 
(Kerb et al., 2009). Four combination therapies are currently in widespread use and 
recommended by the WHO (Rosenthal, 2009; WHO, 2010b). 
Artemether is commonly used in combination with lumefantrine, the short half life of 
artemisinin derivatives leave residual parasites which are then cleared by a slowly 
eliminated drug such as lumefantrine, which has a half-life of three days (Kremsner and 
Krishna, 2004; WHO, 2010b). This combination is highly effective and well tolerated 
(Kremsner and Krishna, 2004; Rosenthal, 2009).   
Artesunate is also commonly used in combination with amodiaquine or mefloquine or SP 
(WHO, 2010b). However, combination regimens of artesunate plus amodiaquine have 
shown to cause neutropenia, a side effect attributed to amodiaquine, which is worsened in 
HIV-infected persons (Kremsner and Krishna, 2004; National Department of Health, 2010; 
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WHO, 2010b).  Additionally, hepatotoxicity has been reported when artesunate plus 
amodiaquine and efavirenz were taken concomitantly (WHO, 2010b). Clinical trials of 
artesunate plus SP have shown the combination to be more effective than SP alone and 
well tolerated; however, it is not recommended in most countries due to widespread SP 
resistance (Rosenthal, 2009; Kremsner and Krishna, 2004). Artesunate plus mefloquine 
appears to be safe and highly effective, however as with most ACTs it is costly (Kremsner 
and Krishna, 2004). 
1.4 Antimalarial drug resistance 
Owing to stringent malaria control campaigns the disease was virtually eradicated by the 
early 1960’s, however malaria has staged an enormous comeback, and is now emerging as 
one of the biggest killers in the tropics (Vangapandu et al., 2007). Antimalarial drug 
resistance is particularly worrying due to the massive distribution of malaria worldwide, the 
degree of mortality attributed to the disease, as well as the time and associated costs of 
developing replacements drugs (WHO, 2010b). Resistance has been reported to all widely 
used antimalarials, such as: chloroquine, amodiaquine, mefloquine, quinine, SP, and more 
recently, artemisinin derivatives (WHO, 2010b; WHO, 2011). Drug resistance may be 
geographically localised, as is the case with mefloquine, amodiaquine, artemisinin and 
quinine, or more widespread as with chloroquine and SP (WHO, 2010b). It appears as if 
drug resistance is perpetuated in two ways. Firstly, by the use of an antimalarial to which 
partial resistance has already occurred, as it confers an advantage to parasites which are 
resistant to the drug, with these parasites also shown to produce higher gametocyte 
numbers. This is compounded by antimalarials which induce gametocytogenesis, such as 
the antifolates, which further promotes the transmission of drug resistant parasites (Vinetz 
et al., 2011). Secondly, gametocytes which carry drug resistant genes are shown to be more 
infectious, by producing more oocytes within the mosquito; as well as by infecting a higher 
percentage of mosquitoes (Butcher, 1997; WHO, 2010b). Genetic mutations on parasitic 
chromosomes confer antimalarial drug resistance by altering drug transport and 
accumulation within the parasite, as is the case with chloroquine, amodiaquine, quinine 
and mefloquine. Or by reducing the affinity of the antimalarial drug to the parasitic target, 
as is the case with pyrimethamine, cycloguanil, sulphonamides and atovaquone (Kerb et al., 
2009; Rosenthal, 2009; Vinetz et al., 2011). Antimalarial drug resistance provides a major 
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challenge to the treatment of malaria, with treatment failure resulting in a rapid disease 
progression and enormous increase in the risk of mortality (WHO, 2010b). This has initiated 
the urgent development of novel compounds with unique mechanisms of action against 
the parasite, that, when combined with current antimalarial treatments have a favourable 
interaction.         
1.5 The future of malarial prevention and treatment 
Thus far malaria preventative methods include personal protection methods and 
chemoprophylaxis; a third possible option is an antimalarial vaccine. Owing to the massive 
resurgence of malaria and the spread of drug resistance, the global fight against malaria 
has increased to include development of an antimalarial vaccine (The RTS,S clinical trials 
partnership, 2011). Vaccine development has concentrated on targeting stage-specific 
antigens present in the sporozoite, tissue and asexual stages, as well as the blockade of 
transmission of gametocytes and gametes (Figure 1.2) (Greenwood et al., 2008; 
Greenwood and Targett, 2009). In high malaria transmission areas of Africa, children who 
survive P. falciparum infections in early life rarely develop severe malaria in later infections 
(Sauerwein, 2009). This clinical immunity appears to be as a result of a combination of both 
naturally acquired immunity mediated by host antibodies targeting parasite proteins, as 
well as the production of cytokines, such as interferon-γ, which act to inhibit parasite 
growth mainly in the liver stage (Figure 1.2) (Greenwood and Targett, 2009; Sauerwein, 
2009).  
Attempts to develop a vaccine against malaria began over 50 years ago, with the Spf66 
experimental vaccine showing promising results. Spf66 was a synthetic vaccine composed 
of amino acid sequences derived from the P. falciparum merozoite circumsporozoite 
protein and was designed to act against the asexual stage of the parasitic life cycle (Amador 
et al., 1992). Spf66 was shown to be 30% effective in providing immunity against the 
disease; however, this was not validated in later clinical trials (Greenwood and Targett, 
2009). More recently, the RTS,S vaccine, a sub-unit vaccine composed of a polypeptide 
segment of the circumsporozoite protein fused to the hepatitis B surface antigen, designed 
to act against the liver stage of the disease, has displayed promising results (Greenwood et 
al., 2008; Vanderberg, 2009). Results from the RTS,S vaccine trials conducted in Africa 
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showed that the vaccine was approximately 50% effective in reducing the risk of P. 
falciparum infection, whilst also reducing the risk of developing severe malaria by 
approximately 35% in children aged between 6-12 weeks and 5-17 months (The RTS,S 
clinical trials partnership, 2011)    
Another vaccine trial using the rodent malaria model (Plasmodium berghei) examined the 
ability of genetically modified whole P. berghei sporozoites, viable sporozoites 
administered together with a prophylactic agent such as azithromycin, pyrimethamine, 
primaquine or chloroquine and over-irradiated sporozoites to provide protective immunity 
(Friesen and Matuschewski, 2011). Friesen and Matuschewski (2011) found that genetically 
modified P. berghei sporozoites and viable sporozoites administered together with 
azithomycin provided a high degree of protection (80%), whereas over-irradiated P. berghei 
sporozoites failed to elicit any protection against the disease. Despite the promising results 
of these trials, vaccine candidates have been unable to re-produce the same effect as the 
clinical immunity developed from multiple exposures (Vanderberg, 2009).  
An alternative therapeutic strategy included intermittent preventative treatment, wherein 
high-risk populations such as pregnant women and infants are intermittently treated with a 
prophylactic agent such as SP, has shown to reduce malaria infection by 60% in infants 
(Alonso, 2006; Greenwood and Targett, 2009). However, a concern with this strategy is that 
antimalarial drug resistance has limited the number of medications available.  
The current lack of a vaccine, as well as the increase in antimalarial drug resistance, has 
made it imperative to develop new effective antimalarial drugs that are target specific. 
Drug development may be achieved by re-examining existing antimalarials or by developing 
new drugs which act on previously exploited or novel parasitic targets (Figure 1.11) 
(Vangapandu et al., 2007; Greenwood et al., 2008). The efficacy of existing antimalarials 
could be improved upon by synthesising derivatives with various side chains substitutions; 
or by combating drug resistance by the inclusion of a resistance reversal agent 
(Vangapandu et al., 2007). An example of an exploited parasitic target includes the folate 
pathway. The addition of a third drug, capable of inhibiting other processes in the pathway 
and acting synergistically with available antifolate combination therapies, may be a 
possibility to kerb folate resistance (Biagini et al., 2003; Greenwood et al., 2008). 
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Figure 1.11: Drug targets within P. falciparum (adapted from Greenwood et al., 2008). 
Where: DHODH = dihydroorotate dehydrogenase; DHFR = dihydrofolate 
reductase; ER = endoplasmic reticulum. 
 
Novel parasitic targets include: new permeation pathways, transporters, proteases within 
the food vacuole, the mitochondrial system, the apicoplast, as well as protein kinases 
involved in DNA synthesis and replication pathways (Figure 1.11) (Jana and Paliwal, 2007; 
Greenwood et al., 2008; Solyakov et al., 2011). In a recent study by Solyakov et al. (2011) 
36 protein kinases were identified and found to be involved in not only DNA replication 
processes, but also cyto-adherence and red blood cell invasion, thereby providing 
additional targets for novel antimalarial drugs. 
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The benefits of exploiting specific parasitic targets would be to not only decrease the side 
effect profile of the drug, but also to formulate drug combinations, wherein each drug acts 
on a different parasitic target increasing the efficacy of the drugs in combination, as well as 
decreasing the risk of drug resistance (Kremsner and Krishna, 2004; Jana and Paliwal, 2007). 
In this respect, the aim of this study was to investigate the exact nature of the effects of 
three novel classes of compounds on previously exploited and novel parasitic targets; as 
well as to examine the interactions of select compounds from each class with standard 
antimalarial drugs, with the goal of elucidating structure-activity relationships. 
1.6 Study objectives 
To determine the antimalarial activity of metronidazole-thiosemicarbazone derivatives, 
chloroquinoline-chalcones, as well as nucleoside phosphonates, phosphonic acids and 
purine/pyrimidine derivatives: 
 A total of 112 compounds from the three diverse groups of compounds were tested 
against P. falciparum, using the [3H]-hypoxanthine incorporation assay, from which 
lead compounds were identified and structure-activity relationships determined. 
 A flow cytometric methodology as a high-throughput means of testing the 
antimalarial activity of compounds against P. falciparum was established and 
validated against the [3H]-hypoxanthine incorporation assay. 
 Lead compounds were combined with standard antimalarials to assess 
pharmacological interactions. 
 Morphological and stage-specific effects of the lead compounds were examined in 
order to elucidate antimalarial mechanisms of action. 
 Antimalarial mechanisms of action were further examined by use of assays to 
examine the effects of the compounds on haemozoin formation, iron chelation and 
free-radical scavenging. 
 The effect of the compounds on healthy red blood cells was examined to give an 
indication of cytotoxicity. 
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Protocol for the in vitro culturing of P. falciparum 
The first successful attempt at the continuous in vitro culturing of the malaria parasite 
occurred in 1976, with the culture derived from a monkey infected with the Vietnam-Oak 
Knoll chloroquine-resistant strain of P. falciparum (Trager and Jensen, 1976). Following 
which, Jensen and Trager (1978) showed that parasite cultures derived from individuals 
infected with P. falciparum   could also be successfully cultured. These parasite cultures 
were maintained in RPMI-1640 culture media supplemented with (4-(2-
hydroxyethyl)piperazine-1-ethanesulfonic acid) (HEPES) buffer, bicarbonate, and 10 or 15% 
human serum; to which human AB+ erythrocytes were added (Jensen and Trager, 1978). 
The petri dish/candle jar technique was used, wherein the parasite suspension was grown 
in plastic petri dishes which were incubated in a candle jar maintained at 37 °C (Jensen and 
Trager, 1978). However, Freese et al. (1988) found the candle jar technique unsuitable for 
the establishment of South African P. falciparum isolates, with the survival time of the 
cultures ranging from 2 to 44 days. Freese et al. (1988) then modified the methodology of 
Jensen and Trager (1978) so that parasite cultures could be maintained in a tissue culture 
flask gassed with a mixture of 3% O2, 4% CO2 and 93% N2, in addition, the culture media 
was further supplemented with glucose, hypoxanthine, and gentamicin.  
2.1.1 Culture maintanence 
The 3D7 (chloroquine-sensitive) strain of P. falciparum (Biosafety clearance/protocol 
number: 20090503, Appendix B1) was continuously maintained, according to the 
methodology of Jensen and Trager (1978) and Freese et al. (1988).  On a daily basis thin 
blood smears were prepared, fixed with methanol, and stained with a rapid diagnostics kit 
(Global diagnostics), which contained a Giemsa component for detection of the parasite. 
From the blood smear the % parasitaemia was calculated and the stage of the asexual life 
cycle (Figure 2.1) determined. The culture was maintained at a 5% haematocrit and 
parasitaemia below 10%, with nutrient-depleted culture media (Section 2.1.6) aspirated 
and replaced daily with fresh complete culture media. During the trophozoite- and 
schizont-stages, uninfected eythrocytes (Section 2.1.8) were added to the culture. Prior to 
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incubation, at 37 °C, the culture was gassed with a mixture of 92% N2, 5% CO2 and 3% O2 
(Afrox). 
 
Figure 2.1: The various intraerythrocytic developmental stages of P. falciparum. With 
number 1 depicting an uninfected red blood cell, and numbers 2-10, 11-18, 19-
26, 27-10 representative of the ring-, trophozoite-, schizont- and sexual stages, 
respectively (Centres for Disease Control and Prevention, 2009).     
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2.1.2 Synchronisation of the culture 
P. falciparum maintained in vitro loses its natural synchronisity seen in vivo (Lambros et al., 
1979). In order to establish a synchronised culture, for experimental purposes, the culture 
was treated with 5% (w/v) D-sorbitol (Section 2.1.4) when predominantly in the early ring-
stage (Figure 2.1, numbers 2-5). Sorbitol enters red blood cells via new permeation 
pathways inserted into the red blood cell membrane at the end of the ring/early 
trophozoite-stage (Wagner et al., 2003). In this respect, negligible amounts of sorbitol will 
enter a ring-infected red blood cell, whereas sorbitol readily enters trophozoite and 
schizont infected red blood cells resulting in osmotic lysis (Wagner et al., 2003).  
Culture synchronisation was carried out by transferring the parasite suspension to a 50 ml 
centrifuge tube and centrifuging it at 1500 rpm for 5 minutes, following which the 
supernatant was aspirated and replaced with 20 ml of D-sorbitol (Section 2.1.4). 
Subsequent to a 20 minute incubation period at room temperature, the suspension was 
centrifuged at 1500 rpm for 5 minutes and the supernatant aspirated. Complete culture 
media (Section 2.1.6) was added, the culture transferred back to a culture flask, gassed, and 
incubated at 37 °C. 
2.1.3 Preparation of incomplete experimental and culture media 
The incomplete experimental media was prepared as follows: 10.4 g RPMI-1640 (Gibco), 
5.9 g HEPES buffer (Sigma), 4.0 g D-glucose (Merck) were dissolved in 1 litre of MilliQ™ 
water and sterile filtered through a 0.22 µm Millipore™ filter unit. The media was stored at 
4 °C until needed. Incomplete culture media was prepared as above, with the addition of 
100 µl 50 mg/ml gentamicin sulphate (Sigma) and 44 mg hypoxanthine (Sigma). 
 
2.1.4 Preparation of sodium bicarbonate and sorbitol solutions 
The 5% (w/v) solutions of sodium bicarbonate and D-sorbitol were prepared by dissolving 
50 g sodium bicarbonate (Saarchem) and 50 g D-sorbitol (Sigma), respectively, in 1 litre 
MilliQ™. The solutions were then sterile filtered through a 0.22 µm Millipore™ filter unit 
and stored at 4 °C until needed.   
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2.1.5 Preparation of human plasma 
Six bags of human plasma (South African National Blood Services) were thawed at 4 °C and 
heat inactivated at 56 °C for 2 hours. The plasma was then centrifuged at 3000 revolutions 
per minute (rpm) for 10 minutes. Following which, the supernatant was aliquoted into 
sterile 50 ml tubes and stored at -20 °C until required. 
2.1.6 Preparation of complete experimental and culture media 
To prepare complete experimental and culture media, 10 ml of heat-inactivated human 
plasma and 4.2 ml of the 5% (w/v) sodium bicarbonate stock solution were added to either 
incomplete experimental or culture media (Section 2.1.3) up  to a final volume of 100 ml. 
2.1.7 Preparation of phosphate buffered saline 
To prepare phosphate buffered saline (PBS, pH 7.5); 8.0 g NaCl (Saarchem), 0.3 g KCl 
(Sigma), 0.73 g Na2HPO4.2H2O (Merck) and 0.2 g KH2PO4 (Fluka) were dissolved in 1 litre of 
MilliQ™ water and autoclaved at 120 °C for 20 minutes. The solution was stored at 4 °C 
until needed. 
2.1.8 Preparation of erythrocytes 
Whole blood, collected from volunteers (Ethical clearance number: M090532, Appendix 
B2), was stored in anticoagulant tubes (BD) containing acid citrate dextrose-B and 
centrifuged at 2000 rpm for 5 minutes to separate it into its components. The supernatant 
and buffy coat were aspirated and the erythrocyte-containing pellet re-suspended in sterile 
PBS (Section 2.1.7), this was repeated a total of three times. Following this, the pellet was 
re-suspended in an equal volume of incomplete experimental media and stored at 4 °C for 
a maximum of a week. Although the pellet would have contained a small percentage of 
reticulocytes (0.5-1.4%) (d’Onofrio et al., 1995), reticulocytes mature into erythrocytes in 
approximately 2-3 days in vitro, with the reticulocyte population  halving after only 12 
hours in culture (Gronowicz et al., 1984; Koury et al., 2004). In this respect, the term 
‘erythrocytes’ will be used in this study, with the exception of the red blood cell toxicity 
assay (Section 2.4.2) in which blood no older than two days was utilised,  as the term ‘red 
blood cells’ encompasses both erythrocytes and reticulocytes.       
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2.2 Antimalarial activity 
2.2.1 Preparation of the test solutions 
The novel test compounds were prepared to 10 mM stock concentrations in either 
autoclaved MilliQ™ water or dimethyl sulfoxide (DMSO; Merck), depending on the polarity 
of the compounds, as determined by examining  the individual chemical structures. In the 
case of compounds soluble in water, a small volume of DMSO (< 10% final concentration of 
DMSO) was added to ensure sterility. In some instances, the solutions were heated for 
approximately 30 seconds in boiling water and vortexed vigorously as they did not go into 
solution initially. Positive controls included quinine hydrochloride (Sigma) and chloroquine 
diphosphate (Sigma), solubilised in autoclaved MilliQ™ water and sterilised through a 0.22 
µm Acrodisc™ filter; as well as artemisinin (Sigma) and dihydroartemisinin (Sigma) 
solubilised in DMSO, all prepared to 10 mM stock concentrations. Both the test compounds 
and positive controls were stored at -20 °C until needed.  
2.2.2 The [3H]-hypoxanthine incorporation assay 
P. falciparum is incapable of de novo purine synthesis, and through specialised transporters 
and enzymes the parasite scavenges and metabolises host-derived purines (Desjardins et 
al., 1979; Smeijsters et al., 1999; El Bissati et al., 2006). The major route of purine salvage is 
the conversion of adenosine into hypoxanthine, which is then incorporated into parasitic 
DNA during the trophozoite- and schizont-stages (Chulay et al., 1983; Smeijsters et al., 
1999; El Bissati et al., 2006). Incorporation of the [3H]-hypoxanthine isotope into parasitic 
DNA provides a direct measure of the number of parasitised red blood cells in the culture, 
thereby providing a way to quantify parasite growth (Desjardins et al., 1979; Chulay et al., 
1983).   
2.2.2.1 Experimental protocol 
For the initial drug screenings, 1 mM and 10 µM working solutions of the test compounds 
and positive controls, respectively, were prepared in incomplete experimental media. 
Therafter, the working solutions were serially diluted in a 1:10 ratio, in incomplete 
experimental media, to achieve final screening concentrations of 100 µM, 10 µM, 1 µM, 0.1 
µM and 0.01 µM for the test compounds and 1000 nM, 100 nM, 10 nM, 1 nM and 0.1 nM 
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for the positive controls (taking into account the 10 times dilution factor of the 
experiment). All dilutions were plated out in triplicate in a sterile 96-well microtitre plate 
(Techno Plastic Products), so that each well contained 25 µl of the test compound/positive 
control, with the exception of the parasite and erythrocyte control wells, to which 25 µl 
incomplete experimental media was added. Following the initial screening, the 
concentrations were adjusted so as to achieve an optimal sigmoid dose-response curve. 
Synchronised ring-stage parasites, adjusted to a final parasitaemia of 0.5% and haematocrit 
of 1% in complete experimental media were added (200 µl) to each well of the 96-well 
plate; with the exception of four wells that received non-parasitised erythrocytes (1% 
haematocrit), which served as a negative erythrocyte control (Figure 2.2) (Desjardines et 
al., 1979).  
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Figure 2.2: Microtitre plate layout used for IC50 value determination in the [
3H]-
hypoxanthine incorporation assay. 
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The plate was then incubated for 24 hours at 37 °C in a humidifed glass dessicator, to which 
a lit candle was added, in order to produce an oxygen-deficient (approximately 3% O2) 
environment (Jensen and Trager, 1977). Thereafter, 25 μl of the radiolabeled [3H]-
hypoxanthine isotope (185 MBq/5 mCi, Amersham), diluted in incomplete experimental 
media (10 µl:2.7 ml), was added to each well, and the plate returned to the candle jar for a 
further 24 hour incubation period.  The parasitic [3H]-DNA was then harvested onto glass 
fibre filter mats (Wallac™) using a Titertek® semi-automatic cell harvester. The filter mats, 
left to air dry overnight were transferred to sample bags to which 10 ml liquid beta 
scintillation fluid (Wallac™) was added. Incorporation of the [3H]-hypoxanthine isotope into 
the parasitic DNA was quantified using a Wallac™ beta scintillation counter, and expressed 
as counts per minute (cpm). 
The percentage parasite growth was calculated using the formula below: 
% Parasite growth = Compound (cpm) – mean erythrocyte control (cpm) (x100%)
Mean parasite control (cpm) - mean erythrocyte control (cpm)  
2.2.2.2 Data analysis 
Log sigmoid dose response curves were constructed by plotting the % parasite growth 
versus the log of the drug concentration, using the Enzfitter® (version 1.05) software, from 
which IC50 values (concentration required to inhibit parasite growth by 50%) were 
determined. For compounds exhibiting little or no antimalarial activity, the % inhibition of 
parasite growth at 100 µM was calculated. All experiments were repeated at least in 
triplicate to produce a mean ± standard deviation. In order to determine if there was a 
statistically significant difference between a test compound and positive control, an 
unpaired Students T-test was executed using the Graphpad Prism® (version 5) software, 
with a p value of less than 0.05 considered statistically significant. In the case of some 
compounds, a correlation between antimalarial activity and antimalarial mechanisms of 
action (Section 2.3) was determined using linear regression, with a 95% confidence interval. 
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2.2.2.3 Combination studies 
The use of combination therapies to curb the emergence of resistant organisms and ensure 
successful treatment, has long been applied to the treatment of many diseases such as 
tuberculosis and HIV/AIDS, and has also become pivotal in antimalarial chemotherapy 
(Nosten and Brasseur, 2002; Kremsner and Krishna, 2004). An ideal antimalarial 
combination would be one where there is a synergistic interaction between the two drugs, 
so that the doses of the individual drugs needed to produce the same overall effect may be 
reduced. Conversely, an antagonistic interaction is regarded as unfavourable as it would 
result in treatment failure (Nosten and Brasseur, 2002; Bell, 2005).  
The most active compound(s) from each drug class were combined with quinine or 
dihydroartemisinin, and by means of the tritiated hypoxanthine incorporation assay 
(Section 2.2.2.1) their pharmacological interactions assessed. Solutions of the test 
compound and quinine/dihydroartemisinin were prepared at concentrations 20 times 
higher than the final concentration required in the experiment, in order to account for the 
10 times dilution factor of the tritiated hypoxanthine assay (Section 2.2.2.1) and 2 times 
dilution factor generated by combining equal volumes of the test compound and 
quinine/dihydroartemisinin.  
The two drugs were  combined in various ratios (10:0, 9:1, 8:2, 7:3, 6:4, 5:5, 4:6, 3:7, 2:8, 
1:9, 0:10) and serially diluted seven times, from which log sigmoid dose response curves 
were constructed. From the dose response curves, IC50 values (Section 2.2.2.2) for the drug 
alone and the drug in combination were obtained and relative ratios or fractional IC50 
values (FIC50) calculated using the formula below: 
FIC50 value =  IC50 value of compound in combination
IC50 value of compound alone  
The FIC50 values were plotted, from which an isobologram was generated. The degree of 
the interaction, which is equivalent to the sum of the FIC50 values (ΣFIC50) for the test 
compound and quinine/dihydroartemisinin at each combination ratio, was then calculated 
(Berenbaum, 1978). The cut-off points used to define the possible interactions differ 
amongst authors, therefore, for the purpose of this study a ΣFIC50 < 0.5 indicates synergism, 
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a 0.5 < ΣFIC50 < 2 indicates an additive relationship, and a ΣFIC50 > 2 indicates antagonism 
(Figure 2.3) (Fidock et al., 2004).  
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Figure 2.3: The cut-off points for possible drug interactions between 
quinine/dihydroartemisinin and a test compound. 
 
2.2.3 The use of flow cytometry to assess in vitro parasite growth 
Widely-used techniques for the assessment of parasite growth include microscopic 
examination of Giemsa-stained blood smears, as well as the tritiated hypoxanthine 
incorporation and parasite lactate dehydrogenase assays (Scott et al., 2002; Bennett et al., 
2004; Grimberg et al., 2008). There are limitations to all three methodologies. Microscopic 
examination of blood smears is time consuming and prone to human error; the tritiated 
hypoxanthine incorporation assay requires the use of costly radioactive material and 
provides no information on the stage-specific activity of drugs; and lastly, the lactate 
dehydrogenase assay requires multiple processing steps and only measures metabolic 
activity in the latter half of the parasitic asexual life cycle (Bennett et al., 2004; Grimberg et 
al., 2008). A rapid, sensitive and stage-specific technique for the screening of potential 
antimalarial drugs would be invaluable in antimalarial drug development.  
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Flow cytometry technology was developed during the Second World War as a means to 
detect anthrax spores (Grimberg, 2011). Since then, there has been a rapid technological 
progression to include a wide range of applications such as drug screening, receptor 
pharmacology, protein expression systems and signalling pathways, together with 
improved instrument sensitivity (Nolan et al., 1999; Waller et al., 2004; Sklar et al., 2007). 
The modern flow cytometer is capable of analysing up to 50 000 cells per second, based on 
size, morphology and fluorescence of the probe or dye (Nolan et al., 1999; Waller et al., 
2004; Sklar et al., 2007). Flow cytometric probes extend beyond conjugated antibody’s to 
include dyes which show increased fluorescence upon interaction with a target, such as 
DNA (Nolan et al., 1999; Waller et al., 2004; Sklar et al., 2007).  
The use of flow cytometry and fluorescent DNA dyes has been well documented in the 
analysis of the cell cycle of mammalian cells, and has since extended into the study of the 
intra-erythrocytic growth of the malaria parasite (Whaun et al., 1983; Hare and Bahler, 
1986). The use of DNA dyes to study intra-erythrocytic parasite growth works on the 
principle that uninfected erythrocytes do not contain DNA, whereas parasitised 
erythrocytes do, and upon addition of a DNA dye will fluoresce upon exposure to a certain 
wavelength of light (Whaun et al., 1983; Waki et al., 1986; Grimberg et al., 2008). The 
intensity of fluorescence equates to the amount of DNA present, and therefore the stage of 
the erythrocytic life cycle (Whaun et al., 1983; Waki et al., 1986; Grimberg et al., 2008). The 
ratio of erythrocytes staining positive for DNA to the total number of erythrocytes in the 
sample provides a percentage parasitaemia (Grimberg, 2011). Thereby providing a means 
in which both quantitative and qualitative results may be obtained (Whaun et al., 1983).  
Several DNA dyes have been examined for use in the detection of the malaria parasite, 
including: Hoechst 33258, acridine orange, thiazole orange, propidium iodide, and 
hydroethidine (Wyatt et al., 1991; van Vianen et al., 1993; Grimberg et al., 2011). Hoechst 
33258 is a DNA binding dye with selectivity for AT regions, making it ideal for the detection 
of the AT rich malaria parasite (Grimberg, 2011). However, it requires excitation by an 
ultraviolet laser (van Vianen et al., 1993; Grimberg, 2011), which is not standard in most 
flow cytometers available for use. Acridine orange is capable of binding to both DNA and 
RNA, emitting green and red fluorescence, respectively, thereby permitting two-colour 
analysis (Whaun et al., 1983; Hare and Bahler, 1986; Grimberg, 2011). It was excluded as a 
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potential fluorochrome on the basis that it quenches upon nucleic acid binding and 
accumulates in acidic compartments due to its weak base properties, forming aggregates 
which fluoresce red, thereby interfering with RNA detection (Wissing et al., 2002; 
Grimberg, 2011). Furthermore, single-stranded and denatured DNA also fluoresce red 
following staining with acridine orange, all of which provide difficulty in quantifying DNA 
and RNA (Grimberg, 2011). 
As no flow cytometric protocol was available in the department, a method was developed, 
and validated, to assess overall percentage parasitaemia, identify the various asexual 
intraerythrocytic parasitic stages, as well as the percentage of parasites in each stage.   
2.2.3.1 Method development 
2.2.3.1.1 Thiazole orange as a potential fluorochrome 
Thiazole orange is a membrane-permeable nucleic acid dye which primarily stains RNA, by 
intercalating into AU doublets, and has been used primarily to detect reticulocytes in blood 
samples (Makler et al., 1987; Grimberg, 2011). A methodology for fixing the samples prior 
to staining with thiazole orange has been previously described (Schulze et al., 1997). This 
methodology was selected for this study, thus allowing for samples to be analysed in large 
batches and at a more convenient time, according to the availability of the flow cytometer.  
In order to set up a protocol wherein the various stages of the parasitic life cycle and 
percentage parasitaemia could be detected, samples of ring-, trophozoite- and schizont-
staged parasites were initially prepared to a stock culture of a 10% haematocrit and 8% 
parasitaemia. With a 10% haematocrit uninfected erythrocyte solution also being prepared 
to act as a diluent, as well as the uninfected erythrocyte control. Both solutions were 
prepared in complete experimental media (Section 2.1.6). The stock culture was then 
serially diluted with the uninfected erythrocyte suspension, in order to maintain the 10% 
haematocrit, and achieve parasitaemias of 4, 2 and 1%. Duplicate samples were prepared 
so that the flow cytometry results could be verified from Giemsa-stained blood smears and 
parasite counts, wherein the overall % parasitaemia was determined by counting 1000 
erythrocytes or 10 microscope fields.   
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The samples were then fixed in the following solution: a Tris-saline buffer consisting of 10 
mM (hydroxymethyl)aminomethane (TRIS; Saarchem), 150 mM NaCl (Saarchem) and 10 
mM sodium azide (Sigma); to which 37.23% formaldehyde (Calbiochem) and D-glucose 
(Saarchem) were added, in order to achieve a 10% formaldehyde and 4% D-glucose fixing 
solution (Schulze et al., 1997). The pH of the solution was then adjusted to 7.3, in order to 
prevent lysis of the erythrocytes, before being filtered through a 0.22 µm Millipore™ filter, 
and stored at 4 °C until needed. Fixing solution (100 µl) was added to 100 µl of the sample, 
so that the final haematocrit was reduced to 5%, whilst the percentage parasitaemia of the 
samples remained unchanged. The samples were then stored at 4 °C for 18 hours or longer, 
before being analysed.  
The 10 mM thiazole orange (Sigma) stock solution was prepared in DMSO and kept 
wrapped in foil at -20 °C until needed. For the flow cytometric analysis, a working solution 
of 1 µM thiazole orange in sterile PBS (Section 2.1.7) was prepared. A 50 µl sample was 
added to 1 ml working solution and incubated at room temperature in the dark, for an 
hour. Thereafter, the samples were transferred to flow cytometric tubes (Becton, Dickinson 
and Company) and read on a Becton, Dickinson and Company (BD) FACSCalibur™ flow 
cytometer, with argon laser excitation at 488 nm and detection at 533 nm, located in the 
Department of Surgery, 9th Floor of the University of the Witwatersrand Medical School. A 
total of 50 000 cells per sample were counted and analysed using BD CellQuest Pro™ and 
FlowJo software (Version 7.6.1, under licence from Tree Star Inc, serial numbers: 
gQQ3Gy1i&8-TgZ0E, d5T@C1sMWM34tU01, validity: 07/10/2010-07/10/2012) (Figure 2.4). 
 Troubleshooting 
However, upon analysis of the samples several problems were identified, with the following 
steps taken to correct them:  
A large amount of erythrocyte lysis was noted in the supernatant of the samples following a 
24 hour incubation period in the fixative solution. Therefore, the percentage of 
formaldehyde in the fixing solution was reduced to 5%, whereupon cell lysis, although to a 
lesser degree, was still observed. To determine if the sodium azide present in the fixing 
solution was the causative factor of the lysis, the Tris-saline buffer was replaced with sterile 
PBS; however lysis was still observed. As an alternative, a fixing solution of 2% 
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formaldehyde was prepared, whereupon no lysis was observed. However, examination of 
the blood smears showed that the parasites in the sample had progressed into the next 
stage of the life cycle, despite the samples being stored at 4 °C.  To determine whether a 
reduction in the amount of cells to fixing solution would decrease the amount of lysis, 
samples were then prepared to a final haematocrit of 1%, whilst the % parasitaemias 
remained as previously described. The degree of lysis in a 5% formaldehyde fixing solution 
decreased. However, upon flow cytometric analysis of the samples, a lack of discrimination 
between the unparasitised and parasitised erythrocyte populations was noted, exhibiting 
similar results to samples prepared to a 5% haematocrit. Furthermore, the acquisition time 
per sample was approximately three minutes, making a 1% haematocrit parasite solution 
unsuitable for high-throughput screening. 
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Figure 2.4: Flow cytometric analysis of a fixed sample of late rings/early trophozoites at a 
5% haematocrit and 8% parasitaemia, stained with thiazole orange. Where: a = 
a dot-plot of the size (forward scatter) versus the granularity (side scatter) of 
the erythrocytes; b = dot-plot of the maximal fluorescence of thiazole orange 
(FL1-H) versus the granularity of the erythrocytes; c = histogram of maximal 
fluorescence of thiazole orange versus the cell count, where pE = % parasitised 
erythrocytes. 
 
The wide distribution of cells in the forward scatter axis (Figure 2.4a), indicated a range of 
different sized cells, which could have been due to cell aggregation, as a result of 
formaldehyde treatment (Deitch et al., 1982). The lack of discrimination between 
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unparasitised and parasitised erythrocyte populations (Figure 2.4b), wherein the 
parasitaemia as determined by flow cytometry and microscopic analysis were 51.5% (Figure 
2.4c) and 7.57%, respectively, may be attributed to the indiscriminate staining of cell debris 
and parasitic DNA remnants or the induction of auto-fluorescence in fixed erythrocytes 
(Deitch et al., 1982; Grimberg, 2011). Furthermore, formaldehyde treatment may have 
interfered with the uptake of the thiazole orange or altered the emission spectra of the 
dye, as observed with the antibody-conjugated fluorochrome, allophycocyanin (APC) 
(Deitch et al., 1982; BD, 2011).  
A study conducted by Apte et al. (2011), wherein Plasmodium-infected blood was fixed in 
various concentrations of paraformaldehyde and stained with the DNA dye, 4’, 6-
diamidino-2-phenylindole (DAPI), found that fixation resulted in a loss of side and forward 
scatter properties of unparasitised red blood cells, when compared to unfixed samples, and 
attributed it to a loss of cytosolic components and haem. The study concluded that a 
reliable method for parasite detection would require a one-step fixation and lysis. 
However, cell lysis was not an option in this study, as it could result in inaccurate 
determination of  overall % parasitaemia, with the calculation of % parasitaemia reliant on 
the ratio of infected to uninfected erythrocytes. 
As a result, the fixing step was then disregarded and unfixed samples were stained with 
thiazole orange, whereupon two separate populations could be visualised. However, the % 
parasitaemia as per flow cytometric analysis was higher than those ascertained from 
microscopic analysis, especially at low % parasitaemias, where the overall % parasitaemia 
as determined by flow cytometry and microscopic analysis was 2.95% and 0.87%, 
respectively. This could not be attributed to the co-staining of the RNA in reticulocytes, 
which have been shown to degrade after approximately 20 hours in cultured mammalian 
reticulocytes (Koury et al., 2005), or any whole blood remnants present in the sample. The 
effect may have been attributed to the indiscriminate staining of other cellular components 
containing DNA or RNA (Scott et al., 2002). Alternatively, it may have been due to the 
staining of the erythrocyte membrane upon standing of the sample (S. Lauterbach; 
personal communication). With a sample of uninfected erythrocytes exhibiting thiazole 
orange fluorescence and erroneously reflecting a parasitaemia of 1.77% (Figure 2.5), which 
   
40 
 
would result in over-estimated overall % parasitaemias, particularly in large  batches of 
samples.     
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Figure 2.5: Histogram of the maximal fluorescence of thiazole orange (FL1-H) versus cell 
count of an unfixed sample of uninfected erythrocytes, adjusted to a 5% 
haematocrit. 
 
To compare instrument sensitivity, both fixed and unfixed samples (Figure 2.6) were then 
analysed on a Beckman Coulter Inc. (BC) FC 500 flow cytometer using CXP (version 2.2) 
software, located in the Department of Molecular Medicine and Haematology, 7th Floor, 
University of the Witwatersrand Medical School.  
Although two cell populations were visible in a dot-plot of complexity versus size  in the 
samples fixed with a 5% formaldehyde solution (Figure 2.6a), the larger population 
appeared to be cell debris, and gating of the smaller population (Figure 2.6, Region A) 
produced no cells staining positive for thiazole orange (Figure 2.6b, Region E).   
In contrast, the unfixed samples exhibited a uniform distribution of cells in a dot-plot of 
complexity versus size (Figure 2.6c); as well as complete separation of the unparasitised 
and parasitised erythrocyte populations (Figure 2.6d, Region E). Furthermore, the overall % 
parasitaemia and % of parasites in each stage as determined by flow cytometric and 
microscopic analysis were similar; 8.68%, composed of 53% rings and 47% trophozoites, 
compared to 8.20%, composed of 46% rings and 54% trophozoites, respectively. 
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Figure 2.6: Flow cytometric analysis of samples consisting of fixed trophozoites (a and b) 
and unfixed rings and trophozoites (c and d), at a 5% haematocrit and 8% 
parasitaemia,  stained with thiazole orange, and read on a BC FC 500 flow 
cytometer. Where: a and c are dot-plots of the granularity (side scatter) versus 
the size (forward scatter) of the erythrocytes; b and d are histograms of 
thiazole orange fluorescence versus cell count, wherein gate E = overall % 
parasitaemia, D = ring-stage parasites and C = trophozoite- and schizont-stage 
parasites. 
 
However, the availability of the BC FC 500 flow cytometer was highly limited, and due to 
the fact that the fixing of samples was not a viable option, another nucleic acid dye was 
identified for the assessment of parasite growth using the BD FACSCalibur™ flow 
cytometer. 
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2.2.3.1.2 Propidium iodide as a potential fluorochrome   
Propidium iodide is a membrane-impermeable nucleic acid dye used primarily in flow 
cytometric cell viability and apoptosis studies to distinguish dead from live cells and 
necrotic from apoptotic cells, respectively (Jouin et al., 2004) and has been previously used 
to assess in vitro drug sensitivity on P. falciparum (Pattanapanyasat et al., 1997). 
Flow cytometric samples of a 5% haematocrit and 8, 4, 2 and 1% ring-, trophozoite- and 
schizont-staged parasites were prepared (Section 2.2.3.1.1), with a duplicate sample for 
microscopic analysis. To ensure that the dye could penetrate infected erythrocytes, the 
erythrocyte membrane was made permeable by fixing the samples in a   1% formaldehyde 
sterile PBS solution. A 10 mM stock solution of propidium iodide (Sigma) was prepared in 
autoclaved MilliQ™ water, wrapped in foil and stored at -20 °C until required. The staining 
methodology utilised was that as described by Pattanapanyasat et al. (1997), wherein the 
samples were washed with sterile PBS prior to the transfer of 50 µl of each sample to a 1 ml 
working solution of propidium iodide in sterile PBS (14 µM). The samples were left to stand 
in the dark at room temperature for an hour, before being transferred to flow cytometric 
tubes (BD). The samples were then  read on a BD FACSCalibur™ flow cytometer, with argon 
laser excitation at 488 nm and detection at 617 nm, with a total of 50 000 cells per sample  
counted and analysed using BD CellQuest Pro™ and FlowJo (version 7.6.1) software (Figure 
2.7). 
 Troubleshooting 
The wide range of cells of different sizes observed in Figure 2.7a was similar to Figure 2.4a, 
reflecting the effect of formaldehyde treatment on cells, even at a concentration as low as 
1%. A slight separation between unparasitised and parasitised erythrocyte populations was 
visible in Figure 2.7b, as opposed to Figure 2.4b. However, the % overall parasitaemia as 
determined by flow cytometry (Figure 2.7c) and microscopic analysis was 10.4% and 6.68%, 
respectively.  
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Figure 2.7: Flow cytometric analysis of a sample containing ring-, trophozoite- and 
schizont-stage parasites, at a 5% haematocrit and 8% parasitaemia, stained 
with propidium iodide. Where: a = dot-plot of the size (forward scatter) versus 
the granularity (side scatter) of the erythrocytes; b = dot-plot of the maximal 
fluorescence of propidium iodide (FL3-H) versus the granularity of the 
erythrocytes (side scatter); c = histogram of maximal fluorescence of 
propidium iodide versus cell count. 
 
Discrepancies between % parasitaemias as determined by flow cytometric and microscopic 
analysis have been previously reported, with flow cytometric analysis generally producing 
an assessment that is 1.2-fold higher than that determined microscopically (Apte et al., 
2011).  With this effect possibly due to haemolysis of uninfected erythrocytes during flow 
cytometric sample preparation or the loss of infected erythrocytes during blood smear 
preparation (Apte et al., 2011).    
However, the overall % parasitaemia as determined by flow cytometric analysis was far 
greater than 1.2-fold as determined microscopically, and could not be solely attributed to 
these factors. Yet it may be as a result of formaldehyde treatment in the permeabilisation 
step. Propidium iodide has shown to lack the fluorescent intensity needed to overcome 
auto fluorescence induced by formaldehyde treatment, resulting in an incomplete 
separation of uninfected and infected populations, particularly in samples of ring-stage 
parasites, which contain small amounts of DNA and at low parasitaemias (Grimberg, 2011).  
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The discrepancy may also have been as a result of indiscriminate staining of cell debris due 
to over-staining. However, the same effect was observed when the incubation time was 
reduced to 30 minutes and 5 minutes. Furthermore, the methodology proved to be 
unreproducible, with parameters having to be re-adjusted for each experiment.  
Propidium iodide is useful in the detection of dead versus live cells, in the absence of 
fixatives or membrane permeabilisation. However, in this context, its use is hampered by 
the fact that permeabilisation of membranes by fixatives such as formaldehyde, 
glutaraldehyde, ethanol, or methanol results in the induction of auto fluorescence and cell 
aggregation (Grimberg, 2011), and also allows for the indiscriminate staining of DNA of 
both live and dead parasites, which may skew results when using this stain for IC50 value 
determination.   
2.2.3.1.3 Hydroethidine as a potential fluorochrome   
Hydroethidine is a membrane permeable dye that is oxidised by dehydrogenase enzymes 
into ethidium, only in viable cells. The cationic nature of ethidium results in it being trapped 
intracellularly where it intercalates into DNA and fluoresces red upon excitation (Figure 2.8) 
(Olive, 1989; Grimberg, 2011).  
NH2
N
NH2 C2H5
NH2
N
+
NH2 C2H5
NADP+
Hydroethidine (blue) Ethidium (red)
 
Figure 2.8: The oxidation of hydroethidine by parasitic dehydrogenases to form ethidium 
which, upon intercalation into parasitic DNA, fluoresces red (Olive, 1989). 
The initial use of hydroethidine, to detect superoxide anions has extended into the 
assessment of the in vitro growth of intraerythrocytic parasites, including P. falciparum 
(Wyatt et al., 1991; van der Heyde et al., 1995; Grimberg, 2011). The selectivity of this 
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fluorochrome for only viable parasites is highly beneficial in that erythrocytes containing 
viable parasites can not only be distinguished from unparasitised erythrocytes, but also 
from erythrocytes containing dead parasites (Wyatt et al., 1991). 
Three separate suspensions containing predominantly ring-, trophozoite-, and schizont-
staged parasites were prepared (Section 2.2.3.1.1), in duplicate, to achieve samples of a 5% 
haematocrit and parasitaemias of 8, 4 and 2%. A 1% parasitaemia sample was not 
prepared, as counting of parasitised erythrocytes in blood smears proved to be time 
consuming, making a protocol based on a 1% parasitaemia impractical.  
The stock solution (10 mM) of dihydroethidium (Sigma) was prepared in DMSO, wrapped in 
foil and stored at -20 °C until needed. The staining methodology of Wyatt et al. (1991) was 
followed. The samples were centrifuged at 1500 rpm for 5 minutes, the supernatant 
removed and replaced with 1 ml dihydroethidium in PBS (159 µM), and the pellet 
resuspended. The samples were left to incubate in the dark, at 37 °C for 20 minutes; 
thereafter the samples were washed three times in sterile PBS and resuspended in 1 ml 
sterile PBS for analysis. The samples were transferred to flow cytometric tubes  (BD)  and 
read on a BD FACSCalibur™ flow cytometer, with argon laser excitation at 488 nm and 
detection at 610 nm, a total of 50 000 cells per sample were counted and analysed using BD 
CellQuest Pro™ and FlowJo (version 7.6.1) software (Figure 2.9a-c).  
For comparative purposes, fixed samples were also prepared and stained with 
dihydroethidium prior to fixation in a 5% formaldehyde Tris-saline buffer solution (Section 
2.2.3.1.1). Following a 24 hour incubation period at 4 °C, the samples were washed and 
resuspended in 1 ml sterile PBS for analysis (Figure 2.9d-f). 
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Figure 2.9: Flow cytometric analysis of an unfixed parasite sample of early rings (a-c) and a 
fixed parasite sample of late rings and early trophozoites (d-f), at a 5% 
haematocrit and 2% parasitaemia, stained with dihydroethidium. Where: a and 
d are dot-plots of the size (forward scatter) versus the granularity (side scatter) 
of the erythrocytes; b and e are dot-plots of the maximal fluorescence of 
dihydroethidium (FL2-H) versus side scatter, and c and f are histograms of 
maximal fluorescence of dihydroethidium versus cell count. 
 
The dot-plot of forward versus side scatter of the fixed parasite sample (Figure 2.9d) is 
similar to those of Figures 2.4a and 2.7a, indicating definitively that formaldehyde 
treatment results in the change of the scatter properties of erythrocytes, and is not  a result 
of the fluorochrome used. The dot-plot and histogram of Figures 2.9e and f, respectively, 
showed two separate populations; however this did not correspond to unparasitised and 
parasitised populations, nor represent parasite stage. The overall % parasitaemia, as 
determined by flow cytometric analysis, was 49.6% (Figure 2.9f) composed of 28% rings 
and 71% trophozoites; whereas the overall % parasitaemia as determined by microscopic 
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analysis was 1.95%, composed of 55% rings and 45% trophozoites. The massively inflated 
parasitaemia, as determined by flow cytometric analysis, was similar to that noted in fixed 
parasite samples stained with thiazole orange  (Figure 2.4c),  ruling out fixation post-
staining as a viable option.  
In contrast, unfixed samples of early rings stained with dihydroethidium showed a higher 
degree of uniformity in their forward scatter characteristics (Figure 2.9a), as well as 
discrimination between unparasitised and parasitised erythrocyte populations, as seen in 
the dot-plot and histogram (Figures 2.9b and c). The overall % parasitaemia as determined 
by flow cytometric and microscopic analysis was 2.54%, composed of 89% rings and 9% 
trophozoites (Figure 2.9c), and 2.20%, composed of 88% rings and 12% trophozoites, 
respectively.    
Samples of trophozoite- (Figure 2.10a) and trophozoite- and schizont-staged parasites 
(Figure 2.10b) exhibited the same level of discrimination from the unparasitised 
erythrocyte population and, when compared to ring-stage parasites, an increase in 
dihydroethidium fluorescence (Figure 2.11).  
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Figure 2.10: Histograms of the maximal fluorescence of dihydroethidium (FL2-H) versus cell 
count of samples of trophozoites (a) and trophozoites and schizonts (b) at a 5% 
haematocrit and 2% parasitaemia, stained with dihydroethidium. 
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Figure 2.11: An overlay of flow cytometric histograms depicting the increasing 
fluorescent intensity of dihydroethidium (FL2-H) in samples of ring-, 
trophozoite-, and trophozoite/schizont-staged parasites, at a 5% haematocrit 
and 2% parasitaemia.  
 
The overall % parasitaemias as determined from flow cytometric analysis correlated with 
those as determined from blood smears; 2.04%, 2.27%, and 1.98%, 1.93%, respectively. 
Furthermore, schizont-stage parasites could be distinguished from trophozoites in a sample 
of trophozoite and schizont-staged parasites based on increased dihydroethidium 
fluorescence (Figure 2.11); wherein   28.9% and 29.2% of the sample was composed of 
schizonts, as determined by flow cytometric and microscopic analysis, respectively. A 
similar correlation between the overall % parasitaemia as determined by flow cytometric 
and microscopic analysis was observed at parasitaemias prepared to 8% and 4% (Table 2.1). 
Table 2.1:  A comparison of the overall % parasitaemia obtained from flow cytometric and 
microscopic analysis of samples prepared to an 8, 4 and 2% parasitaemia and 
stained with dihydroethidium (n = 4). 
 
Overall parasitaemia (%) 
Prepared Flow cytometry Microscopic analysis 
8 7.42 ± 0.81 7.96 ± 0.23 
4 4.48 ± 0.55 4.71 ± 0.33 
2 2.30 ± 0.38 2.03 ± 0.17 
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2.2.3.2 Method optimisation 
After establishing that dihydroethidium proved to be a viable fluorochrome, and provided a 
means in which total parasitaemia and parasite stages could be determined, the protocol 
was tailored to decrease the amount of stock parasite culture required.   
A 5% haematocrit parasite solution was deemed unfeasible for drug screening, as it not 
only required a large amount of parasite stock, even at lower parasitaemias, but also 
affected parasite viability during a 48 hour incubation period in a 96-well plate. A 
haematocrit solution of 1%, with a parasitaemia of 0.5% would have been ideal, as this 
would have correlated with that used in the [3H]-hypoxanthine incorporation assay (Section 
2.2.2.1). However, a 1% haematocrit solution was previously assessed in samples stained 
with thiazole orange (Section 2.2.3.1.1), and ruled out for high-throughput screening on the 
basis of the lengthy sample acquisition time (approximately 3 minutes per sample). 
Furthermore, microscopic analysis of a 0.5% parasite solution would be an unviable option; 
particularly with the decreased number of erythrocytes per field at a 1% haematocrit.   
To overcome this, a 2% haematocrit and 2% parasitaemia suspension, as used in the 
methodology of Verhaeghe et al. (2009), was then assessed. This proved to be acceptable 
in terms of sample acquisition time, i.e. 30-45 seconds to acquire 50 000 cells, as well as the 
volume of parasite stock required  for the duplicate samples for comparative analysis of  
flow cytometric and microscopic results. Following optimisation of the % haematocrit and 
% parasitaemia suspension suitable for analysis, three separate suspensions of 
predominantly ring-, trophozoite- and schizont-staged parasites were prepared. The ring-, 
trophozoite-, and schizont-staged samples prepared to a 2% parasitaemia, exhibited overall 
% parasitaemias of 1.66%, 2.83%, 2.14% and 1.68%, 2.45%, 2.17%, in the two 
methodologies, respectively.  
Thereafter,  the parasites stages were determined by optimal gating of each stage of the 
parasitic life cycle (Figure 2.12) and, finally, a protocol constructed wherein  % overall 
parasitaemia, parasite stage, and % of parasites in each stage could be assessed (Figure 
2.13). 
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Figure 2.12: An overlay of flow cytometric histograms of samples of uninfected 
erythrocytes (2% haematocrit), ring-, trophozoite- and schizont-staged 
parasites prepared to a 2% haematocrit and 2% parasitaemia. 
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Figure 2.13: The final protocol used for the determination of overall % parasitaemia, as 
well as parasite stage and % parasites present in each stage, when stained 
with dihydroethidium. 
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The overlap between the ring- and trophozoite-stages may have been due to the fact that 
ring- and early trophozoite-stage parasites have a single nucleus, and would exhibit similar 
dihydroethidium fluorescence. Whereas in the mid and late trophozoite-stage DNA 
synthesis begins, resulting in increased dihydroethidium fluorescence (Arnot et al., 2011). 
Similarly, the overlap between the trophozoite- and schizont-stages may have been 
attributed to an overlap between the late trophozoite- and early schizont-stages, with this 
transition being undetectable by blood smear analysis (Arnot et al., 2011). The overlap 
between the stages made it imperative to prepare a duplicate sample for blood smear 
analysis, in order to correlate it with the % of parasites present in each stage as obtained 
from flow cytometric analysis.      
Following method optimisation, the staining methodology was adapted for use in a 96-well 
plate, so that parallel [3H]-hypoxanthine incorporation assays and flow cytometric analysis 
of samples could be performed, in order to compare the results obtained from the two 
methodologies. 
2.2.3.3 Experimental protocol for the assessment of total parasitaemia 
Positive controls, chloroquine and quinine, as well as compounds from each drug class 
were selected for drug screening and IC50 value determination by flow cytometric analysis, 
based on [3H]-hypoxanthine incorporation assays performed at a 1% haematocrit and 0.5% 
parasitaemia. As the previous drug screenings and IC50 value determinations were carried 
out at this lower % haematocrit and % parasitaemia, and the optimal haematocrit and 
parasitaemia for flow cytometric analysis was determined to be at 2% for both haematocrit 
and parasitaemia, the [3H]-hypoxanthine incorporation assay (Section 2.2.2.1) was 
performed concurrently, at this optimal higher % haematocrit and % parasitaemia, for 
comparative purposes.  
Working solutions for IC50 value determination was calculated from the previous [
3H]-
hypoxanthine incorporation assays, whilst compensating for the higher haematocrit and 
parasitaemia. Those compounds that showed little or no activity at a final drug 
concentration of 100 µM were re-screened at 100 µM to confirm lack of antimalarial 
activity. 
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The preparation of 96-well plates for flow cytometric analysis paralleled those prepared for 
the [3H]-hypoxanthine incorporation assay (Section 2.2.2.1), with a few alterations in 
methodology. Working solutions of the positive controls and test compounds were 
prepared and serially diluted in incomplete experimental media; however, dilutions were 
carried out in duplicate, to allow for one sample to be used for flow cytometric analysis and 
one for blood smear analysis. Control wells included three wells: one erythrocyte control 
well and one parasite control well to be used for flow cytometric analysis; as well as one 
parasite control well to be used for blood smear analysis. The 2% haematocrit erythrocyte 
and 2% haematocrit and 2% parasitaemia solutions were prepared in complete culture 
media, as the interference of hypoxanthine present in culture media with isotope uptake 
was not a concern. Duplicate plates were prepared simultaneously for the [3H]-
hypoxanthine incorporation assay, according to the methodology described in Section 
2.2.2.1, to which 2% haematocrit erythrocyte and 2% haematocrit/2% parasitaemia 
suspensions prepared in complete experimental media were added.  
The plates were then incubated at 37 °C in a humidified candle jar. Following a 24 hour 
incubation period, 25 µl of incomplete culture media was added to each well of the plates 
for flow cytometric analysis, whereas the plates for the [3H]-hypoxanthine incorporation 
assay received 25 µl of the [3H]-hypoxanthine isotope, prepared (Section 2.2.2.1). The 
plates were then returned to the candle jar for a further 24 hour incubation period. 
Thereafter, the parasitic [3H]-DNA was harvested and quantified from the plates for the 
[3H]-hypoxanthine incorporation assay (Section 2.2.2.1).  
Whereas, from the plates for flow cytometric analysis, the wells reserved for blood smear 
analysis were removed and thin blood smears prepared, from which the overall % 
parasitaemia was obtained by counting 10 microscope fields, or the equivalent of 1000 
erythrocytes. These plates were then centrifuged at 1500 rpm for 5 minutes, the 
supernatant (200 µl) removed and replaced with dihydroethidium in sterile PBS (159 µM), 
before being gently shaken at 1500 rpm for 2 minutes, and incubated in a candle jar for 20 
minutes at 37 °C.  
The plates were centrifuged at 1500 rpm for 5 minutes, following the incubation period,  
and the supernatant removed and replaced with the same volume of sterile PBS (200 µl), 
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this was repeated three times. The samples were then transferred to flow cytometric tubes 
(BD) containing 1 ml of sterile PBS, as such, the final volume was 1.2 ml. The samples were 
acquired on a BD FACSCalibur™ flow cytometer, with argon laser excitation at 488 nm and 
detection at 610 nm, a total of 50 000 cells per sample were counted and analysed using BD 
CellQuest Pro™ and FlowJo (version 7.6.1) software (Figure 2.14). 
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Figure 2.14: Flow cytometric histogram overlays of the cell count versus the maximal 
fluorescence of dihydroethidium (FL2-H) of samples treated with varying 
concentrations of quinine, following a 48 hour incubation period.  
 
Thereafter, the overall % parasitaemia (pE) for each sample was obtained from the flow 
cytometric protocol (Figure 2.13), and % parasite growth calculated using the following 
equation: 
% Parasite growth = % pE of test sample or positive control (x100%)
% pE of parasite control
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2.2.3.4 Final experimental protocol used for the assessment of the stage-specific and 
morphological effects of the compounds on P. falciparum 
Working solutions of a compound from each drug class and a positive control, quinine, 
were prepared in incomplete experimental media so that their final concentrations were 
representative of their IC90, IC50 and IC25 values (concentrations required to inhibit parasite 
growth by 90%, 50% and 25%, respectively), as determined by construction of log sigmoid 
dose response curves of data generated by flow cytometric analysis (Section 2.2.3.3). IC90, 
IC50 and IC25 values were chosen in order to assess if the compounds exhibited any 
concentration-dependant effects, as well to ensure the optimal concentration was achieved 
at which their stage-specific and morphology effects were most evident. 
 The study was carried out in 25 cm3 culture flasks (BD), to provide an adequate volume for 
the frequent removal of samples for flow cytometric and blood smear analysis. Separate 
culture flasks were reserved for each drug concentration, as well as for erythrocyte and 
parasite controls, such that 600 µl of the test compound, positive control or incomplete 
experimental media was placed in the flask. To which, 5.4 ml of synchronised ring-stage 
parasites (2% haematocrit and 2% parasitaemia), or, in the case of the erythrocyte control, 
a 2% haematocrit solution was added.  
The flasks were then gassed (Section 2.1.1), sealed, and incubated at 37 °C. Prior to removal 
of the samples, the flasks were gently agitated to resuspend the erythrocytes. Samples (250 
µl) for flow cytometric and blood smear analysis were taken eight hourly during the ring- 
stage, and five hourly during the trophozoite- and schizont-stages, with the last sample 
taken approximately four hours post-invasion, or four hours into the next asexual cycle. 
Following removal of the samples, the flasks were gassed, sealed, and placed back in the 
incubator. The samples were then centrifuged at 1500 rpm for 5 minutes; thereafter, thin 
blood smears were prepared (Section 2.1.1) to determine the overall % parasitaemia, the % 
of parasites present in each stage, as well as any changes in parasite morphology.  
The staining procedure and flow cytometric acquisition and analysis of the samples was 
performed as described in Section 2.2.3.1.3. From the final flow cytometric protocol (Figure 
2.13), the % overall parasitaemia as well as the stage of parasites present in the sample 
could be determined, and confirmed with the results of the blood smear analysis.  
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2.2.3.5 Data analysis 
A total of 50 000 cells per sample were acquired using a BD FACSCalibur™ flow cytometer, 
with the following instrument settings: Forward Scatter (FSC-H), voltage E-1, amp gain 2, 
mode log; side scatter (SSC-H), voltage 263, amp gain 1, mode log; fluorescence 2 (FL-2), 
voltage 527, amp gain 1, mode log. The % overall parasitaemia was calculated using BD 
CellQuest Pro™  and FlowJo (version 7.6.1) software, based on gates constructed using 
unparasitised and parasitised erythrocyte samples. Gates were constructed to be 
representative of each stage of the parasitic life cycle, based on maximum dihydroethidium 
fluorescence (FL2-H) levels, from which the % of parasites in each stage could be 
determined, using the above software.  
Log sigmoid dose response curves were constructed, from which IC50 values were 
determined, using the Enzfitter® (version 1.05) software. For compounds exhibiting little or 
no antimalarial activity the % inhibition of parasite growth at 100 µM was obtained. All 
experiments were repeated, at least, in triplicate to produce a mean ± standard deviation. 
In order to determine if there were statistically significant differences  between IC50 values 
determined from flow cytometric analysis and the [3H]-hypoxanthine incorporation assay, 
an unpaired Students T-test, with p < 0.05 considered statistically significant was performed 
using  Graphpad Prism® (version 5) software. 
2.3 Antimalarial mechanisms of action 
Elucidating antimalarial mechanisms of actions is imperative, as target identification not 
only provides a means in which structure-activity relationships may be performed and the 
activity of the drug optimised, but also provides an indication as to how a novel compound 
may interact with another antimalarial drug with a known mechanism of action (Olliaro, 
2001).    
2.3.1. β-haematin inhibitory activity assay  
Inhibition of haemozoin formation is a validated antimalarial target, with antimalarial drugs 
such as chloroquine known to act in this manner (Section 1.3.1). The assay works on the 
principle that the synthetic molecule, β-haematin, retains the biological and chemical 
properties of the native malaria pigment, haemozoin, thereby providing a means of 
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quantifying the β-haematin inhibitory activity (BHIA) of compounds (Basilico et al., 1998; 
Egan et al., 2000).   
 A modified BHIA assay was used (Chemaly et al., 2007), wherein β-haematin was 
synthesised from haem under acidic conditions, similar to that in the parasitic food vacuole. 
2.3.1.1. Preparation of the solutions 
The test compounds, positive controls (chloroquine and quinine) and antimalarial reference 
agent (dihydroartemisinin) were prepared in either DMSO or MilliQ™ water to a 
concentration of 3.2 mM, in order to account for the eight times dilution factor of the 
experiment. A freshly made 1 mg/ml (1.53 mM) stock solution of haemin (Sigma) dissolved 
in DMSO, was used for each experiment and stored in the dark until needed. A 0.5 M 
acetate buffer (pH 4.4) was utilised in order to mimic the acidic conditions of the parasitic 
food vacuole and to initiate the reaction (Chemaly et al., 2007). The 0.5 M acetate buffer 
was prepared by adding 19.5 ml of a 0.5M sodium acetate solution to 30.5 ml of a 0.5 M 
glacial acetic acid solution, and the pH determined with a Beckman pH meter. The 0.5 M 
stock solutions of sodium acetate and glacial acetic acid were prepared as follows: 41.015 g 
of anhydrous sodium acetate (Sigma) was dissolved in 1 litre of MilliQ™ water and 14.3 ml 
of undiluted glacial acetic acid (specific gravity 1.05 kg/l; BDH) was added to MilliQ™ water 
to achieve a final volume of 500 ml. Prior to each experiment the buffer was diluted in a 1:1 
ratio in MilliQ™ water. A 10 M sodium hydroxide stock solution was prepared by dissolving 
40 g NaOH pellets (Merck) in 100 ml MilliQ™ water, 2 M and 1 M solutions were prepared 
by diluting the stock solution in MilliQ™ water. 
2.3.1.2 Experimental protocol 
Non-sterile 96-well plates (Greiner Bio-one) were prepared in a specific order: 25 µl of the 
test compound or positive control (400 µM) were plated in triplicate in the first row of the 
test plate and serially diluted, three times, in a 1:2 ratio in either MilliQ™ water or DMSO, 
so that the final volume of drug in each well was 12.5 µl. The last row of the test plate was 
set aside to act as the untreated β-haematin control and contained 12.5 µl of DMSO or 
MilliQ™ water was added. Thereafter, 12.5 µl haem (192 µM) was added to each well, 
followed by 25 µl MilliQ™ water and finally, 50 µl 0.5 M acetate buffer, to achieve a final pH 
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of 4.6-4.8 (Chemaly et al., 2007).  The plates were then incubated at 37 °C in a humidified 
environment for 24 hours. Thereafter, 100 µl of DMSO was added to each well, and the 
plate centrifuged at 3000 rpm for 10 minutes. Following centrifugation, 100-150 µl was 
removed and replaced with the same volume DMSO, a process that was repeated three 
times to ensure removal of any unreacted haemin (Figure 2.15). The wells were then 
washed twice with MilliQ™ water.   
Unreacted haemin
β-haematin crystals
 
Figure 2.15: Formation of β-haematin crystals from haemin. Unreacted haemin is soluble in 
DMSO, whereas β-haematin crystals do not dissolve in DMSO and remain 
intact. 
 
Finally, 100 µl was removed and substituted with the same volume of 2 M NaOH in order to 
dissolve the β-haematin crystals. The solution was then diluted in a 1:2 or 1:4 ratio in 1 M 
NaOH, so that the absorbance was < 1, and the absorbance read at 405 nm in a Labsystems 
iEMS microplate Reader MF, using  Ascent software (version 2.4). 
The inhibitory activities of the compounds, relative to the untreated control, were 
calculated using the formula below: 
% Inhibition of β-haematin formation = ABSControl – ABSCompound (x100%)
ABSControl  
2.3.1.3 Data analysis 
This constituted the methodology for the initial screening of compounds. For compounds 
exhibiting strong inhibitory activity at 100 µM, seven 1:2 serial dilutions were prepared, and 
log sigmoid dose response curves  constructed using the Enzfitter® (version 1.05) software, 
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from which IC50 values (concentration required to inhibit the formation of β-haematin 
formation by 50%) were determined. For compounds exhibiting little or no inhibitory 
activity, the % inhibition of β-haematin formation at 400 µM was recorded. All experiments 
were repeated at least in triplicate to produce a mean ± standard deviation. In order to 
determine if there was a statistically significant difference between a test compound and 
positive control, an unpaired Students T-test with p < 0.05 was performed using the 
Graphpad Prism® (version 5) software.  
2.3.2. Anti-oxidant activities 
The effects of ROS in malaria can be both harmful and beneficial depending on the amount 
and site of ROS production. Pro-oxidants acting directed against the parasite are highly 
effective in combating the infection. However, excessive ROS production outside of the 
infected red blood cell overcomes the hosts’ anti-oxidant defence systems and results in 
altered red blood cell deformability and lipid peroxidation of both parasitised and healthy 
red blood cells, contributing towards  anaemia and vascular damage seen in P. falciparum 
malaria (Delmas-Beauvieuz et al., 1995; Postma et al., 1996; Griffiths et al., 2001). Anti-
oxidants such as ascorbic acid and tocopherol have been shown to have protective effects 
by reinforcing the hosts defence systems, scavenging ROS and maintaining redox 
homeostasis, even in severe malaria (Postma et al., 1996; Gülçin et al., 2004; Quaye, 2008). 
Iron chelators may also act as anti-oxidants by chelating iron, thereby preventing the 
formation of ROS (Postma et al., 1996; Gülçin et al., 2004). Iron chelators also act to 
withhold iron from the parasite, thereby inhibiting the activity of enzymes to which iron is 
essential, including; enzymes involved in DNA synthesis, pyrimidine synthesis, glycolysis and 
haem synthesis amongst others (Postma et al., 1996; Mabeza et al., 1999).       
2.3.2.1 The 2,2-diphenyl-1-picrylhydrazyl  free-radical scavenging assay 
The 2,2-diphenyl-1-picrylhydrazyl (DPPH•) free-radical scavenging assay measures the 
ability of an anti-oxidant to scavenge the free-radical of DPPH•, converting it to the stable 
molecule, 2,2’-diphenyl-1-picrylhydrazine (DPPH-H). A decrease in absorbance at 540 nm 
corresponds to the colour change from purple (DPPH•) to yellow (DPPH-H), as the free-
radical is scavenged (Figure 2.16) (von Gadow et al., 1997; Jagetia et al., 2003; Gülçin et al., 
2004).  
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Figure 2.16: The conversion of DPPH• to DPPH-H by the donation of a hydrogen atom 
(Jagetia et al., 2003). 
   
2.3.2.1.1 Preparation of the solutions 
A 96.16 µM stock solution of DPPH• (Sigma) was prepared in HPLC grade methanol 
(Rochelle Chemicals), and stored in the dark at 4 °C for a maximum period of a week.   
The test solutions, antimalarial reference agents (chloroquine, quinine and 
dihydroartemsinin); as well as the positive control, ascorbic acid (Riedel de Haen), were 
prepared in either DMSO or MilliQ™ water to a starting concentration of 1.2 mM, in order 
to account for the five times dilution factor of the experiment.   
2.3.2.1.2 Experimental protocol 
Test compounds, antimalarial reference agents, and ascorbic acid were initially screened at 
a concentration of 240 µM or a 3:1 ratio of drug: DPPH•. This was achieved by pipetting 25 
µl of the 1.2 mM solution into triplicate wells of a non-sterile 96-well plate and adding 
DPPH• (100 µl) to the test wells, or HPLC grade methanol (100 µl) to colour control wells in 
order to negate the effects of colour interference by the compounds. Wells containing 
DMSO or MilliQ™ water (25 µl) and DPPH• (100 µl) were included as a 100% DPPH• control; 
whereas wells containing 25 µl DMSO or MilliQ™ water and 100 µl HPLC grade methanol 
were included as blanks. The plates were then incubated at room temperature, in the dark 
for 30 minutes. Thereafter, the absorbance was read at 540 nm in a Labsystems iEMS 
microplate Reader MF, using Ascent software (version 2.4). The free-radical scavenging 
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activities of the compounds were expressed as the percent decrease in the absorbance 
(scavenging activity) when compared to the DPPH• control, using the formula below: 
% Scavenging activity =  (ABSDPPH• control – ABSBlank) - (ABSCompound – ABSColour control/Blank)   (x100%)
(ABSDPPH• control – ABSBlank)
 
2.3.2.1.3 Data analysis 
Compounds that exhibited over 50% DPPH• free-radical scavenging activity in the initial 
screening were serially diluted seven times, in either DMSO or MilliQ™ water. Following the 
above protocol, IC50 values (concentrated at which 50% of the free-radical of DPPH
• was 
scavenged) were calculated using the Enzfitter® software.  In the case of compounds 
exhibiting activity of less than 50% at 240 µM, the % free-radical scavenging activity at 240 
µM was recorded. All experiments were repeated, at least, in triplicate to produce a mean 
± standard deviation. In order to determine if there was a statistically significant difference 
between a test compound, antimalarial reference agent and the positive control an 
unpaired Students T-test with p < 0.05 was performed, using the Graphpad Prism® (version 
5) software. 
2.3.2.2 Iron chelating activity 
The iron chelating activity assay works on the principle that the test compound was capable 
of binding ferrous iron, thereby  preventing  ferrozine-Fe2+ complex formation, with a 
resultant decrease in the red colour of the complex corresponding  to a decreased 
absorbance at 550 nm (Gülçin et al., 2004; Zhan et al., 2006). The decrease in absorbance 
thereby provides a manner in which the iron chelating activity of the compound may be 
determined. 
2.3.2.2.1 Preparation of the solutions 
The test solutions, antimalarial reference agents, chloroquine, quinine and 
dihydroartemsinin, as well as the positive control, ethylenediaminetetraacetic acid (EDTA; 
Rochelle Chemicals), were prepared in either DMSO or MilliQ™ water to a concentration of 
1.5 mM, in order to account for the 7.5 times dilution factor of the experiment.   
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A 649 µM ammonium acetate (Fluka) solution was prepared in MilliQ™ water, and stored at 
room temperature until needed. A 1.2 mM ferrozine (3-[2-pyridyl]-5,6-diphenyl-1,2,4-
triazine; Fluka) solution was prepared in MilliQ™ water and stored in the dark, at room 
temperature until needed. A 0.48 mM ferrous chloride solution (FeCl2.4H2O; Fluka) was 
freshly prepared in the ammonium acetate solution, for each experiment, and stored in the 
dark until just before use. 
2.3.2.2.2 Experimental protocol 
Test compounds, antimalarial reference agents, and EDTA were plated out (20 µl), in 
triplicate wells in a non-sterile 96-well plate. To which ferrous chloride (30 µl) and ferrozine 
(100 µl) were added, providing a drug concentration of 200 µM/well or a 2:1 ratio of drug: 
ferrous chloride.  In the case of compounds possessing a background colour, additional 
wells were plated, to which ferrous chloride (30 µl) and MilliQ™ water (100 µl) were added.  
Experimental controls included: eight 100% ferrozine-Fe2+ complex formation wells, which 
contained DMSO or MilliQ™ water (20 µl), ferrous chloride (30 µl) and ferrozine (100 µl); as 
well as four blank wells, which contained DMSO or MilliQ™ water (20 µl), ferrous chloride 
(30 µl) and MilliQ™ water (100 µl). The test plate was left to incubate at room temperature 
in the dark for 30 minutes. Thereafter, the absorbance was read at 540 nm in a Labsystems 
iEMS microplate Reader MF with Ascent software (version 2.4). 
The percentage iron chelating activity of the test compounds, antimalarial reference agents 
and EDTA were calculated using the following equation: 
% Iron chelating activity = (ABSControl - ABSBlank) – (ABSCompound – ABSColour control/Blank) (x100%)
(ABSControl - ABSBlank)  
2.3.2.2.3 Data analysis 
Compounds exhibiting over 50% metal chelating activity in the initial screening at 200 µM 
were serially diluted in a 1:2 ratio, seven times, in either DMSO or MilliQ™ water, and the 
IC50 value (concentration at which 50% of Fe(II) was chelated) calculated using the 
Enzfitter® software.  In the case of compounds exhibiting activity of less than 50% at 200 
µM, the % chelating activity at 200 µM was recorded. All experiments were repeated, at 
least, in triplicate to produce a mean ± standard deviation. In order to determine if there 
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was a statistically significant difference between a test compound, antimalarial reference 
agent and the positive control, an unpaired Students T-test with p < 0.05 was performed 
using the Graphpad Prism® (version 5) software. 
2.4 Red blood cell toxicity assay 
Distinct morphological changes in the red blood cell membrane, such as membrane 
internalisation or externalisation occur during the process of haemolysis, with compounds 
exhibiting differing effects on the rate and severity of the haemolysis (Aki and Yamamoto, 
1991). In this respect, the effects on the stability of the red blood cell membrane provide an 
indication of the ability of a drug to cause drug-induced haemolysis (Aki and Yamamoto, 
1991; Sharma and Sharma, 2001).  The haemolytic activity of compounds may be assessed 
by an in vitro method, wherein healthy red blood cells are treated with differing 
concentrations of a drug, with the amount of haemoglobin released by the red blood cell 
indicating the degree of haemolysis (Sharma and Sharma, 2001). 
2.4.1 Preparation of the solutions 
Solutions of the test compounds, antimalarial reference agents (chloroquine, quinine and 
dihydroartemisinin); as well as the positive haemolytic control, Triton™ X-100 (Sigma), were 
all prepared in incomplete experimental media to concentrations 10 times higher than that 
of the final concentration, in order to account for the dilution factor of the experiment. A 
1% haematocrit of red blood cells was prepared in complete experimental media (Section 
2.2.2.1) with red blood cells no older than two days utilised to ensure that the red blood 
cell membrane was not compromised. 
2.4.2 Experimental protocol 
A modified in vitro haemolytic assay was followed, wherein the experimental set up was 
that of the [3H]-hypoxanthine incorporation assay (Section 2.2.2.1).  
The 1 mM and 500 µM solutions of test compounds and antimalarial reference agents were 
plated out (25 µl) in duplicate, in a sterile 96-well plate, with extra wells plated for 
compounds with a background colour. Experimental controls included: a positive Triton™ X-
100-induced haemolysis control; as well as negative haemolysis and media controls, to 
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which incomplete experimental media (25 µl) was added. Complete experimental media 
(200 µl) was added to the background and media control wells; whereas the red blood cell 
suspension (200 µl) was added to the experimental wells, as well as the positive and 
negative haemolysis control wells.  
The plate was then incubated at 37 °C in a humidified candle jar for 24 hours, thereafter, 25 
μl of incomplete experimental media was added to each well, and the plate returned to the 
candle jar for a further 24 hour incubation period. Following the 48 hour exposure period, 
the plate was sealed with a microplate sealer (Nunc), and shaken at 1500 rpm for 5 minutes 
to disrupt the red blood cell pellet. Thereafter, the plate was centrifuged at 1500 rpm for 5 
minutes. The supernatant (100 µl) was then removed and plated out into a non-sterile 96-
well plate. In the case of the positive Triton™ X-100-induced haemolysis control  and 
compounds exhibiting haemolytic activity, the supernatant was diluted in PBS (pH 7.5) at a 
1:2 or 1:4 ratio, to a final volume of 100 µl, in order to ensure the that absorbance was < 1. 
Finally, the latter plate was left to stand at room temperature for 10 minutes, before being 
gently shaken at 1000 rpm for 2 minutes, and the absorbance read at 412 nm in a 
Labsystems iEMS microplate Reader MF, with Ascent software (version 2.4). The 
percentage haemolysis was calculated using the formula below: 
% Haemolysis = (ABSCompounds – ABSCC/MC) – (ABSNC - ABCMC) (x100%)
(ABSPC – ABSNC)  
Where: 
ABSCC/MC = mean absorbance of the colour control or media control wells 
ABSNC = mean absorbance of the negative red blood cell lysis control wells 
ABSPC = mean absorbance of the Triton™ X-100-induced haemolysis control 
2.4.3 Data analysis 
For each experiment, two replicates of each concentration (100 µM and 50 µM/well) were 
obtained. Experiments were repeated, at least, in quadruplicate to produce a mean ± 
standard deviation. For compounds exhibiting haemolytic activity of < 50% at 100 µM, the 
% haemolysis was recorded. For compounds exhibiting haemolytic activity of > 50% at 50 
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µM, IC50 values (concentration at which 50% haemolysis occurred) were calculated using 
the Enzfitter® software.  
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CHAPTER 3: THE ANTIMALARIAL PROPERTIES OF METRONIDAZOLE-
THIOSEMICARBAZONE ANALOGUES 
3.1 Introduction 
3.1.1 Metronidazole 
Metronidazole, 1-(2-hydroxyethyl)-2-methyl-5-nitroimidazole, (Figure 3.1a) is used to treat 
a variety of bacterial and protozoal infections, such as bacterial vaginosis, amoebic 
dysentery, trichomoniasis and giardiasis (Rossiter, 2010). It exhibits good oral availability, is 
widely distributed in body fluids and tissues and has a favourable side effect profile; 
exhibiting selective toxicity against microorganisms due to a lack of conversion to its 
cytotoxic form in mammalian cells (Jenks and Edwards, 2002; Mendz and Mégraud, 2002). 
However, sensory disturbances and peripheral neuropathies have been reported at high 
doses and following prolonged administration (Athar et al., 2005). Metronidazole exerts its 
effects via the inhibition of nucleic acid synthesis, by causing DNA oxidation resulting in 
strand breakages and cell death (Edwards, 1993; Mendz and Mégraud, 2002). Following 
diffusion into the cell, the 5-nitro group of metronidazole is reduced, via interactions with 
redox systems such as ferrodoxins or flavodoxins, to form the cytotoxic nitro radical and 
other reduction products which cause single and double-strand DNA breakage and DNA 
helix destabilisation (Edwards, 1993; Hoffman et al., 1996; Mendz and Mégraud, 2002).   
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Figure 3.1: The chemical structure of metronidazole (a) and the basic thiosemicarbazone       
structure (b). Where: R1 = aryl, alkyl or heterocyclic group; R2 = H, aryl, alkyl 
group; R3 and R4 = H, alkyl, aryl or heterocyclic group (Chellan et al., 2010). 
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3.1.2 Thiosemicarbazones 
Thiosemicarbazones (Figure 3.1b) are of considerable clinical interest, with compounds of 
the thiosemicarbazone structure possessing antidepressant, psychoanaleptic and hypnotic 
properties; whilst also displaying antibacterial, anticancer, antifungal and antimalarial 
activity (Greenbaum et al., 2004; Khan et al., 2008; Chellan et al., 2010). It appears as if 
they exert their biological activity through their thiourea moiety, which contains donor 
atoms that are capable of forming complexes with transition metals such as iron, copper 
and zinc (Dilović et al., 2008; Chellan et al., 2010; Hancock et al., 2011). The presence of 
iron in the active sites of enzymes involved in a wide variety of metabolic processes has 
propelled the search for compounds capable of acting as iron chelators (Rodriguez-Lucena 
et al., 2011).  
Triapine®, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, is one such compound 
currently in Phase II clinical trials as an anticancer agent, with its efficacy attributed to its 
strong binding affinity for Fe3+ (Mackenzie et al., 2007; Rodriguez-Lucena et al., 2011). One 
such metabolic process relying heavily on iron-containing enzymes is cell division. 
Ribonucleotide reductase is an enzyme involved in DNA synthesis, with the inhibition of this 
enzyme resulting in the depletion of nucleotides needed for cell division and DNA repair 
(Mackenzie et al., 2007; Dilović et al., 2008).  
Another possible mechanism of the anticancer properties of thiosemicarbazones is the 
alkylation of thiol residues of topoisomerase-II-DNA complexes, leading to stabilisation of 
these cleavage complexes (Dilović et al., 2008). Recent evidence has also pointed to the 
redox effects of the Triapine®-Fe3+ complex. Studies with copper-chelated 
thiosemicarbazones have shown that these complexes were capable of depleting GSH and 
forming reactive oxygen species, thereby inducing cell death (Hancock et al., 2011).  
Nitroaromatic compounds have shown activity against P. falciparum via the formation of 
ROS, mediated by flavoenzyme redox cycling (Grellier et al., 2001). The parasite is 
particularly vulnerable to attack by free-radicals and is under constant oxidative stress from 
the hosts’ immune system and haemoglobin breakdown; but possesses limited anti-oxidant 
capabilities (Müller, 2004). In this manner, a compound such as metronidazole, which may 
be activated within the microaerobic environment of the parasite and capable of forming 
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DNA damaging intermediates with an affinity for AT rich regions (Edwards, 1993) may be an 
effective antimalarial agent. The purpose of synthesising metronidazole-thiosemicarbazone 
analogues was to examine if hybridisation of metronidazole with the thiosemicarbazone 
scaffold could produce compounds acting in a synergistic manner to inhibit parasite growth 
by inducing DNA damage, as well as inhibit other crucial metabolic processes such as haem 
degradation and biosynthesis pathways. 
The objectives of this chapter were to: 
 Determine the antimalarial properties of metronidazole-thiosemicarbazones 
analogues 
 Determine the pharmacological interactions of lead compounds when combined 
with quinine or dihydroartemisinin. 
 Examine the stage-specific and morphological effects of a lead compound on 
parasite development. 
 Elucidate possible antimalarial mechanisms of action of the compounds. 
 Test for haemolytic activity as an indication of toxicity. 
3.2 Materials and methods 
3.2.1 Chemical synthesis and structural verification 
The compounds were acquired from Professor A. Azam, Department of Chemistry, Jamia 
Millia Islamia, New Delhi, India. The analogues (1-8) were synthesised as depicted in Figure 
3.2. Intermediate A was formed by the reaction of metronidazole with 
terepthaldialdehyde-monodiethylacetal, following which it was dissolved in 
tetrahydrofuran  and recrystallised in ethanol to form intermediate B (Figure 3.2) (Abid et 
al., 2008). Thereafter, intermediate B was condensed with various N4 cyclic and aromatic-
substituted thiosemicarbazides to produce the metronidazole-thiosemicarbazone 
analogues (Table 3.1) (Abid et al., 2008).  
The compounds were found to be stable both in solution as well as in their solid form, with 
structural analysis carried out by infrared, electronic, 1H and 13C nuclear magnetic 
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resonance and purity determined by thin layer chromatography and elemental analysis 
(Abid et al., 2008). 
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Figure 3.2: The synthesis of metronidazole-thiosemicarbazone analogues. (i) Sodium 
methoxide, DMSO, methanol, room temperature; (ii) HCl, tetrahydrofuran, 50 
°C; (iii) ethanol, 80 °C, reflux (Abid et al., 2008). 
 
3.2.2 Pharmacological evaluation 
The in vitro antimalarial activity of the analogues (Table 3.1), metronidazole and positive 
controls were assessed using the tritiated hypoxanthine incorporation (Section 2.2.2.1) and 
flow cytometry (Section 2.2.3.3) methodologies. The most active compounds were selected 
for combination studies with quinine and dihydroartemisinin (Section 2.2.2.3), as well as for 
stage sensitivity and parasite morphology studies (Section 2.2.3.4). The β-haematin 
inhibitory activity (Section 2.3.1.2), DPPH• free-radical scavenging (Section 2.3.2.1.2) and 
iron chelation assays (Section 2.3.2.2.2) were carried out to identify possible antimalarial 
mechanisms of action of the analogues. The red blood cell toxicity assay was performed to 
give an indication of the toxicity of the analogues (Section 2.4.2).  Due to the fact that only 
small amounts of the analogues were received and no more could be made available, some 
studies could not be completed on all analogues and, in some cases, lead compounds had 
to be substituted with the next most active analogue available. 
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Table 3.1: The metronidazole-thiosemicarbazone analogues evaluated for antimalarial 
activity. 
Chemical name Chemical 
code 
N4 (R-group) 
substitution 
(Figure 3.2) 
1-(4-(2-(1-(2-Hydroxyethyl)-5-nitro-1H-imidazol-2-
yl)vinyl) benzylidene)-4-cyclooctylthiosemicarbazide 
Y-1 Cyclooctyl amine 
1-(4-(2-(1-(2-Hydroxyethyl)-5-nitro-1H-imidazol-2-
yl)vinyl) benzylidene)-4-p-tolylthiosemicarbazide 
Y-2 p-Toluidine 
4-(2-Chlorobenzyl)-1-(4-(2-(1-(2-hydroxyethyl)-5-
nitro-1H-imidazol-2-yl)vinyl)benzylidene)-thiosemi-
carbazide 
Y-3 2-Chloro-benzyl 
amine 
1-(4-(2-(1-(2-Hydroxyethyl)-5-nitro-1H-imidazol-2-
yl)vinyl) benzylidene)-4-cyclohexylthiosemicarbazide 
Y-4 Cyclohexyl amine 
N’-(4-(2-(1-(2-Hydroxyethyl)-5-nitro-1H-imidazol-2-
yl)vinyl) benzylidene)pyrrolidine-1-carbo-thio-
hydrazide 
Y-5 Pyrrolidine 
N’-(4-(2-(1-(2-Hydroxyethyl)-5-nitro-1H-imidazol-2-
yl)vinyl) benzylidene)-4-methylpiperidine-1-carbo-
thio-hydrazide 
Y-6 4-Methyl 
piperidine 
N’-(4-(2-(1-(2-Hydroxyethyl)-5-nitro-1H-imidazol-2-
yl)vinyl) benzylidene)-3,4-dihydroquinoline-1(2H)-
carbothiohydrazide 
Y-7 1,2,3,4-Tetra-
hydroquinoline 
1-(4-(2-(1-(2-Hydroxyethyl)-5-nitro-1H-imidazol-2-
yl)vinyl) benzylidene)-4-benzyl-4-methylthiosemi-
carbazide 
Y-8 N-Methyl benzyl 
amine 
 
3.3 Results 
3.3.1 In vitro antimalarial and haemolytic activity 
The criteria for the classification of a compound as being active against P. falciparum 
depend on the study design and the class of compounds. Generally, compounds exhibiting 
activity in the order of less than 1-5 µM in initial drug screenings necessitate further study, 
with compounds exhibiting activity similar to existing antimalarial drugs such as quinine, or 
compounds active in the low nanomolar range considered potent (Fidock et al., 2004). For 
the purpose of this study; compounds with an IC50 value ≤ 5 µM were considered active, 
compounds with an IC50 value of between 5 and 10 µM were considered promising, 
compounds with an IC50 value of between 10 and 50 µM considered moderately active, 
   
70 
 
compounds with an IC50 value of between 50 and 100 µM considered to have low activity, 
and finally, compounds with an IC50 value ≥ 100 µM were considered to be inactive.  
As seen in Table 3.2, the compounds exhibited promising antimalarial activity against P. 
falciparum, with six compounds inhibiting parasite growth in a dose-dependant manner, 
with IC50 values below 10 µM (Figure 3.3). Compounds Y-1 and Y-3 were the most active 
(IC50 values: 2.99 ± 0.16 µM and 2.83 ± 0.20 µM, respectively); however they were 19.9- 
and 18.9-fold less active than quinine (IC50 value: 0.15 ± 0.012 µM). Compounds Y-5 and Y-6 
showed weak antimalarial activity, with parasitic growth inhibition of 51.91 ± 6.03% at 
100µM and an IC50 value of 71.07 ± 8.97 µM, respectively (Table 3.2). Metronidazole 
showed very little antimalarial activity, and was only capable of inhibiting parasite growth 
by 22.94 ± 5.61% at 100 µM.  
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Figure 3.3: Log sigmoid dose-response curves of compound Y-3 compared to quinine and 
dihydroartemisinin. 
 
The haemolytic activity of the derivatives were negligible (Table 3.2), ranging from 0.55 ± 
0.18% to 1.97 ± 0.56% at 100 µM and were comparable to that of quinine (1.22 ± 0.98% at 
100µM). Dihydroartemisin proved to be highly haemolytic at 100 µM (100.00 ± 5.29%), 
however, at 50 µM only 1.13 ± 0.51% haemolysis was observed. Furthermore, due to its 
potent antimalarial activity (IC50 value: 0.0014 ± 0.00020 µM), the dosage at which 
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haemolysis would be observed would be well in excess of that required to inhibit parasite 
growth. 
Table 3.2: The in vitro antimalarial activity, as determined by the [3H]-hypoxanthine 
incorporation assay (1% haematocrit and 0.5% parasitaemia) and haemolytic 
effects of metronidazole-thiosemicarbazone analogues and reference agents  
  (n = 5). 
Compound 
Antimalarial activity % Haemolytic activity 
 
(100µM ± s.d.) 
IC50 value 
(µM ± s.d.) 
% inhibition 
(100µM ± s.d.) 
Y-1 2.99 ± 0.16 
 
1.12 ± 0.97 
Y-2 7.55 ± 0.49 
 
1.15 ± 0.60 
Y-3 2.83 ± 0.20 
 
1.49 ± 1.13 
Y-4 6.92 ± 0.68 
 
1.97 ± 0.56 
Y-5 > 100 51.91 ± 6.03 0.72 ± 0.92 
Y-6 71.07 ± 8.97 
 
0.99 ± 0.63 
Y-7 3.79 ± 0.72 
 
0.80 ± 0.79 
Y-8 8.74 ± 0.30 
 
0.55 ± 0.18 
Metronidazole > 100 22.94 ± 5.61 0.78 ± 0.32 
Chloroquine 0.0064 ± 0.00019 
 
0.72 ± 0.32 
Quinine 0.15 ± 0.012 
 
1.22 ± 0.98 
Dihydroartemisinin 0.0014 ± 0.00020 
 
100.00 ± 5.29 
 
In order to confirm if antimalarial activity as determined by flow cytometric analysis 
produced results similar to that of the [3H]-hypoxanthine incorporation assay; compounds 
Y-3, Y-7 and Y-5 as well as reference agents were selected for comparison, wherein the % 
haematocrit and % parasitaemia were 2-fold and 4-fold, respectively, higher than that 
utilised to obtain the values in Table 3.2. On comparison of the IC50 values obtained by the 
two methodologies (Table 3.3), all show statistically significant differences (p < 0.05), with 
the exception of chloroquine. The greatest discrepancy occurred between the IC50 values of 
quinine as determined by flow cytometric analysis (IC50 value: 0.058 ± 0.0026 µM) and the 
[3H]-hypoxanthine incorporation assay (IC50 value: 0.15 ± 0.0014 µM) (Table 3.3). The IC50 
values for compounds Y-3 and Y-7 as obtained by flow cytometry (IC50 values: 12.35 ± 0.84 
µM and 10.35 ± 0.41 µM, respectively) were 1.7- and 1.4-fold higher than those obtained 
from the tritiated hypoxanthine assay (IC50 values: 7.46 ± 0.41µM and 7.45 ± 0.21 µM, 
respectively). The % growth inhibition of compound Y-5 in the two methodologies was 
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similar, 36.10 ± 5.28% and 39.60 ± 3.39% (Table 3.3). The % growth inhibition of 
metronidazole showed a slight difference, exhibiting 6.00 ± 2.21% inhibition in the [3H]-
hypoxanthine incorporation assay and 12.74 ± 4.53% inhibition in the flow cytometric 
analysis.  
Table 3.3: Comparison of the IC50 values and % inhibition of parasite growth at a 2% 
haematocrit and 2% parasitaemia, as determined by the [3H]-hypoxanthine 
incorporation assay and flow cytometric analysis. Values in parenthesis indicate 
the % inhibition of parasite growth at 100 µM (n = 7). 
Compound 
Antimalarial activity 
[3H]-hypoxanthine 
incorporation assay 
Flow cytometric analysis 
IC50 value: µM ± s.d. 
(% inhibition at 100 μM) 
IC50 value: µM ± s.d. 
(% inhibition at 100 μM) 
Y-3 7.46 ± 0.41 12.35 ± 0.84 
Y-7 7.45 ± 0.21 10.35 ± 0.41 
Y-5 > 100 (36.10 ± 5.28%) > 100 (39.60 ± 3.39%) 
Metronidazole > 100 (6.00 ± 2.21%) > 100 (12.74 ± 4.53%) 
Chloroquine 0.012 ± 0.0013 0.014 ± 0.00068 
Quinine 0.15 ± 0.0014 0.058 ± 0.0026 
 
3.3.2 Combination studies 
The isobolograms of Figure 3.4 depict the additive interactions of Y-3 and Y-7 in 
combination with quinine and dihydroartemisin. The ΣFIC for each experiment was 
calculated from FIC values generated for each data point (Appendix C). The ΣFIC values for 
compound Y-3 and quinine (1.14 ± 0.09), compound Y-3 and dihydroartemisinin (1.29 ± 
0.075), compound Y-7 and quinine (1.21 ± 0.14) and compound Y-7 and dihydroartemisinin 
(1.14 ± 0.057) were calculated over three experiments. The ΣFIC values confirm the additive 
interaction depicted in the isobolograms, falling well within the guidelines of an additive 
interaction, wherein the ΣFIC50 range lies between 0.5 and 2 (Section 2.2.2.3). 
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Figure 3.4: The additive pharmacological interactions between compounds Y-3 and Y-7 
when combined with quinine and dihydroartemisinin (n = 3).  
 
3.3.3 Morphological and stage-specific effects of compound Y-3 
The morphological and stage-specific effects of compound Y-3 were assessed at its IC90 (30 
µM), IC50 (12 µM) and IC25 (7 µM) values, and compared to that of quinine. When treated 
with compound Y-3 at its IC90 value, parasites showed no progression past the late ring-
stage, appeared to be smaller (pyknotic) than the untreated control, and exhibited intense 
staining, similar to so-called ‘crisis forms’, which may be an indication of chromatin 
condensation and cell shrinkage (Deponte and Becker, 2004; Lopez et al., 2010).  
Compound Y-3 at its IC25 value produced little stage-specific or morphological effects. 
However, a slight lag in parasite development was noted, with most of the treated 
parasites appearing as late trophozoites when the untreated control was in the early to mid 
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schizont-stage, and most treated parasites appearing as early-mid schizonts when the 
parasite control was in the late schizont- and early ring-stages. An examination of the blood 
smears four hours post-invasion or four hours into the next parasitic showed that the early-
mid schizonts had progressed through the cycle, with early rings evident.   
The stage-specific and morphological effects of compound Y-3 at its IC50 value were similar 
to those of its IC90 value, and are depicted in Figures 3.5 and 3.6.  
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Figure 3.5: The effects of compound Y-3 and quinine at their IC50 (12 µM) and IC90 (200 nM) 
values, respectively, on parasite morphology and development. Indicating 
morphological changes:  Haemozoin (red arrows), ’crisis forms’ (black arrows), 
possible DNA fragmentation (green arrows) (n = 1). 
 
   
75 
 
C
el
l c
o
u
n
t
C
el
l c
o
u
n
t
Control
Compound Y-3
Quinine
A
Early trophozoites
A
Mid-late 
trophozoites
B
Early-mid 
schizonts
C
Late schizonts and
early rings
D
 
Figure 3.6: The effects of compound Y-3 (black line) and quinine (blue line) at their IC50 (12 
µM; left) and IC90 values (200 nM; right), respectively, on parasite development 
compared to the untreated control (red line) (n = 1). 
  
No notable changes in parasite morphology occurred during the ring-stage. However, upon 
progression from the late ring- to trophozoite-stage, a distinct lack of haemozoin formation 
was visible when compared to the control (Figure 3.5a). When compared to parasite 
controls of mid to late trophozoites, early to mid schizonts, and late schizonts and early 
rings, the treated parasites appeared smaller (pyknotic) (Deponte and Becker, 2004; Lopez 
et al., 2010) and exhibited intense staining. A parasite count revealed that when the 
untreated control was in the early to mid schizont-stage, 82% of the compound Y-3-treated 
parasites remained in the early trophozoite-stage (Figure 3.5c), and when the untreated 
control proceeded into the late schizont- (29%) and early ring-stages (71%), 28% of 
compound Y-3 treated parasites were in the ring-stage, 56% were halted in the early 
trophozoite-stage, and 16% were present as mid to late schizonts (Figure 3.5d). When 
examining the histogram overlays (Figures 3.6a,b,c,d) of compound Y-3 at its IC50 value 
along with the parasite control, it can be seen that parasitic development past the early 
trophozoite-stage (Figure 3.6a) was affected.  
   
76 
 
The stage-specific and morphological effects of quinine were most visible at its IC90 value 
(200 nM) and are depicted in Figures 3.5 and 3.6.  The treated parasites progressed through 
the ring-stage into the early trophozoite-stage with no notable morphological changes; 
haemozoin crystals were clearly visible in the early trophozoite-stage (Figure 3.5a). When 
compared to the mid-late trophozoite parasite control, it appeared as if parasitic 
development was stalled in the mid trophozoite-stage (Figures 3.5b and 3.6b). When 
comparing treated parasites to the early-mid schizont control, a lag in parasitic 
development was evident, with 87% of the quinine treated parasites present in the mid to 
late trophozoite-stage (Figures 3.5c and 3.6c). Finally, as the parasite control progressed 
into the late schizont- (29%) and early ring-stages (71%), 58% of the quinine treated 
parasites remained in the trophozoite-stage with 17% and 25% of parasites in the early 
ring- and late schizont-stages, respectively (Figure 3.6d). Additionally, quinine treated 
parasites exhibited signs of possible DNA fragmentation (Figure 3.5d) (Deponte and Becker, 
2004), although this would need to be confirmed by DNA gel electrophoresis or the TUNEL 
assay. When examining blood smears of treated parasites four hours post invasion, or four 
hours into the next parasitic cycle, the treated parasites resembled that of Figure 3.5d, and 
did not progress into the ring-stage. In contrast, no distinct morphological and stage-
specific effects were noted at quinine’s IC50 (60 nM) or IC25 value (30 nM), with treated 
parasites progressing through the trophozoite-stage, where haemozoin formation was 
comparable to that of the untreated control. A slight lag in parasite development was 
evident, with treated parasites appearing mainly as late trophozoites when the untreated 
control was in the early-mid schizont stage. However, four hours into the next parasitic 
cycle early rings were evident indicating that the treated parasites had progressed through 
the cycle.  
3.3.4 Antimalarial mechanisms of action 
3.3.4.1 Inhibition of β-haematin formation 
All the analogues, with the exception of two (compounds Y-5 and Y-6), inhibited β-
haematin formation with IC50 values ranging from 19.08 ± 2.37 µM to 64.80 ± 6.61 µM 
(Figure 3.7). Compounds Y-5 and Y-6 only inhibited the formation of β-haematin by 26.46 ± 
5.72% and 61.73 ± 5.50% at 400 µM, respectively. When compared to chloroquine (IC50 
value: 29.64 ± 3.35 µM), all analogues were statistically less effective (p < 0.05) with the 
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exception of compound Y-3 (IC50 value: 19.08 ± 2.37 µM), which was more effective in 
inhibiting β-haematin formation (p > 0.05). When compared to quinine (IC50 value: 63.00 ± 
3.27 µM), all analogues, with the exception of compound Y-2, Y-5 and Y-6 were more 
potent inhibitors of β-haematin formation. Metronidazole and dihydroartemisinin did not 
inhibit the formation of β-haematin, where 100 µM inhibited 14.76 ± 2.94% and 7.46 ± 
2.27% of β-haematin formation, respectively.  
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Figure 3.7: The inhibitory activities of metronidazole-thiosemicarbazone analogues and 
antimalarial reference agents on parasite growth (lighter blue bar) and β-
haematin formation (darker blue bar)   (n = 6). 
 
3.3.4.2 Free-radical scavenging activity 
Of the five analogues tested for free-radical scavenging activity, all but one (compound Y-4) 
exhibited the ability to scavenge DPPH• with IC50 values below 100 µM (Table 3.4). The only 
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statistical difference between the analogues and ascorbic acid (IC50 value: 19.31 ± 2.62 µM) 
was with compound Y-3 (IC50 value: 80.00 ± 2.22 µM) (p value < 0.0001). Compounds Y-5, Y-
7 and Y-8 exhibited potent free-radical scavenging activity, with IC50 values less than 30 µM. 
Compound Y-4 as well as the controls, metronidazole, chloroquine, quinine and 
dihydroartemisinin exhibited poor free-radical scavenging activity at 240 µM (Table 3.4). 
Table 3.4: The free-radical scavenging and iron chelating activity of select metronidazole-
thiosemicarbazone analogues (n = 4). Values in parenthesis depict the % free-
radical scavenging activity at 240 µM and % iron chelating activity at 200 µM. 
N.D = not determined. 
Compound DPPH• free-radical scavenging 
IC50 value: μM ± s.d. 
(%  Activity at 240 μM) 
Fe2+ chelation 
IC50 value: μM ± s.d. 
(% Activity at 200 μM) 
Y-2 N.D. > 100 (0.01 ± 7.84%) 
Y-3 80.00 ± 2.22 > 100 (10.29 ± 4.16%) 
Y-4 > 100 (8.70 ± 2.48%) > 100 (0.01 ± 0.83%) 
Y-5 26.90 ± 4.18 > 100 (9.49 ± 2.98%) 
Y-7 26.06 ± 4.02 > 100 (13.46 ± 2.51%) 
Y-8 21.98 ± 0.56 > 100 (55.64 ± 9.31) 
Metronidazole > 100 (0.01 ± 1.38%) > 100 (0.01 ± 6.14%) 
Chloroquine > 100 (0.31 ± 3.28%) > 100 (70.68 ± 0.97%) 
Quinine > 100 (2.53 ± 1.17%) > 100 (0.01 ± 6.08%) 
Dihydroartemisinin > 100 (0.01 ± 2.70%) > 100 (0.01 ± 2.44%) 
EDTA N.D. 23.90 ± 1.83 
Ascorbic acid 19.31 ± 2.62 N.D. 
 
3.3.4.3 Iron chelation activity 
None of the analogues tested exhibited any significant iron chelating properties when 
compared to EDTA (IC50 value: 23.90 ± 1.83 µM) (Table 3.4).  
Compound Y-8 showed the greatest activity, chelating 55.64 ± 9.31% Fe(II) at 200 µM, 
whilst the remainder  of the analogues exhibited no more than 13.46 ± 2.51% chelating 
activity at 200 µM. Metronidazole, quinine and dihydroartemisinin exhibited no iron 
chelation properties at 200 µM, whilst chloroquine was capable of chelating 70.68 ± 0.97% 
Fe(II) at 200 µM (Table 3.4). 
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3.4 Discussion 
3.4.1 Antimalarial activity of metronidazole-thiosemicarbazone analogues 
The various side chains attached to the imidazole ring of metronidazole provided an 
opportunity to carry out various structural modifications, as well as to determine if 
metronidazole contributed to the overall pharmacological activity of the metronidazole-
thiosemicarbazone analogues. Considering the substitutions at the N4 position of the 
metronidazole-thiosemicarbazone analogues, the most active compounds were those 
possessing a 2-chloro-benzyl amine (compound Y-3), cyclooctyl amine (compound Y-1) or a 
1,2,3,4-tetrahydroquinoline (compound Y-7) substitution (Tables 3.1 and 3.2).  None of the 
metronidazole-thiosemicarbazone derivatives exhibited any toxicity towards the host red 
blood cell, with % haemolysis ranging from 0.55 to 1.97% at 100 µM (Table 3.2). Thus 
indicating that the antimalarial activity of the derivatives was as a result of a direct effect 
on the parasite, with the above substitutions conferring the greatest antimalarial activity. 
Thiosemicarbazones have elicited great interest due to their numerous biological activities 
and generally favourable toxicity profile; in this respect many studies have been conducted 
to investigate the antimalarial properties of thiosemicarbazones. One of the first studies 
showed that from a wide variety of compounds screened, only 2-acetylpyridine-4-phenyl-3-
thiosemicarbazone (Figure 3.8a) exhibited any antimalarial activity against Plasmodium 
berghei in mice (Klayman et al., 1979). Stucture-activity relationships based on this 
compound indicated that a 2-pyridylethylidene moiety on N4 was pivotal to the antimalarial 
activity, with antimalarial activity abolished when this moiety was replaced by another 
aromatic ring system (Klayman et al., 1979). The same study also found that an 
unsubstituted phenyl ring on N4 conferred increased antimalarial activity, whereas a 
substituted phenyl ring or linear aliphatic conferred little or no antimalarial activity 
(Klayman et al., 1979). 
A recent study conducted by de Oliveira et al. (2008) on the chloroquine-resistant W2 strain 
of P. falciparum, wherein the thiourea moiety was replaced by a carbonyl moiety, showed 
that the thiourea moiety was imperative to antimalarial activity. The same study also 
showed that substitution with an aliphatic moiety on N1 (Figure 3.8b) was also critical for 
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antimalarial activity, and that the substitution of an aromatic derivative on N1 proved to 
diminish activity (de Oliveira et al., 2008). 
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Figure 3.8: The chemical structures of thiosemicarbazones previously assessed for various 
pharmacological activities. a = Klayman et al. (1979); b = de Oliveira et al. 
(2008); c = Abid and Azam (2005), Abid et al. (2009). 
 
In contrast to the findings of Klayman et al. (1979) and de Oliveira et al. (2008), none of the 
compounds tested in this study were 2-pyridylethylidene substituted on N4, with the most 
active analogue, compound Y-3, containing a chloro-substituted phenyl ring. Similarly, none 
of the compounds in this study possessed aliphatic substitutions on N3, the equivalent of N1 
in the de Oliveira et al. (2008) study, yet displayed antimalarial activity.  The antimicrobial 
activity linked to substitution on N4 was verified when steroidal thiosemicarbazones were 
tested against various strains of bacteria, with acetoxy- and chloro-substituted cyclopentyl 
and cyclohexyl derivatives proving to be the most active (Khan et al., 2008). This was similar 
to the findings of this study wherein compound Y-3, a chloro-substituted cyclohexyl 
thiosemicarbazone derivative proved to be the most active. 
Previous studies on cyclised thiosemicarbazones (Figure 3.8c) possessing the same side 
chain substitutions as compounds Y-1, Y-2, Y-3, Y-5, Y-6 and Y-8 (Table 3.1; Figure 3.7) 
exhibited poor antimalarial activity against the chloroquine-resistant FCR-3 strain of P. 
falciparum, with IC50 values ranging from 26 µM to greater than 50 µM (C-T Chen; personal 
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communication). The decrease in antimalarial activity may be as a result of the different 
strain of P. falciparum used; however, the cyclised thiosemicarbazones exhibited no β-
haematin inhibitory activity in comparison to the metronidazole-thiosemicarbazone 
analogues, indicating the importance of the acyclic thiosemicarbazone moiety in 
antimalarial and β-haematin inhibitory activity. 
3.4.2 The effect of methodology on antimalarial evaluation 
A comparison of the IC50 values obtained by flow cytometric analysis and the [
3H]-
hypoxanthine incorporation assay (Table 3.3), at a 2% haematocrit and 2% parasitaemia 
revealed statistically significant differences (p < 0.05), with the exception of chloroquine. All 
compounds, with the exception of quinine, exhibited higher IC50 values in flow cytometric 
analysis when compared to those obtained by the [3H]-hypoxanthine incorporation assay 
(Table 3.3). 
A study conducted by Saito-Ito et al. (2001) comparing IC50 values obtained using the [
3H]-
hypoxanthine incorporation assay, microscopic examination and flow cytometric analysis, 
wherein acridine orange was used as a probe, also found no statistically significant different 
in the IC50 value of chloroquine in all methodologies. However, the IC50 value of 
pyrimethamine was greater as determined by flow cytometry and microscopic examination 
than by the [3H]-hypoxanthine incorporation assay. They attributed the differences to the 
fact that microscopic examination and flow cytometric analysis both take a direct measure 
of parasite number, with non-viable parasites counted in blood smears also reflected in the 
flow cytometric analysis, whereas the [3H]-hypoxanthine incorporation assay does not 
directly reflect parasite number, but parasite growth (Saito-Ito et al., 2001).      
The probe utilised in this study, dihydroethidium (hydroethidine) is oxidised into the DNA 
intercalating ethidium cation (E+) by dehydrogenase enzymes present only in viable cells, 
therefore hydroethidine fluorescence should only be attributed to viable parasites (Olive, 
1989; Grimberg, 2011). However, it has been shown that hydroethidine can react with H2O2 
to form E+, and can also react with coordinated Fe(III) as well as mitochondrial cytochromes 
to form an oxidation product with a similar excitation and emission profile to that of E+ 
(Papapostolou et al., 2004;  Zielonka and Kalyanaraman, 2010).   
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The discrepancies between the IC50 values obtained by flow cytometric analysis and the 
[3H]-hypoxanthine incorporation assay (Table 3.3) may, therefore, be attributed to  the 
spontaneous conversion of hydroethidine into E+ within the parasite, and subsequent 
intercalation of E+ into residual  DNA of non-viable parasites, or to fluorescent interference 
by the hydroethidine-coordinated Fe(III) or hydroethidine-cytochrome oxidation products.  
However, in the presence of DNA, the hydroethidine-coordinated Fe(III)/cytochrome 
oxidation products only produce a  7-fold increase in fluorescent intensity, whereas binding 
of E+ to DNA produces a 40-fold increase in fluorescent intensity, when compared to the 
unbound form (Papapostolou et al., 2004; Zielonka and Kalyanaraman, 2010).  
Therefore, the correlation between parasite growth as determined by microscopic and flow 
cytometric analysis and discrepancies between flow cytometric analysis and the [3H]-
hypoxanthine incorporation assay may be due to that fact that non-viable parasites 
counted in microscopic analysis were also reflected in flow cytometric analysis. Thereby 
producing IC50 values that were inflated when compared to those obtained by the [
3H]-
hypoxanthine incorporation assay; where the [3H]-hypoxanthine incorporation assay only 
measured the incorporation of [3H]-hypoxanthine into the DNA of viable parasites.  
In the case of quinine, the IC50 value obtained by flow cytometric analysis was far less than 
that obtained by the [3H]-hypoxanthine incorporation assay (Table 3.3). Quinine itself 
exhibits fluorescence and may have resulted in fluorescent interference. With a solution of 
quinine sulphate or quinine hydrochloride in dilute sulphuric acid used as a fluorescence 
standard for calibrating spectrofluorometers (Chen, 1967; Fletcher et al., 1973). However, 
samples of quinine hydrochloride prepared  to concentrations of 1 µM, 100 nM and 10 nM, 
exhibited excitation and emission spectra of 200-250 nm and 370-500 nm, respectively, 
when read on a Perkin Elmer LS50 luminescence spectrophotometer, differing from the 
excitation and emission spectra of dihydroethidium (Ex = 488 nm, Em = 610 nm). 
The discrepancy may be as a result of quinine, due to its weak base properties, altering the 
pH of the parasite cytosol, resulting in decreased fluorescence of dihydroethidium. With 
decreased fluorescence of ethidium bromide, the oxidised form of hydroethidine, noted at 
both acidic and alkaline pH values as a result of denaturation of double-stranded DNA and 
subsequent lack of intercalation of the probe (LePecq and Paoleti, 1967). 
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3.4.3 The antimalarial activity of metronidazole 
In contrast to the promising antimalarial activity of the metronidazole-thiosemicarbazone 
analogues, metronidazole exhibited disappointing antimalarial activity (Table 3.2), despite 
the fact that all indications pointed to the fact that metronidazole should act as an effective 
antimalarial agent. Metronidazole is activated under microaerobic oxygen concentrations, 
generating superoxide radicals that in the presence of transition metals form the DNA 
damaging hydroxyl free-radical, which attack DNA in AT rich regions. All of which is 
enhanced at an acidic pH (Edwards, 1993; Hoffman et al., 1996; Jenks and Edwards, 2002). 
Similarly, metronidazole exhibited no activity against the W2 and FCR-3 chloroquine-
resistant strains of P. falciparum (IC50 values greater than 800 µM and 1mM, respectively) 
(Pradines et al., 2001; R van Zyl; personal communication).  
The inactivity of metronidazole against P. falciparum may lie in fundamental differences of 
the fermentation processes used by metronidazole-sensitive organisms and the malaria 
parasite (Figure 3.9) (Ginsburg, 2011).  
 
Figure 3.9: The activation of metronidazole in the hydrogenosome of the trichomonad 
protozoa (Kulda, 1999). PFO: pyruvate:ferrodoxin oxidoreductase; HY: 
hydrogenase; 2Fe-2S: ferrodoxin.   
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The nitro group of metronidazole requires activation by accepting electrons from the 
electron carrier ferrodoxin, with the electrons originating from the decarboxylation of 
pyruvate by pyruvate:ferrodoxin oxidoreductase (PFO), the complex responsible for the 
fermentation of pyruvate to ethanol or acetate (Figure 3.9) (Samuelson, 1999; Jenks and 
Edwards, 2002; Land et al., 2002). 
Furthermore, the reduction of the nitro group establishes a transmembrane concentration 
gradient, facilitating the entry of metronidazole into the cell (Samuelson, 1999; Jenks and 
Edwards, 2002).  In this manner, the lack of activity against P. falciparum may be due to the 
fact that metronidazole requires activation by a redox system with a lower reduction 
potential than that of the drug (-486 mV), with a lack of activation resulting in the 
decreased accumulation of metronidazole in the parasite (Kulda, 1999; Mendz and 
Mégraud, 2002).  
Although P. falciparum possesses a strong reducing environment, as well as an apicoplast-
located ferrodoxin and ferrodoxin-NADP+ reductase which form a short electron chain for 
the production of isoprenoid precursors, it lacks the PFO complex, which may be necessary 
in producing a sufficient reduction potential for metronidazole activation (Balconi et al., 
2009; Ginsburg, 2011). With metronidazole resistance in trichomonads partially attributed 
to a decrease in PFO activity, and subsequent lack of activation of the drug (Kulda, 1999; 
Land et al., 2002). 
P. falciparum lacks the PFO complex possibly due to the fact that, in contrast to 
metronidazole-sensitive organisms, pyruvate produced by glycolysis is converted into 
lactate, through the action of lactate dehydrogenase enzymes, and transported out of the 
parasite into the host cell (Samuelson, 1999; Olszewski et al., 2010). The resultant acetyl-
CoA produced through the action of the pyruvate dehydrogenase complex is used for fatty 
acid elongation instead of acetate or ethanol production (Samuelson, 1999; Olszewski et 
al., 2010; Ginsburg, 2011).       
3.4.4 Possible mechanisms of action of the metronidazole-thiosemicarbazone analogues 
Although the latter proved not to be a possible mechanism of action of the metronidazole-
thiosemicarbazone analogues, the unique biochemical pathway in which haemoglobin is 
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digested by the parasite to form haemozoin and amino acids, is a viable antimalarial drug 
target (Biot and Chibale, 2006). With this in mind, the ability of the metronidazole-
thiosemicarbazone analogues to inhibit the formation of synthetic haemozoin (β-haematin) 
in a manner similar to chloroquine was tested.  
The ability of the analogues to inhibit the formation of β-haematin correlated (r2 = 0.868) to 
their antimalarial activity (Figure 3.10), with compounds incapable of inhibiting β-haematin 
formation exhibiting low or no antimalarial activity. Thus indicating a possible mechanism 
of action of the metronidazole-thiosemicarbazones under investigation. 
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Figure 3.10: The correlation between antimalarial and β-haematin inhibitory activity of the 
metronidazole-thiosemicarbazone analogues. Plotted with a 95% confidence 
interval. 
 
On examination of the structure-activity relationship of the aminoquinolones, whose 
primary mechanism of action is inhibition of haemozoin formation, three criteria were 
established for antimalarial activity: 1) The compound must contain basic side chains so as 
to allow accumulation in the food vacuole due to pH trapping; 2) the compound must be 
able to form complexes with Fe(III) protoporphyrin IX and, 3) the compound must be 
capable of inhibiting β-haematin formation (Figure 3.11) (Egan et al., 2000).  
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Figure 3.11: Proposed structure-activity relationships for the antimalarial and  
β-haematin inhibitory activities of chloroquine (Egan et al., 2000). 
 
The proposed mechanism by which chloroquine exerts its effects on β-haematin formation 
involves the following: the weak base diffuses into the food vacuole along the pH gradient, 
where it is trapped due to protonation at the low pH of the food vacuole (Figure 3.12).  
 
Figure 3.12: The proposed mechanism of action of chloroquine (Kouznetsov and Gómez-
Barrio, 2009). 
 
Increased protonation of the drug results in more compound entering the food vacuole, 
where it forms a complex with Fe(III) protoporphyrin IX (Figure 3.12), possibly through the 
interaction of the nitrogen atom of the quinoline ring and Fe(III) or through the interaction 
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with haem propionate groups, thereby inhibiting the formation of haemozoin (Sullivan, 
2002; de Dios et al., 2003; Egan, 2008).     
When examining the structures of the metronidazole-thiosemicarbazone analogues, it can 
be hypothesised that the nitrogenous groups may act as weak bases, trapping the drug in 
the acidic food vacuole of the parasite, in a manner similar to chloroquine (Figure 3.11), 
and that the N4 substitutions confer the β-haematin inhibitory activity of the analogues. 
Upon examining the N4 substitutions of the compounds, it can be seen that substitutions 
which do not contain an amine group lack antimalarial activity, as observed in compounds 
Y-5 and Y-6 (Table 3.2). Thus indicating that the thiourea moiety appears to be essential for 
β-haematin inhibitory and subsequent antimalarial activity, possibly through complex 
formation with haem propionate groups or with Fe(III) directly (Egan et al., 2000; de Dios et 
al., 2003). The exception is compound Y-7 which does not contain an amine group, yet still 
exhibits strong β-haematin inhibitory and antimalarial activity (Figure 3.7). However, 
compound Y-7 has a quinoline ring structure, similar to that of chloroquine (Figure 3.11), 
wherein the nitrogen atom of the quinoline ring  may act to complex Fe(III) protoporphyrin 
IX (Egan et al., 2000; de Dios et al., 2003).  
Metronidazole-thiosemicarbazone analogues may, therefore, act in a similar manner to 
chloroquine, by accumulating in the food vacuole and forming drug-haemin complexes via 
interaction with haem propionate groups or with Fe(III), thereby sequestering haem and 
preventing its polymerisation into haemozoin (Sullivan, 2002; Egan, 2008). Particularly in 
the case of compound Y-3 (IC50 value: 19.08 ± 2.37 µM) (Figure 3.7) which contains a chloro-
atom, known to be involved in the inhibition of haemozoin formation (Figure 3.11) 
(Sullivan, 2002; Egan, 2008).  
Various mechanisms of antimalarial action have been proposed for thiosemicarbazones, 
with the majority pointing towards processes affecting haemoglobin digestion such as the 
formation of complexes with iron via amine and thiocarbonyl moieties (Figure 3.13). With 
the iron-thiosemicarbazone complexes inhibiting  cysteine protease activity; where the 
nucleophilic attack of the thiosemicarbazone moiety on the electrophilic centres of the 
cysteine protease enzymes inhibit activity (Chellan et al., 2010; Zhong et al., 2010; 
Rodriguez-Lucena et al., 2011). 
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Figure 3.13: The general structure of the metronidazole-thiosemicarbazone analogues, 
indicating the donor groups capable of chelating metals (Liberta & West, 1992; 
Athar et al., 2005). 
 
The ability of thiosemicarbazones to chelate iron has been well documented, with the 
resultant effect of not only the inhibition of haemoglobin digestion and haem biosynthesis, 
but also withholding iron from vital enzymes such as ribonucleotide reductase, thereby 
interfering with  DNA synthesis and division (Chipeleme et al., 2007; Chellan et al., 2010; 
Rodiquez-Lucena et al., 2011). In this study, the analogues exhibited no Fe(II) chelation 
properties (Table 3.4), with compound Y-8 only capable of chelating 55.64 ± 9.31% of Fe(II) 
at 200 µM. This may be explained by the fact that the iron atom has six coordination sites; 
the thiosemicarbazone moiety of the metronidazole-thiosemicarbazone analogues provides 
two donor groups, whilst the metronidazole moiety contributes one donor group shown to 
be capable of chelating transition metals (Figure 3.13) (Athar et al., 2005).  
In this manner, the compounds may act as tridentate chelators, chelating iron in a 2:1 ratio 
of drug to iron (200 µM). However at this drug concentration all, with the exception of 
compound Y-8, exhibited little activity, possibly indicating that the structure of the 
compounds does not allow for the optimal conformation for the chelation of Fe(II). 
Additionally, this group of analogues may preferentially bind Fe(III). In studies conducted 
with derivatives of desferrioxamine (DFO), a potent iron chelator, it was shown that the 
derivatives maintained the ability to bind Fe(III), but exhibited a reduced affinity to bind 
Fe(II). Whilst still maintaining their activity against P. falciparum, possibly due to the fact 
that the parasite’s iron pool is in the form of Fe(III) (Mabeza, 1999; Chipeleme et al., 2007; 
Chellan et al., 2010).     
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Thiosemicarbazones are known to chelate a wide variety of transition metals and as such 
this set of analogues may preferentially chelate other transition metals, such as copper. 
Copper ions have five coordination sites and exist in two oxidation states, as the reduced 
cuprous form, Cu(I), and the oxidised cupric form, Cu(II), with both forms favouring 
different donor groups (Ding et al., 2011). The cuprous form is capable of adopting 
geometries which are not usually favoured by other metals, forming complexes with 
thiolates and thioethers, whereas the cupric form favours complex formation with amines 
(Ding et al., 2011).  Depending on the geometry of the bond formed between the ligand 
and the copper ion, a chelator may not only favour Cu(I) over Cu(II), but may also result in 
the reduction of Cu(II) to Cu(I), as is the case with the nitrogen-heterocyclic, neocuprine 
(2,9-dimethyl-1,10-phenanthroline), a bidentate copper ion chelator (Ding et al., 2011).  
Copper is a co-factor of many malarial enzymes, such as Cu/Zn superoxide dismutase, 
which is ingested from the erythrocyte cytoplasm together with haemoglobin (Rasoloson et 
al., 2004). Cu/Zn superoxide dismutases act as part of the enzymatic anti-oxidant defence 
systems, such that chelation of copper would not only impair these defence systems, but 
the partial dissociation of a drug-copper complex may result in ROS formation. This may 
deplete GSH, thereby inhibiting haem detoxification (Müller, 2004; Rasoloson et al., 2004; 
Hancock et al., 2011). One such sulphur based compound, N, N-diethyldithiocarbamate 
(Figure 3.14) has been shown to inactivate Cu/Zn superoxide dismutases in erythrocytes by 
reacting with oxyhaemoglobin, resulting in the production of free-radicals and oxidised N, 
N-diethyldithiocarbamate, which in turn reacts with thiols resulting in GSH depletion and 
enzyme inactivation (Ding et al., 2011). 
SHNCH3
CH3
S
 
Figure 3.14: The chemical structure of N, N-diethyldithiocarbamate (Ding et al., 2011). 
 
Although the analogues did not act as secondary anti-oxidants by chelating iron, thereby 
preventing ROS formation, they did exhibit strong free-radical scavenging activity, proving 
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highly effective in scavenging the free-radical of DPPH• (Table 3.4). Compounds Y-8, Y-5 and 
Y-7 exhibited the most promising anti-oxidant ability, and were comparable (p > 0.05) to 
the anti-oxidant capabilities of ascorbic acid (Table 3.4). Compound Y-3 exhibited poor free-
radical scavenging activity, whereas compound Y-6 and metronidazole proved to be 
inactive (Table 3.4), indicating that the N-methyl benzyl amine, 1,2,3,4-tetrahydroquinoline 
and pyrrolidine side chain substitutions appeared to confer increased anti-oxidant activity. 
A study conducted on benzyloxybenzaldehyde-4-phenyl-3-thiosemicarbazone (Figure 3.8d), 
a thiosemicarbazone exhibiting strong structural similarities with this set of analogues, 
showed that it exhibited similar DPPH• free-radical scavenging activities (42% scavenging at 
100 µM) to the standard anti-oxidant, α-tocopherol (53% scavenging at 100 µM)   (Prathima 
et al., 2011).  
The anti-oxidant capabilities of the analogues may be due to the nitrogen-containing 
moieties of the analogues, where amine groups have been shown to act as anti-oxidants 
through the dissociation of the N-H bond, and in this way donate a hydrogen atom to the 
DPPH• free-radical (Saito and Ishihara, 1997; Nishiyama et al., 2002). Compounds that 
exhibit both antimalarial and anti-oxidant capabilities are highly beneficial, in that not only 
do they cause parasite death, but they also neutralise the ROS which cause lipid 
peroxidation and the consequent vascular damage seen in patients infected with P. 
falciparum malaria (Postma et al., 1996; Quaye, 2008). 
Combinations of compounds Y-3 or Y-7 with quinine or dihydroartemisinin exhibited 
additive interactions at most tested ratio of analogue:quinine or dihydroartemisinin (Figure 
3.4; Appendix C). In order to improve treatment outcome and decrease the risk of 
antimalarial drug resistance, the WHO advocates the use of combination therapy in the 
treatment of malaria, specifically the use of quinine or artemisinin derivatives (Section 1.3) 
(WHO, 2010b). It is, therefore, imperative to understand the interaction of compounds in 
combination, as ultimately their interaction could indicate their efficacy in a clinical setting.     
The pharmacological interaction of two drugs in combination is said to be synergistic when 
the activity of the combination is higher than that of the activities of the individual drugs 
added together, additive when the combination produces the same effect as the activity of 
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the individual drugs added together, and antagonistic when the activity of the combination 
is lower than the activities of the individual drugs added together (Bell, 2005).  
A synergistic interaction may result from: 1) The binding of drug X to a target enhancing the 
binding of drug Y to the same target, 2) the binding of drug X to a transporter resulting in 
an influx of drug Y, 3) the formation of a toxic complex by drugs X and Y or 4) the 
conversion of drug X into its active form by the activity of drug Y (Bell, 2005). With 
synergism regarded as favourable due to that fact that the doses of the individual drugs 
may be reduced thereby not only minimising side effects, but also the cost of the treatment 
regimen (Fidock et al., 2004; Bell, 2005). However, a synergistic drug combination wherein 
both drugs act on the same metabolic pathway, wherein the development of resistance to 
either component results in loss of efficacy of the combination is not beneficial, as is the 
case of sulphadoxine-pyrimethamine (Fidock et al., 2004). Sulphadoxine-pyrimethamine is a 
fixed-dose combination of 20 parts sulphadoxine to 1 part pyrimethamine, wherein both 
drugs act to inhibit enzymes of the folate pathway, resulting in a sequential blockade of 
folate metabolism (Nzila, 2006; WHO, 2010b). The long elimination half lives of 
sulphadoxine and pyrimethamine (80 hours and 120 hours, respectively) allows for 
prolonged exposure of any residual parasites to the combination, and subsequent selection 
for drug-resistant parasites, which has resulted in high levels of resistance to the 
combination such that it is no longer recommended for the treatment of malaria in South 
Africa (Kremsner and Krishna, 2004; National Department of Health, 2010; WHO, 2010b). 
Conversely, an antagonistic interaction is unfavourable as the decreased efficacy of the two 
drugs results in treatment failure, increasing the likelihood of mortality and the spread of 
drug-resistant organisms (Berenbaum, 1978; Bell, 2005). Antagonism may occur when two 
drugs act on the same target, as is the case with chloroquine and mefloquine, with the 
antagonistic interaction possibly due to the inhibition of chloroquine uptake by mefloquine, 
or the inhibition of haemoglobin uptake into the food vacuole, resulting in reduced haem 
concentrations (Bell, 2005).   
An appropriate combination regimen would be one where an additive or synergistic 
relationship exists, with the separate components active against different parasitic 
metabolic targets in different  stages of the asexual parasitic life cycle (Fidock et al., 2004; 
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WHO, 2010b). Furthermore, it should be composed of one fast-acting drug, as well as a 
slowly-eliminated partner drug to clear residual parasites, an example of which is the 
combination of artemether and lumefantrine (WHO, 2010b). 
The additive interaction between the analogues and quinine (Figure 3.4; Appendix C) 
appears to be as a result of the two groups of drugs acting on different targets. The 
analogues inhibit parasitic growth past the late ring/early trophozoite-stage. Following the 
inhibition of haemozoin formation the parasites exhibit intense staining (Figures 3.5b,c) 
similar to so-called ‘crisis forms’ observed in P. falciparum cultures treated with 
chloroquine or hydrogen peroxide (Deponte and Becker, 2004). Some authors claim that 
the nuclear condensation is a hallmark of apoptosis, and others claim that parasitic death 
occurs via autophagy (Deponte and Becker, 2004; Lopez et al., 2010). Residual parasites are 
then inhibited at the mid to late trophozoite-stage through the action of quinine.  
The proposed antimalarial mechanism of action of the quinolines is the inhibition of 
haemozoin formation (Olliaro, 2001; Biagini et al., 2003; Vangapandu et al., 2007).  
Although quinine was capable of inhibiting the formation of β-haematin ex vivo (Figure 3.7), 
an examination of its stage-specific and morphological effects showed no effect on 
haemozoin formation at all  concentrations tested  (Figure 3.5), indicating that inhibition of 
haemozoin formation is not the primary mechanism of action of quinine. Instead, quinine 
appeared to exert its effects in the mid to late trophozoite-stage, possibly through effects 
on protein synthesis or parasitic DNA replication; as it has been shown to inhibit parasitic 
DNA gyrase and intercalate between base pairs in double-stranded DNA (Frayha et al., 
1997; Padmanaban et al., 2007). In this manner, neither drug enhances the activity of the 
other, but rather act to inhibit parasitic growth through their activity on different targets in 
different stages of the parasitic life cycle. As seen with the additive interaction noted 
between chloroquine and quinine in the 3D7 strain of P. falciparum (Bell, 2005). 
 In a similar manner, the interaction between the analogues and dihydroartemisinin also 
produced an additive effect (Figure 3.4; Appendix C). Artemisinin and its derivatives are 
active against all stages of the erythrocytic parasitic life cycle, including the ring stage 
(Vangapandu et al., 2007; Krishna et al., 2010). The most recently accepted hypothesis of 
the antimalarial mechanism of action of this class of antimalarials involves the inhibition of 
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PfATP6, a Ca2+-ATPase localised to the endoplasmic reticulum and possibly the plasma 
membrane (Vangapandu et al., 2007; Krishna et al., 2010). PfATP6 maintains cytosolic 
calcium levels, inhibition of which leads to increased cytosolic calcium levels causing 
dysregulation of various parasitic processes such as parasite invasion and egress, as well as 
progression through the life cycle (Vangapandu et al., 2007; Krishna et al., 2010).  
Studies conducted combining FR 160, a dicatecholate Fe(II) and Fe(III) chelator, with 
artesunate and dihydroartemisinin showed antagonistic interactions (Pradines et al., 2002; 
Bell, 2005). The antagonistic interaction may be explained by the fact that Fe(II) is required 
for the activity of artemisinin and its derivatives on PfATP6 or that FR 160 acts to induce 
free-radical generation, thereby interfering with the mechanism of action of the artemisinin 
derivatives (Pradines et al., 2002; Bell, 2005). The fact that iron chelators appear to 
antagonise the activity of the artemisinin derivatives, whereas the thiosemicarbazone 
analogues interacted in an additive manner (Figure 3.4; Appendix C), points to the fact that 
the mechanism of action of the analogues does not  lie in their ability to chelate iron and 
generate free-radicals. If this were their mechanism of action, an antagonistic interaction 
should have been observed.  
Similarly to that observed with the quinine combination studies, it appears as if the 
metronidazole-thiosemicarbazone analogues and dihydroartemisinin act on different 
targets within the parasite, with dihydroartemisinin inhibiting the activity of PfATP6 
throughout the parasitic life cycle, and the analogues inhibiting haemozoin formation in the 
late ring/early trophozoite-stages (Figure 3.5).  
Previous studies have hypothesised that the artemisinin derivatives act by inhibiting 
haemozoin formation (Pandey et al., 1999; Kannan et al., 2005), however when screened 
for β-haematin inhibitory activity, dihydroartemisinin was only capable of 7.46 ± 2.27% 
inhibition at 100 µM (Section 3.3.4.1). In accordance with this observation, no inhibition 
was observed by other investigators when using the β-haematin inhibitory activity (BHIA) 
assay, indicating that these compounds do not  form π-π interactions with haematin  
(Haynes et al., 2003; Feng et al., 2011).   
Thiosemicarbazones may attack various biological targets within the malaria parasite, such 
as DNA synthesis, haemoglobin digestion, and haem biosynthesis (Chellan et al., 2010; 
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Hancock et al., 2011). This study has included an extra possible antimalarial mechanism of 
action, in their ability to inhibit haemozoin formation. The fact that the strong β-haematin 
inhibitory activity of some analogues, one of which exceeded the activity of chloroquine, 
did not equate to antimalarial activity in the nanomolar range of chloroquine indicated that 
perhaps the lipophilicity of the analogues needs to be enhanced, to facilitate the 
movement of the analogues through membranes so as to enhance their accumulation in 
the food vacuole of the parasite. The addition of aminoalkyl side chains in the place of 
metronidazole may also prove beneficial, in order to enhance pH trapping of the 
compounds within the food vacuole. A study conducted by Egan et al. (2000), showed that 
aminoquinoline derivatives lacking an aminoalkyl side chain showed strong Fe(III) 
protoporphyrin IX complexing activity and β-haematin inhibitory activity. However, their 
antimalarial activity lay between 3.8 and 5 µM when compared to chloroquine, which had 
an IC50 value of 38 nM (Egan et al., 2000).  
It can be concluded that the thiosemicarbazone class of compounds show promising 
antimalarial activity; however, the addition of metronidazole to the thiosemicarbazone 
backbone may in fact hamper the iron chelation abilities of thiosemicarbazones by 
hindering the rotation of the analogues. The additive interaction between compounds Y-3 
and Y-7 when combined with currently used antimalarials, as well as their ability to act as 
anti-oxidants would prove beneficial in the treatment of P. falciparum infected individuals. 
However, a concern would be the pharmacokinetic profile of thiosemicarbazone analogues. 
It has been shown that Triapine®, a thiosemicarbazone derivative, although generally well 
tolerated at doses of up to 160 mg/m2 daily (intravenously),  possessed an elimination half-
life ranging from 1.67 to 2.30 hours (Giles et al., 2003; Murren et al., 2003). In this respect, 
a combination of a thiosemicarbazone analogue with an artemisinin derivative; wherein 
both drugs have short half-lives may result in recrudescence or require the patient to be on 
an intravenous drip. Synthesis of derivatives and further investigation into these 
compounds to include a more favourable pharmacokinetic profile, and an examination of 
their toxicity on mammalian cells lines may in time provide a new class of potent 
antimalarials. 
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CHAPTER 4: THE ANTIMALARIAL PROPERTIES OF  
CHLOROQUINOLINE-CHALCONES 
4.1 Introduction 
Strategies for antimalarial drug discovery include: combination therapies, drug-resistance 
reversers, analogues of existing antimalarials, the development of target-specific 
compounds, and the mass screenings of plant-derived compounds (Biagini et al., 2003; 
Muregi and Ishih, 2010). Another drug discovery strategy is the hybridisation of two 
validated antimalarial drug scaffolds. The principle behind molecular hybridisation is that 
two compounds, with differing antimalarial mechanisms of action, are fused to produce a 
single compound with antimalarial activity exceeding that of its components in singularity 
(Guantai et al., 2010; Muregi and Ishih, 2010). Hybridisation is an attractive strategy when 
applied to compounds to which resistance has developed, such as chloroquine, as the 
addition of the second compound may act to circumvent or reverse drug resistance 
(Guantai et al., 2010; Muregi and Ishih, 2010).  
 4.1.1 Chalcones 
Chalcone or 1,3-diaryl-2-propen-1-ones (Figure 4.1a) act as key intermediates for the 
assembly of various heterocyclic scaffolds (Ren et al., 2003; Nowakowska, 2007; 
Bhattacharya et al., 2009). They typically consist of two aromatic rings, linked by a three 
carbon α, β-unsaturated ketone bridge (Figure 4.1a), with many naturally occurring 
chalcones capable of acting as anti-oxidants, due to polyhydroxylation of their aromatic 
rings (Go, 2003; Ren et al., 2003; Nowakowska, 2007). 


O
   N  
a)       b) 
Figure 4.1: The basic structure of a) a chalcone (Bandgar et al., 2010) and b) a quinoline 
(Guantai et al., 2010). 
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Chalcones are the precursors to a large family of compounds known collectively as 
flavonoids, which encompass more than 4000 natural polyphenolic compounds abundant 
in fruits, spices and vegetables (Go, 2003; Ren et al., 2003; Nowakowska, 2007), and 
possess a wide range of biological activities, including anti-inflammatory, anticancer, 
antiprotozoal and antibacterial effects (Nowakowska, 2007; Mishra et al., 2008). One such 
chalcone is isoliquiritigenin, a component of Glycyrrhiza glabra L. (liquorice root), which is 
currently used as a vasorelaxant, exerting its effects through inhibition of 
phosphodiesterase III; whilst also possessing antiplatelet aggregation, anti-allergy and anti-
cancer properties (Wegener and Nawrath, 1997; Takahashi et al., 2004).   
The antimalarial properties of chalcones was discovered during a routine screening, where 
it was found that licochalcone A, an oxygenated chalcone also extracted from Glycyrrhiza 
glabra L., exhibited antimalarial activity (Chen et al., 1994; Go et al., 2004). The antimalarial 
effects of licochalcone A  was similar in both chloroquine-sensitive (3D7) and chloroquine-
resistant (Dd2) strains of P. falciparum, with licochalcone A inhibiting parasite growth by 
50% at  0.6 µg/ml, compared to chloroquine which inhibited 50% of parasite growth by 50 
ng/ml and 86 ng/ml in the two strains, respectively (Chen et al., 1994). In addition, 
licochalcone A has shown to act as a potent in vitro inhibitor of pro-inflammatory 
responses, which would be beneficial in the treatment of malaria (Kolbe et al., 2006).  
This discovery prompted an interest in chalcones as antimalarial agents, with various 
alkoxylated and hydroxylated chalcones; as well as sulphonamide and phenylurea-chalcone 
derivatives shown to exhibit variable activity against P. falciparum in vitro (Go et al., 2004; 
Nowakowska, 2007; Mishra et al., 2008).     
4.1.2 Quinolines 
Quinolines (Figure 4.1b), quinine and cinchonine, isolated from the bark of the cinchona 
tree in the 18th century constituted the first successful treatment of malaria (Wozniacka et 
al., 2002; Sharma, 2005; Solomon and Lee, 2009). During the Second World War, due to the 
difficulty in the chemical synthesis of quinine, the synthetic quinoline derivative, 
chloroquine, replaced quinine as the primary prophylactic and antimalarial agent 
(Wozniacka et al., 2002; Sharma, 2005; Solomon and Lee, 2009). For decades chloroquine 
has been the primary antimalarial chemotherapy due to its low cost, clinical efficiency, and 
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favourable pharmacokinetic profile (Fidock et al., 2004; Sharma, 2005). Chloroquine is 
absorbed rapidly following oral, intramuscular, or subcutaneous administration and is 
largely bound to plasma proteins, exhibiting a terminal elimination half-life of one to two 
months (WHO, 2010b). Metabolism occurs in the liver to form monodesethylchloroquine, 
which exhibits similar activity against P. falciparum (WHO, 2010b). However, decades of use 
has contributed to the widespread resistance of P. falciparum, rendering the drug 
ineffective in most parts of the world, including South Africa (Fidock et al., 2004; National 
Department of Health, 2009).  
Chloroquine is a diprotic weak base, existing as unprotonated, mono-protonated and di-
protonated forms (Sanchez et al., 2010). Chloroquine, in its unprotonated form, is capable 
of crossing the membrane of the food vacuole where, upon exposure to the acidic pH, it 
becomes protonated making it membrane impermeable (Sanchez et al., 2010). It exerts its 
effects in the food vacuole by binding to haem, thereby inhibiting the formation of 
haemozoin (Figure 3.12), resulting in parasite death due to oxidative stress (Olliaro, 2001; 
Vangapandu et al., 2007; Sanchez et al., 2010). Under physiological conditions, the pH of 
the food vacuole of the malaria parasite is maintained by a H+-ATPase pump moving H+ ions 
into the food vacuole to counter the outward leak of H+ by an as-yet uncharacterised 
pathway (van Schalkwyk and Egan, 2006; Lehane et al., 2008). It has been previously 
hypothesised that chloroquine-resistance may be attributed to an increase in the pH of the 
food vacuoles of chloroquine-resistant parasites, compared to those of sensitive strains 
(Ginsburg, 1988), which would result in decreased chloroquine accumulation due to weak 
base trapping (Ginsburg, 1988). However, recent publications have shown that there is no 
significant difference between the pH of the food vacuoles of chloroquine-resistant and 
sensitive strains (van Schalkwyk and Egan, 2006; Lehane et al., 2008; Sanchez et al., 2010).  
A more likely hypothesis is that chloroquine-resistance is attributed to mutations in 
parasitic chromosomes, resulting in the decreased accumulation of chloroquine in the food 
vacuole (Vangapandu et al., 2007; Sanchez et al., 2010; WHO 2010b). Plasmodium 
falciparum chloroquine resistance transporter (PfCRT), localised to the food vacuole 
membrane, mediates the transport of drugs in and out of the food vacuole, both directly 
and indirectly by transporting drugs and by contributing to the generation of the pH 
gradient (Figure 4.2) (Vangapandu et al., 2007; van Schalkwyk and Egan, 2006; Sanchez et 
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al., 2010). PfCRT mutations confer chloroquine-resistance by resulting in the efflux of 
chloroquine from the food vacuole at rates 40 times higher than that observed in 
chloroquine-sensitive strains of P. falciparum (Vangapandu et al., 2007; Fidock et al., 2008).   
 
Figure 4.2: Mechanisms of chloroquine-resistance in P. falciparum (Fidock et al., 2008). 
With the circled question mark referring to the hypothesis that the efflux of 
chloroquine from the food vacuole might be H+-coupled and the black boxed 
question mark referring to the outward leak of H+ by an as-yet uncharacterised 
pathway. Where: CQ/CQH+/CQH2
2+ = chloroquine/monoprotonated 
chloroquine/diprotonated chloroquine; RBC = red blood cell; PfMDR1 = 
Plasmodium falciparum multi-drug resistance transporter; PfCRT = Plasmodium 
falciparum chloroquine resistance transporter. 
 
Chloroquine-resistance has been attributed to numerous polymorphisms within the pfcrt 
gene, however, conserved amongst the mutant alleles is the replacement of the charged 
amino acid lysine with the neutral amino acid threonine (K76T) (Fidock et al., 2008; Sanchez 
et al., 2010). With the loss of positive charge resulting in the efflux of the protonated form 
of chloroquine back into the parasite cytoplasm (Figure 4.2) (Fidock et al., 2008).  Lehane et 
al. (2008) showed that upon inhibition of parasitic H+-ATPase pumps with concanamycin A, 
a macrolide antibiotic which inhibits vacuolar H+-ATPase pumps, alkalinisation of the food 
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vacuoles of chloroquine-resistant strains were up to 4-fold higher than that observed in 
chloroquine-sensitive strains. The same study also showed that in the presence of 
chloroquine a rapid alkalinisation of the food vacuole was noted in chloroquine-resistant 
strains, with chloroquine-sensitive strains exhibiting a decreased rate of food vacuole 
alkalinisation (Lehane et al., 2008). A process that was inhibited by verapamil, a calcium 
channel blocker, possibly due to the fact that the positively charged amino group of 
verapamil compensates for the loss of positive charge in mutated PfCRT’s (van Schalkwyk 
and Egan, 2006; Lehane et al., 2008). All of which favours the hypothesis that PfCRT 
transports chloroquine in symport with H+ ions, with PfCRT mutations resulting in the efflux 
of chloroquine and H+, and subsequently increased rate of alkalinisation of the food vacuole 
(Lehane et al., 2008; Sanchez et al., 2010). 
Furthermore, mutations within the Plasmodium falciparum multi-drug resistance 
transporter (pfmdr 1) gene, implicated in mefloquine and halofantrine resistance, have also 
been implicated in chloroquine-resistance in certain strains (Vangapandu et al., 2007; 
Johnson et al., 2008). It has been shown that the anticonvulsant, phenobarbitone, 
increased the expression of the gene product of pfmdr 1, P-glycoprotein homologue 
protein 1 (Pgh1), resulting in decreased sensitivity to chloroquine in both chloroquine-
resistant and -sensitive strains in vitro (Figure 4.2) (Johnson et al., 2008).   
A possible means of potentiating the effects chloroquine is through the synthesis of 
modified chloroquine analogues. Sulphonamide-analogues have shown promising 
antimalarial activity, with one analogue exhibiting 100-fold higher activity and different 
mechanism of action to that of chloroquine (Vangapandu et al., 2007). Various other 
analogues, in which the alkyl side chain of chloroquine was modified, also exhibited 
promising antimalarial activity against chloroquine-resistant strains, providing an indication 
that the aminoalkyl side chain is an important determinant in chloroquine resistance 
(Vangapandu et al., 2007; van Schalkwyk and Egan, 2006).  
The rationale behind the synthesis of a series of chloroquinoline-chalcones was that the 
molecular hybridisation of the active chloroquinoline and chalcone groups may produce a 
more potent compound capable of evading chloroquine-resistance. 
  The objectives of this chapter were to: 
   
100 
 
 Evaluate the efficacy of the chloroquinoline-chalcone derivatives against a 
chloroquine-sensitive strain of P. falciparum and, pending antimalarial activity 
similar to or more potent than that of chloroquine, examine the activity of the 
compounds against a chloroquine-resistant strain. 
 Determine possible pharmacological interactions between a lead compound and 
quinine. 
 Examine the stage-specific and morphological effects of a lead compound on 
parasite development. 
 Elucidate possible antimalarial mechanisms of action of the compounds. 
 Test for haemolytic activity as an indication of toxicity. 
4.2 Materials and methods 
4.2.1 Chemical synthesis and structural verification 
The chloroquinoline-chalcones (1-14) were acquired from Professor A. Azam, Department 
of Chemistry, Jamia Millia Islamia, New Delhi, India. The compounds were synthesised as 
depicted in Figure 4.3. A series of 2-chloro-3-formylquinolines were prepared by the 
condensation of different anilines with acetic acid in the presence of acetic anhydride 
(Figure 4.3a). Following which the 2-chloro-3-formylquinolines were condensed with 
various aromatic ketones in the presence of aqueous NaOH in ethanol (Figure 4.3b), to 
produce the chloroquinoline-chalcones (Table 4.1) (Hayat et al., 2011). The chemical 
structures of the 14 chloroquinoline-chalcones were verified by infrared, 1H, 13C nuclear 
magnetic resonance and mass spectrophotometry, and purity confirmed by elemental 
analysis (Hayat et al., 2011).   
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Figure 4.3: The synthesis of chloroquinoline-chalcones (1-14). Reagents and conditions: a) 
dimethylformamide/phosphoryl chloride, 75 °C reflux 17 hours, b) aqueous 
sodium hydroxide, ethanol, various aromatic ketones (Hayat et al., 2011). 
Table 4.1: The chloroquinoline-chalcones evaluated for antimalarial activity. 
Chemical name Chemical code 
(E)-3-(2-Chloroquinoline-3yl)-1-(pyridine-2yl)prop-2-en-1-one F-1 
(E)-1-(3-Bromophenyl)-3-(2-chloroquinoline-3yl)-2-methylprop-2-
en-1-one 
F-2 
(E)-1-(4-Chlorophenyl)-3-(2-chloroquinoline-3yl)prop-2-en-1-one F-3 
(E)-1-(3-Bromophenyl)-3-(2-chloroquinoline-3yl)prop-2-en-1-one F-4 
(E)-1-(4-Bromophenyl)-3-(2-chloroquinoline-3yl)prop-2-en-1-one F-5 
(E)-1-(3-Bromophenyl)-3-(2-chloro-6-methylquinolin-3-yl)-2-
methylprop-2-en-1-one 
F-6 
(E)-3-(2-Chloro-6-methylquinolin-3-yl)-1-(3-chlorophenyl)-2-
methylprop-2-en-1-one 
F-7 
(E)-1-(4-Bromophenyl)-3-(2-chloro-6-methylquinoline-3yl)prop-2-
en-1-one 
F-8 
(E)-1-(3-Bromophenyl)-3-(2-chloro-6-methylquinolin-3-yl)prop-2-
en-1-one 
F-9 
(E)-3-(2-Chloro-6-methylquinoline-3yl)-1-(pyridine-2yl)prop-2-en-
1-one 
F-10 
(E)-3-(2-Chloro-7-methylquinoline-3yl)-1-(3-chlorophenyl)-2-
methylprop-2-en-1-one 
F-11 
(E)-1-(3-Bromophenyl)-3-(2-chloro-7-methylquinoline-3yl)-2-
methylprop-2-en-1-one 
F-12 
(E)-3-(2-Chloro-7-methylquinoline-3yl)-1-(pyridine-2yl)prop-2-en-
1-one 
F-13 
(E)-1-(3-Bromophenyl)-3-(2-chloro-7-methylquinoline-3yl)prop-2-
en-1-one 
F-14 
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4.2.2 Pharmacological evaluation 
The in vitro antimalarial activity of the compounds and positive controls were assessed 
using the [3H]-hypoxanthine incorporation (Section 2.2.2.1) and flow cytometry (Section 
2.2.3.3) methodologies. The most active compound was selected for a combination study 
with quinine (Section 2.2.2.3), as well as for stage sensitivity and parasite morphology 
studies (Section 2.2.3.4). To elucidate possible antimalarial mechanisms of action; β-
haematin inhibitory activity (Section 2.3.1.2), DPPH• free-radical scavenging (Section 
2.3.2.1.2) and iron chelation assays (Section 2.3.2.2.2) were carried out. In order to provide 
an indication of the toxicity of the compounds, a red blood cell toxicity assay was 
performed (Section 2.4.2). Statistically significant differences were determined by means of 
an unpaired Students T-test, with p < 0.05, using the Graphpad Prism® (version 5) software. 
4.3 Results 
4.3.1 In vitro antimalarial and haemolytic activity 
Of the 14 compounds tested for activity against P. falciparum, 10 inhibited parasite growth 
in a dose-dependent manner (Figure 4.4). Of the 10 active compounds, six inhibited 
parasite growth with IC50 values below 50 µM, four between 50 µM and 100 µM, and the 
remaining four were ineffective at inhibiting parasite growth below 100 µM (Table 4.2).  
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Figure 4.4: Log sigmoid dose-response curves of compound F-14, chloroquine and quinine. 
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Table 4.2: The in vitro antimalarial (1% haematocrit, 0.5% parasitaemia) and haemolytic 
activity of chloroquinoline-chalcones and positive controls (n = 4). Percentage 
inhibition of parasite growth at 100 µM is shown in parenthesis. 
H
N Cl
O
R
2
R
1
R
4
R
3
 
 
Compound R1 R2 R3 R4 
Antimalarial 
Activity 
Haemolytic  
activity 
IC50 value:  µM ± s.d. % Haemolysis 
(% growth inhibition 
at 100 μM) 
 
at 100 µM (± s.d.) 
F-13 H CH3 H 
N
 
31.31 ± 0.87 0.47 ± 0.77 
F-10 CH3 H H 
N
 
31.54 ± 3.03 1.55 ± 1.15 
F-1 H H H 
N
 
31.98 ± 1.27 1.10 ± 1.04 
F-3 H H H 
Cl 
39.17 ± 2.05 1.74 ± 0.67 
F-5 H H H 
Br 
44.56 ± 1.75 2.20 ± 0.54 
F-12 H CH3 CH3 
Br
 
47.06 ± 2.76 1.04 ± 0.64 
F-9 CH3 H H 
Br
 
50.11 ± 3.58 1.68 ± 0.66 
F-11 H CH3 CH3 
Cl
 
50.44 ± 3.22 1.44 ± 0.66 
F-14 H CH3 H 
Br
 
59.73 ± 1.19 1.09 ± 0.55 
F-8 CH3 H H 
Br 
74.84 ± 3.39 1.40 ± 0.96 
F-4 H H H 
Br
 
> 100 
(61.22 ± 13.09%) 
1.38 ± 0.67 
F-6 CH3 H CH3 
Br
 
> 100 
(51.15 ± 8.10%) 
1.53 ± 0.34 
F-2 H H CH3 
Br
 
> 100 
(34.30 ± 8.93%) 
2.17 ± 0.59 
F-7 CH3 H CH3 
Cl
 
> 100 
(8.74 ± 13.66%) 
1.24 ± 0.78 
Chloroquine     0.0065 ± 0.0002 0.72 ± 0.32 
Quinine     0.14 ± 0.0007 1.22 ± 0.98 
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Compounds F-13, F-10 and F-1 proved to be the most active; with IC50 values of 
approximately 31 µM (Table 4.2). However, when compared to the antimalarial activity of 
chloroquine and quinine their activity was statistically less effective (p < 0.05).  
The haemolytic activity of the compounds was low with percentage haemolysis at 100 µM 
ranging from 0.47 ± 0.77% to 2.20 ± 0.54%, and were comparable to chloroquine and 
quinine (0.72 ± 0.32% and 1.22 ± 0.98% haemolysis at 100 µM, respectively) (Table 4.2).  
In order to compare results obtained using flow cytometry and the [3H]-hypoxanthine 
incorporation assay, six compounds were selected for comparison, wherein the % 
haematocrit and % parasitaemia were 2- and 4-fold higher than that used to obtain the 
results shown in Table 4.2. 
Generally, the IC50 values and % parasite growth inhibition at 100 µM exhibited a similar 
trend in the two methodologies. When comparing the IC50 values obtained for compound 
F-13 using flow cytometric analysis (IC50 value: 70.39 ± 0.38 µM) and the [
3H]-hypoxanthine 
incorporation assay (IC50 value: 59.48 ± 3.38 µM), no statistically significant difference was 
noted (p > 0.05). A statistically significant difference was apparent (p < 0.05) when 
comparing the  IC50 values of compound F-1 in the two methodologies,  54.19 ± 3.08 µM 
and 33.15 ± 1.35 µM as determined by flow cytometric analysis and the [3H]-hypoxanthine 
incorporation assay, respectively. The % growth inhibition at 100 µM of compounds F-2, F-
4, F-6 and F-7 exhibited a similar trend in the [3H]-hypoxanthine incorporation assay and 
flow cytometric methodologies, although the % growth inhibition as determined by flow 
cytometry (25.20 ± 1.06% to 34.54 ± 5.39%) was higher than that as determined by the 
[3H]-hypoxanthine incorporation assay (10.08 ± 4.40 to 12.68 ± 2.32%).        
4.3.2 Combination study 
The isobologram (Figure 4.5) depicts an additive interaction when compound F-13 was 
combined with quinine in various ratios. The ΣFIC (1.35 ± 0.11), generated from four 
experiments (Appendix D), verified the additive interaction shown in Figure 4.5. Falling well 
within the guidelines of an additive interaction, wherein the ΣFIC50 range lies between 0.5 
and 2 (Section 2.2.2.3).  
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Figure 4.5: The additive pharmacological interaction between compound F-13 and quinine 
(n = 4). 
 
4.3.3 Morphological and stage-specific effects of compound F-13 
The morphological and stage-specific effects of compound F-13 were best visualised using 
the IC50 value (70 µM) (Figures 4.6 and 4.7). No notable changes in parasite morphology or 
shape occurred during the ring-stage. However, when the untreated parasite control 
progressed into the early trophozoite-stage, the treated parasites exhibited altered 
morphology. The treated parasites appeared smaller, with reduced haemozoin formation 
(Figure 4.6A), and appeared to be in the ring-stage rather than early trophozoite-stage 
(Figures 4.7A). When compared to the untreated control of parasites in the mid-late 
trophozoite stage, the treated parasites appeared smaller in size (Figure 4.6B), were 
primarily in the early trophozoite-stage (Figure 4.7B), and although haemozoin formation 
was visible, the crystals were not as compact as noted in the untreated control (Figures 
4.6B). Thereafter, the parasite control progressed into the early to mid schizont-stage, 
where merozoite formation was evident (Figure 4.6C). In contrast, treated parasites 
remained primarily in the trophozoite-stage (Figure 4.7C), with 86% of the treated parasites 
appearing to be in the early to mid trophozoite-stage, and only 14% of the treated parasites 
progressing into the schizont-stage (Figure 4.6C). Finally, the parasite control progressed 
into the late schizont- and early ring-stages (Figures 4.6 and 4.7D), with 71% of parasites in 
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the early ring-stage, and 29% in the late schizont-stage, equating to an increased 
parasitaemia of 4.81% (Figure 4.6D). Of the treated parasites, no early ring-stage parasites 
were present and 48% of parasites were in the early to mid trophozoite-stage (Figure 4.6D). 
The remaining 52% had progressed into the mid schizont-stage, with the schizonts 
appearing condensed and the number of merozoites formed reduced (Figure 4.6D), when 
compared to the early-mid schizont parasite control (Figure 4.6C). An examination of blood 
smears of the treated parasites four hours post-invasion, or four hours into the next cycle, 
showed that the schizonts had progressed through the cycle to form merozoites and 
consequently early rings. However, none of the mid trophozoites had progressed into the 
schizont-stage, and appeared condensed and intensely stained (data not shown).              
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Figure 4.6: The effects of compound F-13 at its IC50 value (70 µM) on parasite morphology and 
development (n = 1). 
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Figure 4.7: Flow cytometric analysis depicting the effects of compound F-13 at its IC50 value 
(70 µM) on parasite development (n = 1). Where: FL2-H represents the 
maximum fluorescent intensity of dihydroethidium.  
 
An examination of the morphological and stage-specific effects of compound F-13 at 200 
µM (IC90 value) indicated that treated parasites were able to progress through the ring-
stage with no distinct morphological changes (Figure 4.8A). However, there was no 
progression past the late ring-stage, with treated parasites appearing condensed and 
exhibiting a distinct lack of haemozoin formation (Figure 4.8B), when compared to the 
untreated parasite control sample that was in the early to mid schizont-stage (Figure 4.6C). 
In contrast, the morphological and stage-specific effects of compound F-13 at 25 µM (IC25 
value) provided little stage-specific or morphological information, with the exception that a 
slight lag in parasite development was noted. Treated parasites were mainly present in the 
   
108 
 
late trophozoite-stage compared to the early to mid schizont-stage of the untreated 
control. 
A B
 
Figure 4.8: The effects of compound F-13 at 200 µM (IC90 value) on parasite growth and 
development (n = 1). Where A = compound F-13 treated parasite that was in 
the late ring-stage when the parasite control was in the early trophozoite-
stage; B = compound F-13 treated parasite’s that were in the late ring-stage 
when the parasite control was in the early to mid schizont-stage. 
 
4.3.4 Antimalarial mechanisms of action 
4.3.4.1 Inhibition of β-haematin formation 
None of the compounds were capable of inhibiting the formation of β-haematin as 
effectively as chloroquine or quinine, with the β-haematin inhibitory activity of the 
compounds ranging from 12.57 ± 8.30% to 92.73 ± 4.11% at 400 µM (Table 4.3). 
Compounds F-14, F-8 and F-3 were the most active, with inhibitory activities of 92.73 ± 
4.11%, 91.97 ± 8.10%, and 89.46 ± 10.00% at 400 µM, respectively (Table 4.3). However, at 
100 µM they were only capable of inhibiting the formation of β-haematin by 22.56 ± 6.53%, 
9.68 ± 3.20% and 21.34 ± 7.60%, respectively. 
4.3.4.2 DPPH• free-radical scavenging activity 
When compared to ascorbic acid (IC50 value: 19.31 ± 2.62 µM), the compounds proved to 
be poor scavengers of the free-radical of DPPH•, with activity ranging from 0.01 ± 0.65% to 
11.34 ± 8.91% at 240 µM (Table 4.3).  
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4.3.4.3 Iron chelating activity 
None of the compounds exhibited any iron chelating activity comparable to that of EDTA 
(IC50 value: 23.90 ± 1.83 µM) (Table 4.3), with % Fe(II) chelation ranging from 0.01 ± 1.28% 
to 7.57 ± 4.13% at 200 µM. In contrast, chloroquine was capable of chelating 70.68 ± 0.97% 
Fe(II) at 200 µM (Table 4.3). 
Table 4.3: The β-haematin inhibitory, free-radical scavenging, and Fe(II) chelating activity of 
the compounds (n = 4). Values in parenthesis indicate where IC50 values (< 100 
μM) were obtained. 
Compound 
% Inhibition of β-haematin 
formation 
% DPPH• free-radical 
scavenging activity 
% Fe(II) chelation 
at 400 µM (± s.d.) at 240 µM (± s.d.) at 200 µM (± s.d.) 
F-14 92.73 ± 4.11 0.01 ± 1.97 7.57 ± 4.13 
F-8 91.97 ± 8.10 0.01 ± 0.70 0.01 ± 3.42 
F-3 89.46 ± 10.00 0.01 ± 0.65 3.00 ± 1.82 
F-11 41.95 ± 4.19 0.01 ± 1.39 0.01 ± 5.77 
F-6 40.77 ± 13.63 0.01 ± 2.80 0.01 ± 3.42 
F-7 32.89 ± 5.21 0.01 ± 2.18 0.01 ± 6.96 
F-9 32.20 ± 13.42 2.39 ± 2.25 0.01 ± 8.73 
F-10 31.71 ± 10.77 2.27 ± 1.21 0.01 ± 5.24 
F-13 30.56 ± 5.00 0.78 ± 1.90 0.01 ± 6.72 
F-5 26.83 ± 10.39 0.01 ± 0.95 0.01 ± 1.28 
F-12 22.60 ± 12.24 1.43 ± 1.18 0.01 ± 5.60 
F-1 20.86 ± 6.06 11.34 ± 8.91 0.01 ± 2.23 
F-4 14.56 ± 6.46 0.01 ± 1.17 0.01 ± 7.60 
F-2 12.57 ± 8.30 0.01 ± 0.87 0.01 ± 5.95 
Chloroquine (29.64 ± 3.35 μM) 0.31 ± 3.28 70.68 ± 0.97 
Quinine (63.00 ± 3.27 μM) 2.53 ± 1.17 0.01 ± 6.08 
EDTA N.D. N.D. (23.90 ± 1.83 μM) 
Ascorbic acid N.D. (19.31 ± 2.62 μM) N.D. 
 
4.4 Discussion 
The antimalarial activity of the compounds ranged with IC50 values of 31.31 ± 0.87 µM to 
8.74 ± 13.66% inhibition of parasite growth at 100 µM (Table 4.2), indicating that the 
hybridisation of the chloroquinoline and chalcone moieties did not act in a synergistic 
manner to produce highly potent compounds, and did not warrant further screening 
against a chloroquine-resistant strain of P. falciparum. None of the compounds exhibited 
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any notable haemolytic activity, with % haemolysis ranging from 0.47 ± 0.77% to 2.20 ± 
0.54% at 100µM (Table 4.2), indicating that the variable antimalarial activity of the 
compounds was not due to a direct effect on the erythrocyte itself, but rather due to the 
structural differences of the compounds.       
Compounds F-13 (IC50 value: 31.31 ± 0.87 µM), F-10 (IC50 value: 31.54 ± 3.03 µM), F-1 (IC50 
value: 31.98 ± 1.27µM) and F-3 (IC50 value:  39.17 ± 2.05µM) exhibited the best antimalarial 
activity (Table 4.2). Structure-activity relationship of the compounds revealed that 
compounds F-13, F-10 and F-1 all had pyridine ring substitutions at R4 and a hydrogen group 
at R3, with either hydrogen or methyl groups at R1 and R2. Whilst compound F-3, which had 
the highest IC50 value of the four, had hydrogen groups at R
1, R2 and R3, with a 4-chloro 
phenyl ring at R4. The antimalarial activity conferred by the pyridine ring substitution at R4 
become evident when comparing compounds F-13 and F-14, which had identical groups at 
R1, R2 and R3, yet differed with respect to R4 (Table 4.2), resulting in the 1.9-fold decrease in 
antimalarial activity  observed in compound F-14 (Table 4.2).  
The substitution of either a chloro- or bromo- group on the phenyl ring appeared to have 
no influence on antimalarial activity, as revealed by a comparison of compounds F-11 and 
F-12, which had identical groups at R1, R2, and R3, but differed with respect to a chloro- and 
bromo- substitution at C3 on the phenyl ring of R4 (Table 4.2). Structure-activity 
relationships of the C3 and C4 bromo-substituted compounds revealed that the main 
determinant of antimalarial activity appeared to be the positioning of the methyl and 
hydrogen substitutions at R1, R2 and R3, rather the positioning of the bromo-group on C3 or 
C4 (Table 4.2). 
A study conducted by Domínquez et al. (2001) testing the activity of a similar series of 
quinolinyl chalcones against the FCB1 chloroquine-resistant strain of P. falciparum, showed 
that a single bromo- or chloro-substitution on C4 of the phenyl ring displayed no 
antimalarial activity, with IC50 values > 200 µM. However, di-chloro substitutions at the C
2 
and C4 (Figure 4.9a) and C2 and C5 positions produced compounds with IC50 values of 19 µM 
and 48.6 µM, respectively; whilst di-substitution at C3 and C4 abolished antimalarial activity.  
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Figure 4.9: Quinoline-chalcones previously assessed for antimalarial activity. a: Domínquez 
et al. (2001); b: Liu et al. (2001); c,d: Sharma et al. (2009); e:  Guantai et al. 
(2010); f: Ferrer et al. (2009). 
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Differences between the results obtained by Domínquez et al. (2001) and this study may 
have been attributed to the different strains of P. falciparum used. Domínquez et al. (2001) 
found the IC50 value of chloroquine to be 80nM in the FCB1 strain, as opposed to the IC50 
value of 6.5 ± 0.2 nM as obtained in the 3D7 strain (Table 4.2). Furthermore, the 
compounds tested by Domínquez et al. (2001) had methoxy groups at R1 and R2 (Figure 
4.9a), instead of hydrogen and methyl groups as in this study (Table 4.2). 
In a large structure-activity analysis performed against the chloroquine-resistant K1 strain 
of P. falciparum, Liu et al. (2001) identified 1-(2’,3’,4’-trimethoxyphenyl)-3-(3-quinolinyl)-2-
prop-1-one (Figure 4.9b) as a promising inhibitor of parasite growth, with an IC50 value of 2 
µM (Liu et al., 2001). Structural analysis pointed to the fact that 3-quinolinyl derivatives 
were more active than 4-quinolinyl derivatives, regardless of ring substitutions. Whilst also 
pointing to the fact that electron-acceptor groups, such as difluoro- or dichloro- at C2, C3 or 
C2, C4 positions on ring A were not necessarily contributors to antimalarial activity (Figure 
4.9b) (Liu et al., 2001).  
In general, structure-activity relationships of quinoline and chloroquinoline-chalcones paint 
a complicated and sometimes contradictory picture. Sharma et al. (2009) demonstrated 
that 4-oxo and 4-amino linked quinoline-chalcones (Figure 4.9c and d, respectively) 
displayed no activity against the NF-54 chloroquine-sensitive strain of P. falciparum, when 
the R group was a pyridine ring, or a chloro-, bromo-, nitro-, methyl- or methoxy- 
substituted phenyl ring  (Sharma et al., 2009).   
A recent study conducted by Guantai et al. (2010) examined the antimalarial activity of 
triazole-linked chalcones against the chloroquine-sensitive D10 strain and the chloroquine-
resistant Dd2 and W2 strains of P. falciparum.  Three compounds exhibited IC50 values in 
the sub-micromolar range. The most active, 3-{4-[1-(7-chloro-quinolin-4-yl)-1H-
[1,2,3]triazol-4-ylmethoxy]-3-methoxy-phenyl}-1-(2,4-dimethoxy-phenyl)-propenone, which 
was dimethoxylated at positions C2 and C4 on the phenyl ring (Figure 4.9e), inhibited all 
three strains with IC50 values of  0.04 µM, 0.07 µM and 0.09 µM, respectively (Guantai et 
al., 2010). However, it was only 0.7-fold more active than chloroquine in the Dd2 
(chloroquine-resistant) strain, whereas in the D10 (chloroquine-sensitive) and W2 
(chloroquine-resistant) strains, it was 2.4- and 1.3-fold less active, respectively.   
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The same study found that none of the compounds containing halogen substitutions on the 
phenyl ring exhibited sub-micromolar IC50 values, and pointed to the 7-chloroquinoline 
moiety as a possible contributing factor for the activity of the compounds, through the 
inhibition of haemozoin formation (Guantai et al., 2010). However, when tested for β-
haematin inhibitory activity, no correlation was observed between the β-haematin 
inhibitory activity and the antimalarial activity of the compounds (Guantai et al., 2010).    
Similarly, in this study, compounds F-13, F-10 and F-1, which exhibited the best antimalarial 
activity (Table 4.2) were only capable of inhibiting the formation of β-haematin by between 
21 and 32% at 400 µM (Table 4.3). Whilst compounds F-14 and F-8, which exhibited the 
best β-haematin inhibitory activity at 400 µM (Table 4.3), had the highest IC50 values when 
tested against the parasite (Table 4.2). The only compound in which the antimalarial and β-
haematin inhibitory activity appeared to correlate was compound F-3, which had a chloro-
substitution at C4 on the phenyl ring of R4, with an IC50 value of 39.17 ± 2.05 µM (Table 4.2) 
and % inhibition of β-haematin formation of 89.46 ± 10.00% at 400 µM (Table 4.3), 
respectively. 
Ferrer et al. (2009) also found that a chloro-substitution on C4 of the phenyl ring (Figure 
4.9f) in a series of chloroquinoline-chalcones conferred β-haematin inhibitory activity, 
whereas a chloro-substitution at C3 abolished β-haematin inhibitory activity. This was 
similar to that observed in compounds F-11 and F-7 (Table 4.3). The inverse was noted 
when the phenyl ring was substituted with a different halogen. The substitution of a fluoro- 
group at position C4 abolished β-haematin inhibitory activity, whereas a substitution at C3 
conferred β-haematin inhibitory activity (Ferrer et al., 2009). A comparison of compounds 
F-8 and F-9, which both had a methyl group at R1 and hydrogen at R2 and R3, revealed that 
positioning of the bromo-substitution at C4 (compound F-8) instead of C3 (compound F-9) 
(Table 4.2) resulted in a 2.9-fold increase in β-haematin inhibitory activity (Table 4.3). 
However, when comparing compounds F-14 and F-8, both of which exhibited β-haematin 
inhibitory activity at 400 µM (Table 4.3), compound F-14 had a bromo- substitution at C3, 
whereas compound F-8 had a bromo-substitution at C4 (Table 4.2). Indicating that, as was 
observed with antimalarial activity, the positioning of the methyl and hydrogen 
substitutions at R1, R2 and R3 may also play a role in β-haematin inhibitory activity. 
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However, in the Ferrer et al. (2009) study, active compounds exhibited   β-haematin 
inhibitory activity similar to that of chloroquine (96.61 ± 0.26% inhibition of β-haematin 
formation at 25 µM). Ferrer et al. (2009) concluded that the β-haematin inhibitory activity 
observed was as a result of the 4-amino-7-chloroquinoline moiety; with hydrogen, halogen 
or N,N-dimethylamino substitutions on the phenyl ring of the chalcone moiety resulting in 
secondary interactions with haem (Ferrer et al., 2009). In this respect, the lack of similar β-
haematin inhibitory activity of this series of compounds may be attributed to the 
positioning of the chloro-group at the C2 position of the quinoline ring, as opposed to the C7 
position of chloroquine (Egan et al., 2000). Structure-activity relationships have pointed to 
the fact that although compounds possessing the quinoline ring structure are capable of 
forming a complex with Fe(III) protoporphyrin-IX, the chloro-substitution on C7 of the 
quinoline ring results in the actual β-haematin inhibitory activity of the compound (Egan et 
al., 2000; Kumar et al., 2007).  
Although the antimalarial activity of compounds F-13, F-10 and F-1 may not be attributed 
to the inhibition of haemozoin formation, their mechanisms of action may lie in their ability 
to inhibit haemoglobin digestion and alternative pathways of haem detoxification. The 
pyridine  substitution at R4 (Table 4.2) may have facilitated the accumulation of these 
compounds in the food vacuole; with nitrogen-containing heterocyclic compounds shown 
to concentrate in the acidic environment of the food vacuole due to their low pKa values 
(Mishra et al., 2008).  
Haemoglobin endocytosed from the erythrocyte is catabolised by proteases in a semi-
ordered fashion, to provide amino acids for parasitic protein synthesis (Figure 4.10) 
(Sharma, 2005; Mishra et al., 2008). Several malarial proteases are involved in haemoglobin 
catabolism, namely; the aspartic proteases (plasmepsins I, II, IV and the histoaspartic 
protease, plasmepsin III), the cysteine proteases (falcipains), the metalloprotease 
(falcilysin) (Figure 4.10) and aminopeptidases (Banerjee et al., 2002; Sharma, 2005; 
Naughton et al., 2010).  The plasmepsins initiate the process of haemoglobin catabolism by 
cleaving the haemoglobin molecule in a highly conserved hinge region, thereby separating 
the haemoglobin tetramer (Banerjee et al., 2002; Sharma, 2005; Naughton et al., 2010). 
Thereafter, the globin chains are processed into smaller peptides by falcipains and 
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falcilysin, and finally these peptides are hydrolysed to free amino acids by aminopeptidases 
(Gavigan et al., 2001; Sharma, 2005; Naughton et al., 2010). 
 
Figure 4.10: The catabolism of haemoglobin in the food vacuole of P. falciparum (Egan, 
2003). Where: RBC = red blood cell; Hb =haemoglobin; HAP = histo-aspartic 
protease; HRP2 = histidine-rich protein.  
 
Four falcipains have been identified, namely; falcipain-1, falcipain-2, falcipain-2’, and 
falcipain-3 (Dahl and Rosenthal, 2005; Naughton et al., 2010). Falcipain-2 has been shown 
to localise primarily in the food vacuole, appearing first in the early trophozoite-stage, and 
persisting into the late schizont-stage, where it is also involved in the rupture of the red 
blood cell membrane during merozoite egress; whereas falcipain-3 synthesis peaks in the 
late trophozoite stage (Dahl and Rosenthal, 2005; Dasaradhi et al., 2005).  
The exact mechanism of the antimalarial activity of chalcones has yet to be described, but 
homology models have shown that the chalcone structure assumes a linear or planar 
conformation, and is capable of fitting into the active site of the malarial cysteine protease 
enzyme, thereby inhibiting its functioning (Mishra et al., 2008). Mishra et al. (2008) 
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proposed that the antimalarial activity of a triazolyl-substituted chalcone (IC50 value of 1.52 
± 0.04 µM against the 3D7 strain of P. falciparum) was as a result of the protonation of the 
nitro- groups in the triazolyl moiety, at the acidic pH of the food vacuole, thereby 
enhancing the interaction of the compound with the histidine residue of the enzyme 
(Figure 4.11). 
 
Figure 4.11: The proposed interaction of a chalcone with the histidine residue at the active 
site of a malarial cysteine protease (Mishra et al., 2008). Where: green = 
chloride; red = oxygen; blue = nitrogen. 
 
Previous studies examining the effects of cysteine protease inhibitors on P. falciparum have 
shown that they inhibit parasite growth in the trophozoite stage, resulting in morphological 
effects such as swollen dark-staining food vacuoles due to the accumulation of undegraded 
haemoglobin (Rosenthal, 1995; Rosenthal and Meshnick, 1996; Domínquez et al., 1997). 
Although compound F-13 inhibited parasite growth in the early-mid trophozoite-stage at 
the IC50 value (Section 4.3.3), swollen dark-staining food vacuoles were not observed in 
treated parasites; with haemozoin formation also visible (Figures 4.6B). However, 
Naughton et al. (2010) showed that early trophozoite-stage parasites of the chloroquine-
sensitive 3D7 strain incubated with the cysteine protease inhibitor, ι-trans-epoxy-succinyl-
leucylamido-(4-guanidino)-butane (E-64) at its IC50 value (3 µM) showed no reduction in 
haemozoin formation. Whereas parasites incubated with plasmepsin inhibitor I (PM-I) at its 
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IC50 value (0.8 µM) exhibited an approximate reduction of 70% in haemozoin formation 
(Naughton et al., 2010).  
Thus, based on the morphological and stage-specific effects of compound F-13 at the IC50 
value; it can be proposed that its antimalarial activity may be attributed to possible 
cysteine protease inhibition. Most likely inhibition of falcipain-2, since parasite growth was 
halted in the early-mid trophozoite-stage, with haemozoin formation attributed to the fact 
that falcipain-2 inhibition would not act to inhibit haemozoin formation, but would inhibit 
protein degradation, resulting in parasite death (Naughton et al., 2010). The inhibition of 
falcipain-2 by compound F-13 may have possibly been as a result of the interaction of the 
protonated nitro- group of the pyridine substitution and the carbonyl moiety with the 
histidine residue of the enzyme, in a manner similar to the inhibition of the enzyme by a 
triazolyl-substituted chalcone, as proposed by Mishra et al. (2008) (Figure 4.11). 
However, parasites treated with compound F-13 at the IC90 value showed a lack of 
haemozoin formation and did not develop past the late ring-stage (Figure 4.8), possibly as a 
result of the induction of additional antimalarial mechanisms of action attributed to 
chalcones. 
Alternative mechanisms for the detoxification of haem by the parasite have been 
described, namely GSH-mediated degradation of Fe(III) protoporphyrin-IX and haemozoin 
formation mediated by proteins (Papalexis et al., 2001; Kumar et al., 2007). In the first 
mechanism, it is proposed that the amphipathic nature of Fe(III) protoporphyrin-IX allows it 
to pass through the food vacuole membrane into the parasite cytosol, where it is degraded 
by host-derived GSH which is  endocytosed from the red blood cell cytosol together with 
haemoglobin in the late ring-stage  (Gavigan et al., 2001; Frölich et al., 2005; Kumar et al., 
2007).  
Compounds possessing the α, β-unsaturated carbonyl group (Figure 4.1a) are capable of 
forming conjugates with GSH by an enzyme catalysed addition of GSH to the double bond. 
Some chalcones have been shown to form a conjugate with GSH, thereby inhibiting the 
degradation of Fe(III) protoporphyrin-IX  (Nadelmann et al., 1997; Go, 2003; Frölich et al., 
2005). In this respect, the compounds may have inhibited the GSH-mediated degradation of 
Fe(III) protoporphyrin-IX, resulting in parasite death due to oxidative stress, thus mimicking 
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the proposed mechanism of action of chloroquine (Figure 4.12) (Müller, 2004; Kumar et al., 
2007).  
Chloroquine
Haem
Haem-chloroquine
complex
Lipid peroxidation
of membranes
Oxidative stress
Reactive oxygen species
Increase in free haem
concentration
Inhibition of haemozoin
formation
DNA
damage
Protein-carbonyl
formation
PARASITE DEATH
Inhibition of GSH-mediated
haem degradation
 
Figure 4.12: Proposed mechanisms of action of chloroquine (adapted from Kumar et al., 
2007). 
 
In the case of the mechanism involving proteins, the in vitro polymerisation of Fe(III) 
protoporphyrin-IX is proposed to be promoted by histidine-rich proteins produced by P. 
falciparum, specifically histidine-rich protein-II (PfHRP-II) (Papalexis et al., 2001; Sharma, 
2005; Kumar et al., 2007). PfHRP-II is produced throughout the ring-, trophozoite- and 
schizont-stages, and has been shown to bind between 17 and 50 Fe(III) protoporphyrin-IX 
molecules, possibly acting as a catalyst of β-haematin formation by facilitating dimer 
formation in the biocrystallisation process (Papalexis et al., 2001). The role of PfHRP-II in 
haemozoin formation is contentious, with some authors claiming that the inhibition of 
PfHRP-II results in parasite death; whilst others have shown that parasites carrying a PfHRP-
II knock-out gene are still capable of haemozoin formation, and remain viable (Sharma, 
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2005; Egan, 2008). Chalcones have shown to alkylate proteins, and may inhibit the HRP-II 
mediated-formation of haemozoin, although the majority of chalcone-mediated protein 
alkylation appears to occur in sulphur-based nucleophiles (O’ Neill and Posner, 2004).  
Protein alkylation by chalcones may be a concern if it is not specific to the parasite, and 
results in host toxicity. When screened for cytotoxicity against a breast cancer cell-line 
(MCF-7), compounds F-9, F-3, F-12, and F-7 inhibited cell growth by less than 20% at 100 
µM, whereas  compound F-13 inhibited cell growth by 66% and 36%  at 100 µM and 50 µM, 
respectively (Hayat et al., 2011). However, in the red blood cell toxicity assay the 
compounds showed low levels of toxicity, only causing between 0.47 and 2.20% haemolysis 
at 100 µM (Table 4.2). It has been shown that quinolines have antitumour activity and 
suppress the growth of various cancer cell-lines, including the MCF-7 cell-line; where 
chloroquine and quinine inhibited cell growth with IC50 values of 33 µM and 40 µM, 
respectively, following a 48 hour incubation period (Martirosyan et al., 2004; Ferrer et al., 
2009). In this respect, the toxicity of the compounds may be selective to cancer cells only; 
however, the compounds should be screened against a normal cell-line and their safety 
indices compared to that of chloroquine and quinine. 
Despite their abilities to induce oxidative stress, chalcones have shown to exhibit anti-
oxidant properties (Go, 2003; Ren et al., 2003; Nowakowska, 2007). However, in this study, 
none of the compounds were capable of acting as anti-oxidants by scavenging the free-
radical of DPPH• or by chelating Fe(II) (Table 4.3). With compounds F-1 and F-14 exhibiting 
the best DPPH• free-radical scavenging and Fe(II) chelating activity, respectively, and only 
been capable of scavenging 11.34 ± 8.91% of DPPH• at 240 µM, and chelating 7.57 ± 4.13% 
of Fe(II) at 200 µM, respectively (Table 4.3). However, the iron chelating and anti-oxidant 
capabilities of chalcones has largely been attributed to polyhydroxylation of the phenyl ring 
(Cheng et al., 1998; Ren et al., 2003; Grazul and Budzisz, 2009), with none of the test 
compounds containing hydroxyl- substitutions at R1, R2 or R4 (Table 4.2). Chloroquine was 
capable of chelating 70.68 ± 0.97% Fe(II) at 200 µM (Table 4.3), most likely through the 
interaction of Fe(II) with the nitro- donor groups of chloroquine; with removal of the 
aminoalkyl side chain possibly resulting in the loss of Fe(II) chelating activity observed in the 
compounds. 
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Numerous other antimalarial mechanisms of action of chalcones have been proposed. 
However, these mechanisms of action were not correlated with the antimalarial activity, 
indicating that chalcone derivatives may act on different parasitic metabolic pathways 
depending on their side-chain substitutions. For example, Go et al. (2004) proposed that 
chalcones were capable of inhibiting the parasite-induced new permeation pathways 
formed in the erythrocyte membrane at the end of ring-stage, concluding that dimethoxy- 
and methoxychalcones were capable of inhibiting sorbitol-induced haemolysis. However, 
this did not necessarily correlate with their antimalarial activity (Go et al., 2004). A 
subsequent study by Bhattacharya et al. (2009) testing three chalcone derivatives with IC50 
values below 10 µM against P. falciparum, found that only a triazole-substituted chalcone, 
and not a pyrrole or benzotriazole-substituted chalcone, inhibited sorbitol-induced 
haemolysis (Bhattacharya et al., 2009).  
The general chalcone structure was identified as a pharmacophore capable of inhibiting 
Plasmodium falciparum MO15-related kinase (Pfmrk), a plasmodial CDK expressed 
throughout the trophozoite- and schizont-stages, responsible for activating other 
CDK/cyclin complexes (Geyer et al., 2005; Keenan et al., 2005). Geyer et al. (2009) showed 
that from a series of structurally related chalcone derivatives, the most potent Pfmrk 
inhibitors also displayed the best antimalarial activity. However, they also found that some 
chalcone derivatives that exhibited no Pfmrk inhibitory activity (IC50 value > 100 µM) 
inhibited parasite growth with IC50 values < 10 µM, concluding that Pfmrk and antimalarial 
activity was weakly correlated (Geyer et al., 2009).     
It is evident from the antimalarial activity of the compounds that the hybridisation of the 
chloroquinoline and chalcone moieties produced compounds with antimalarial activity 
similar to that of chalcones, which generally exhibit IC50 values against P. falciparum in the 
micromolar concentration range (Chen, 2003; Nowakowska, 2007). However, this 
unsuccessful hybridisation could be improved if a synergistic or additive interaction could 
be achieved when combined with a standard antimalarial, such as quinine. When 
compound F-13 was combined with quinine an additive interaction was noted (Figure 4.5; 
Appendix D). It is proposed that the activity of the two components in the combination 
acted on different parasitic targets, with compound F-13 inhibiting growth in the early-mid 
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trophozoite-stage (Figure 4.6) and quinine appearing to act mainly in the late trophozoite-
stage (Figure 3.5).  
Interestingly, hybrid compounds in which an endoperoxide-like compound was linked to a 
chalcone were active against the chloroquine-resistant K1 strain of P. falciparum in the 
nanomolar concentration range, similar to the antimalarial activity of endoperoxides 
(Jefford, 2007). It was proposed that the endoperoxide component would target haem in 
the food vacuole, resulting in decomposition of the carbon-centred radical to release the 
chalcone, which would inhibit malarial cysteine proteases in the food vacuole (Jefford, 
2007; Walsh and Bell, 2009).  Similarly, in combination studies with triazole, pyrrole, and 
benzotriazole-substituted chalcones and the endoperoxide, artemisinin, an additive 
interaction was also noted. This interaction was attributed to the chalcone derivatives 
inhibiting parasite growth in the trophozoite-stage, and artemisinin inhibiting all stages of 
asexual growth (Bhattacharya et al., 2009).   
Although the antimalarial activity of the compounds was not as promising as expected, 
factors such as the additive interaction when combined with quinine, and that chalcones 
provide an excellent antimalarial drug scaffold, warrant further investigation into a second 
generation of these compounds. Structural improvements which may produce a potent 
compound capable of inhibiting parasite growth by various mechanisms of action include 
the following: a) substitution of a chloro- group on C7 instead of C2 of the quinoline ring to 
improve β-haematin inhibitory activity; b) increasing the compound lipophilicity and c) 
substitution of nitrogen-containing heterocyclics or groups at R4 to not only facilitate the 
accumulation of the compounds in the food vacuole, but also the formation of hydrogen 
bonds with the histidine residues of falcipain-2. 
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CHAPTER 5: THE ANTIMALARIAL PROPERTIES OF NUCLEOSIDE 
PHOSPHONATES, PHOSPHONIC ACIDS AND  
PURINE/PYRIMIDINE DERIVATIVES  
5.1 Introduction 
Various discrepancies exist in the processes of nucleic acid metabolism and the overall base 
composition in the malaria parasite and human host. Purine and pyrimidine metabolism in 
P. falciparum occur via salvage and de novo pathways, respectively, to replicate a parasitic 
genome that is highly AT skewed (81%) (Hyde, 2007). In contrast, purine and pyrimidine 
metabolism in the human host occur via de novo synthesis and both de novo and salvage 
pathways, respectively (Jana and Paliwal, 2007; Hyde, 2007).    
5.1.1 Purine uptake 
The malaria parasite lacks the necessary enzymes to synthesise the purine scaffold de novo. 
Instead, a wide variety of parasite-derived purine transporters and salvage enzymes, 
together with host-derived enzymes allow the parasite to transport and metabolise 
salvaged purines (Jana and Paliwal, 2007; Hyde, 2007). P. falciparum scavenges purines in 
the form of bases or nucleosides, as purine nucleotides are unlikely to cross lipophilic 
membranes due to their deprotonation at a physiological pH (Carter et al., 2001; Downie et 
al., 2008; Hocková et al., 2009). 
The erythrocytic purine pool is not sufficient to maintain growth of the parasite, with 
parasitic growth depending on an exo-erythrocytic supply of purines. The salvage pathway 
begins with the translocation of purines across the host cell, parasitophorous vacuole, and 
the parasite plasma membranes (Carter et al., 2001; Downie et al., 2008). The transport of 
nucleosides into the infected red blood cell is mediated by both the host cells nucleoside 
transporters, as well as new permeation pathways (Gero et al., 2003). The new permeation 
pathways induced during the trophozoite-stage, transport substances that ordinarily would 
not be able to penetrate the red blood cell membrane. These transporters are polyspecific, 
non-saturable, preferential transporters of hydrophobic solutes and anions (Gero et al., 
2003; Biagini et al., 2005; Jana and Paliwal, 2007). Nucleoside transporters in mammalian 
cells are high-affinity integral membrane glycoproteins that mediate the uptake of both 
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purine and pyrimidine bases and nucleosides, as well as synthetic analogues. The 
transporters may be divided into two classes, namely; equilibrative nucleoside transporters 
(ENTs) and concentrative nucleoside transporters (CNTs) (Carter et al., 2001; Lin and 
Buolamwini, 2007). CNTs are sodium-dependant transporters which transport nucleosides 
against a concentration gradient, whereas ENTs transport nucleosides down their 
concentration gradient (Carter et al., 2001; Lin and Buolamwini, 2007). The nucleoside 
transporters located in the red blood cell membrane are transporters of the ENT type, 
specifically equilibrative sensitive (ENT1). It is a high-affinity nucleoside transporter that is 
sensitive to inhibition by both the nucleoside transport inhibitor 6-[(4-nitrobenzyl)thio]-9-β-
D-ribofuranosyl purine (NBMPR), and the coronary vasodilator, dipyridamole (Gupte and 
Buolamwini, 2004; Lin and Buolamwini, 2007). 
Once inside the red blood cell cytosol, the salvaged purines cross the parasitophorous 
vacuole membrane via large pores present on the membrane, and are then transported 
across the parasite plasma membrane by the Plasmodium falciparum equilibrative 
nucleoside transporter 1 (PfENT1) (El Bissati et al., 2006; Downie et al., 2008). PfENT1 is 
localised to the parasite plasma membrane, and although it shares some similarities with 
the human ENT family, it differs with respect to its substrate specificity, kinetics and lack of 
sensitivity to NBMPR. However, it retains sensitivity to inhibition by dipyridamole (El Bissati 
et al., 2006; Lin and Buolamwini, 2007). PfENT1 is a low-affinity rapid transporter that has a 
broad-specificity for both D- and L-nucleosides and bases, and transports purines with a 
much higher affinity than pyrimidines (El Bissati et al., 2006; Downie et al., 2008; 
Riegelhaupt et al., 2010). In contrast to human ENT1, a variety of purines are transported 
by PfENT1, including adenosine, inosine, hypoxanthine, guanine, guanosine and xanthine 
(Downie et al., 2008; Riegelhaupt et al., 2010). Although PfENT1 is the primary mechanism 
of uptake of adenosine, hypoxanthine and inosine, parasites carrying a deletion of the 
PfENT1 gene are capable of transporting these purines, at supraphysiological 
concentrations, indicating that perhaps a secondary transport mechanism exists (El Bissati 
et al., 2006; Downie et al., 2008; Riegelhaupt et al., 2010). 
 
 
   
124 
 
5.1.2 Purine salvage and metabolism 
Purine metabolism begins in the cytosol of the infected red blood cell. Adenosine is 
converted into inosine by human adenosine deamininase enzymes and then into 
hypoxanthine by purine nucleoside phosphorylase enzymes (Figure 5.1) (Hyde, 2007; 
Downie et al., 2008). Inosine and hypoxanthine are then transported into the parasite by 
PfENT1 (Hyde, 2007; Downie et al., 2008). Alternatively, adenosine and inosine may be 
transported directly into the parasite (Figure 5.1) (Downie et al., 2008). Hypoxanthine, 
guanosine, guanine and xanthine require no further metabolism, and are transported into 
the parasite cytosol by PfENT1. Whereas adenine, which may be metabolised to other 
bases or nucleosides within the red blood cell cytosol, enters the parasite via both PfENT1 
and non-PfENT1 mechanisms (Figure 5.1) (Hyde, 2007; Downie et al., 2008). 
P. falciparum lacks an adenosine kinase gene, and is therefore incapable of converting 
adenosine to adenosine monophosphate (AMP) (Riegelhaupt et al., 2010). For this reason, 
upon entry into the parasite cytosol, adenosine is converted into hypoxanthine, via 
Plasmodium falciparum adenosine deaminase and nucleoside phosphorylase enzymes 
(Hyde, 2007; Downie et al., 2008; Riegelhaupt et al., 2010). The ability of the Plasmodium 
falciparum adenosine deaminase  and nucleoside phosphorylase  enzymes  to utilise 
methylthiopurines such as methylthioadenosine and methylthioinosine, respectively, to 
form hypoxanthine, allows for the salvage of purines from the polyamine biosynthesis 
pathway, as well as from traditional purine salvage pathways (Downie et al., 2008).  
Given the central role for hypoxanthine in the purine salvage pathway of P. falciparum, the 
Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase 
(PfHGXPRT) enzyme proves crucial for parasite survival (Hyde, 2007; Hocková et al., 2009; 
Riegelhaupt et al., 2010). PfHGXPRT provides an ideal drug target, as it shares only partial 
homology with its mammalian counterpart, hypoxanthine-guanine phosphorribosyl-
transferase (HGPRT), with the human host not solely dependant on the activity of HGPRT,  
due to the ability of mammalian cells to synthesise purines de novo (Jana and Paliwal, 2007; 
Hocková et al., 2009). 
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Figure 5.1: Purine salvage pathways in P. falciparum (Downie et al., 2008).                   
Abbreviations: Ado, adenosine; hADA, human adenosine deaminase; Ino, 
inosine; hPNP, human purine nucleoside phosphorylase; Hxt, hypoxanthine; 
Guo, guanosine; Gua, guanine; Xan, xanthine; Ade, adenine; Ns/Nb, 
nucleoside/nucleobase; RBC, red blood cell; PV, parasitophorous vacuole; 
PfNT1, Plasmodium falciparum equilibrative nucleoside transporter 1; PfADA, 
Plasmodium falciparum adenosine deaminase; MTA, methylthioadenosine; 
MTI, methylthioinosine; PfPNP, Plasmodium falciparum purine nucleoside 
phosphorylase; PRPP, phosphoribosylpyrophosphare; PfHGXPRT, Plasmodium 
falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase; 
PfAPRT, Plasmodium falciparum adenine phosphoribosyltransferase; IMP, 
inosine monophosphate; AMP, adenosine monophosphate; GMP, guanosine 
monophosphate; XMP, xanthosine monophosphate. 
 
PfHGXPRT catalyses the ribophosphorylation of the nucleo(bases), hypoxanthine, guanine, 
and xanthine into their nucleoside monophosphate forms, inosine monophosphate (IMP), 
guanosine monophosphate (GMP), and xanthosine monophosphate (XMP), respectively 
(Hyde, 2007; Downie et al., 2008). A proposed second enzyme, Plasmodium falciparum 
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adenine phosphoribosyltransferase has been suggested for the conversion of adenine to 
AMP. However, the existence of this enzyme remains contentious, with evidence pointing 
to the fact that the conversion of adenine occurs in the red blood cell cytosol, or that 
adenine is not metabolised by the parasite (Downie et al., 2008). 
The majority of salvaged purines results in the formation of IMP from hypoxanthine, with 
IMP acting as the precursor for the formation of other purine nucleotides (Riegelhaupt et 
al., 2010). In order to form AMP, IMP is converted to adenylsuccinate and then AMP by 
adenylsuccinate synthetase and adenylsuccinate lyase, respectively (Downie et al., 2008; 
Bulusu et al., 2011). In the case of GMP formation, IMP dehydrogenase converts IMP to 
XMP, which is then converted to GMP by the activity of the GMP synthetase enzyme 
(Downie et al., 2008; Bulusu et al., 2011). AMP and GMP are then phosphorylated by 
adenylate kinase and guanylate kinase, respectively, to form adenosine diphosphate (ADP) 
and guanosine diphosphate (GDP), which are then processed further to be used for nucleic 
acid synthesis, adenosine triphosphate (ATP) generation and cell signalling (Hyde, 2007; 
Downie et al., 2008; Riegelhaupt et al., 2010). 
5.1.3 De novo pyrimidine synthesis 
In contrast to purine salvage, pyrimidine nucleotide synthesis in P. falciparum occurs 
through a de novo pathway due to the fact that the parasite lacks the uridine kinase and 
thymidine kinase enzymes necessary for pyrimidine salvage (Hyde, 2007). Consequently 
exogenous pyrimidines are not incorporated into nucleic acids, with the exception of orotic 
acid (Hyde, 2007; Jana and Paliwal, 2007; Parker et al., 2000). Cytidine triphosphate (CTP) 
and uridine triphosphate (UTP) are synthesised (Figure 5.2) from the amino acid precursors’ 
glutamine and aspartate (Hyde, 2007; Ginsburg, 2011). Synthesis occurs via a multi-step 
process, whereby orotic acid and a ribose-5-phosphate moiety result in the formation of 
orotodine 5’-monophosphate, which is decarboxylated to form uridine 5’-monophosphate 
(UMP) (Hyde, 2007; Ginsburg, 2011). UMP is then twice phosphorylated to form UTP, and 
finally converted into CTP via the action of CTP synthase (Hyde, 2007; Jana and Paliwal, 
2007; Ginsburg, 2011). Regulation of CTP formation occurs via the first enzyme in the 
pathway, carbamoyl phosphate synthetase, which is activated by the 5-phosphoribosyl 
pyrophosphate enzyme, and inhibited by UTP (Hyde, 2007).  
   
127 
 
 
 
L-glutamine + 2ATP + HCO3
-
 
CPS 
Carbamoyl phosphate 
ATCase L-aspartate 
Carbamoyl aspartate 
DHOase 
Dihydroorotate 
DHODH 
Orotate 
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CTPS 
Cytidine 5’-triphosphate (CTP) 
 
Figure 5.2: The de novo synthesis of pyrimidines in Plasmodium falciparum (adapted from 
Hyde, 2007). Yellow shaded boxes represent enzymes of the pathway. 
Abbreviations: CPS, carbamoyl phosphate synthase; ATCase, aspartate 
carbamoyltransferase; DHOase, dihydroorotase; DHODH, dihydrorotate 
dehydrogenase; OPRT, orotate phosphoribosyltransferase; OMPDC, orotidine 
5’-monophosphate decarboxylase; CTPS, CTP synthase. 
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5.1.3.1 The role of the folate pathway in thymidine synthesis 
Thymidine synthesis in P. falciparum requires the conversion of deoxyuridine 5’-
monophosphate (dUMP) into deoxythymidine 5’-monophosphate (dTMP) and is dependent 
upon cofactors of the folate pathway (Hyde, 2005, 2007; Chango and Abdennebi-Najar, 
2011). The most important of which, 5,10-methylenetetrahydrofolate, provides the methyl 
group that converts dUMP into dTMP, from which dTTP is formed, and consequently 
incorporated into parasitic DNA  (Hyde, 2005, 2007; Chango and Abdennebi-Najar, 2011). 
Blockade of the folate pathway, by either blocking the synthesis of molecules or salvage 
from the host, results in the death of the parasite due to thymidine starvation, as the 
parasite lacks the ability to salvage host thymidine (Hyde, 2005, 2007). The de novo folate 
pathway (Figure 5.3) initiates with the purine precursor, GTP, and requires a source of 
either salvaged para-aminobenzoic acid (ρABA) or de novo ρABA (Hyde 2005, 2007). 
The first reaction in the de novo folate pathway involves the rearrangement of the purine 
ring of GTP by GTP cyclohydrolase I to form a pterin; which is linked to ρABA by the 
dihydropteroate synthase enzyme to form a pteroate derivative (Hyde, 2007; Nzila, 2006). 
The final step in the de novo folate pathway is catalysed by dihydrofolate synthase, and 
involves the conversion of the pteroate derivative to dihydrofolate via the addition of an L-
glutamate moiety (Nzila, 2006; Hyde, 2007; Müller et al., 2010). At this stage, dihydrofolate 
may also be polyglutamated by folylpolyglutamate synthase (Figure 5.3) (Nzila, 2006; Hyde, 
2007; Müller et al., 2010).  
The thymidylate cycle comprises a component of the folate pathway and utilises either 
folates salvaged from the host, or the 7,8-dihydrofolate product of the de novo pathway 
(Figure 5.3) (Hyde, 2005, 2007; Müller et al., 2010). Three enzymes, namely, dihydrofolate 
reductase, thymidylate synthase and serine hydroxymethyltransferase are involved in the 
formation of dTMP and recycling of tetrahydrofolate (Hyde, 2007; Müller et al., 2010). 
Serine hydroxymethyltransferase  is involved in the acquisition of an one-carbon (C1) unit 
from serine to form methylenetetrahydrofolate, which in turns transfers the C1 unit to 
dUMP, through the activity of the thymidylate synthase  enzyme, forming dTMP (Figure 
5.3) (Hyde, 2007; Müller et al., 2010). For each molecule of dTMP formed, one molecule of 
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tetrahydrofolate is oxidised to dihydrofolate, which is then recycled by dihydrofolate 
reductase to form tetrahydrofolate (Hyde, 2005). 
Sulphonamides eg. 
sulphadoxine
Pyrimethamine, cycloguanil
 
Figure 5.3: The folate pathway of P. falciparum (a) and its role in the thymidylate cycle (b) 
(adapted from Müller et al., 2010). Abbreviations: GTP, guanosine 
triphosphate; GTPCH, GTP cyclohydrolase I; PTPS, 6-pyruvoyltetrahydropterin 
synthase; HPPK, 6-hydroxy-methyldihydropterin pyrophosphokinase; DHPS, 
dihydropteroate synthase; DHFS, dihydrofolate synthase; FPGS, 
folylpolyglutamate synthase; DHFR, dihydrofolate reductase;  SHMT, serine 
hydroxymethyltransferase; TS, thymidylate synthase; dUMP, deoxyuridine 
monophosphate, dUMP; deoxythymidine monophosphate, dTMP. 
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Following its synthesis in the thymidylate cycle, dTMP is phosphorylated by the enzyme 
thymidylate kinase to form dTDP which is subsequently converted by nucleoside 
diphosphate kinases to its triphosphate form, dTTP, which is then utilised for nucleic acid 
synthesis (Cui et al., 2010). 
5.1.4 Therapeutic targets 
The essential role of DNA synthesis in the survival of malaria parasite, as well as the striking 
differences in purine and pyrimidine metabolic pathways to that of the human host, 
provides promising targets for antimalarial chemotherapy. Inhibition of nucleoside 
transport via inhibition of NPPs or PfENT1, the major route of purine entry into the 
parasite, would result in purine starvation and parasite death (Parker et al., 2000). 
Alternatively, PfENT1 may be exploited to transport cytotoxic nucleoside derivatives into 
the parasite, where they would interfere with nucleic acid synthesis (Parker et al., 2000; 
Gero et al., 2003). 
Cytotoxic nucleoside and nucleobase derivatives such as 5-fluoro-2’-deoxyuridine, 6-
thioguanosine, 6-mercaptopurine riboside, 5-fluorouracil, 3’-azido-2’,3’-deoxythymidine 
(AZT), dideoxyinosine, and dideoxycytidine are validated anticancer and antiviral agents 
(Gero et al., 2003; Hyde, 2007; Cui et al., 2010). The use of cytotoxic nucleoside derivatives 
against P. falciparum has exhibited promising results. The pyrimidine analogue, 5-
fluorouracil, when used as an anticancer agent, acts as an inhibitor of the thymidylate 
synthase enzyme, however, it was not found to be transported into P. falciparum (Hyde, 
2007). Upon substitution of the uracil moiety with orotic acid, to form 5-fluoroorotic acid, 
the compound was readily taken up by the parasite and once incorporated into the 
pyrimidine biosynthesis pathway, it inactivated parasitic thymidylate synthase, killing the 
parasite at nanomolar concentrations (Hyde, 2007; Muregi et al., 2009). However, 
thymidylate synthase is highly conserved among P. falciparum and the human host, in this 
manner an effective thymidylate synthase inhibitor would be a combination of a cytotoxic 
nucleoside and a nucleoside such as uridine, which can be salvaged by the host to bypass 
host cell toxicity (Biagini et al., 2003; Hyde, 2007; Jana and Paliwal, 2007). 
Following entry into the target cell/organism, pro-drugs of nucleoside analogues are 
phosphorylated into their active triphosphate forms and exert their activity by acting as 
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DNA chain terminators. A study testing the antimalarial activity of AZT hypothesised that 
the plasmodial enzyme thymidylate kinase would be capable of converting the AZT 
monophosphate (AZTMP) pro-drug to AZT diphosphate (AZTDP). The latter would 
subsequently be converted to its triphosphate form (AZTTP) by nucleoside diphosphate 
kinase enzymes and incorporated into parasitic DNA, thereby arresting DNA replication (Cui 
et al., 2010). The results obtained showed that the monophosphate pro-drug was more 
active than the AZT parent compound; however they lacked potent antimalarial activity 
(Cui et al., 2010).  
In contrast, acyclic nucleoside phosphonates (ANPs), which are currently in use as antiviral 
treatments, showed potent antimalarial activity; with an adenine derivative, (S)-(3-hydroxy-
2-phosphonylmethoxy-propyl)adenine ((S)-HPMPA) exhibiting activity at sub-micromolar 
concentrations (Smeijsters et al., 1999). Other non-adenine ANP derivatives have also 
shown promising antimalarial activity, inhibiting growth of P. falciparum with IC50 values of 
1 µM; as well as exhibiting low toxicity towards mammalian cells (Hocková et al., 2009). The 
antimalarial activity of these ANP derivatives appears to lie in their ability to inhibit the 
PfHGXPRT enzyme in the purine salvage pathway (Figure 5.1), and thereby the production 
of nucleoside monophosphates (Hocková et al., 2009; Keough et al., 2010). ANPs, wherein 
selected purine bases are linked to the phosphate moiety via a stable phosphorous-carbon 
bond, act as analogues of the purine nucleoside monophosphate product of the PfHGXPRT-
mediated reaction (Figure 5.4) (Hocková et al., 2009; Keough et al., 2010).  
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Figure 5.4: One of the reactions catalysed by PfHGXPRT (Keough et al., 2010).  
 Where: PPί = pyrophosphate. 
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ANPs appear to be promising antimalarial agents, as currently ANPs and immucillin-5’ 
phosphates are the only known inhibitors of PfHGXPRT; however, ANPs are the only 
inhibitors capable of discriminating between PfHGXPRT and human HGPRT (Hocková et al., 
2009; Keough et al., 2010). 
Nucleoside and nucleobase analogues have been shown to be inhibitors of numerous other 
parasitic enzymes of DNA synthesis and replication, including Plasmodium falciparum 
adenosine deaminase, adenylyl cyclase, guanylyl cyclase, ribonucleotide reductase (the 
rate-limiting enzyme in DNA replication responsible for converting ribonucleotides to 
deoxyribonucleotides), as well as cyclin-dependant kinases (CDKs) (Harmse et al., 2001; 
Biagini et al., 2003; Hyde, 2007). 
5.1.4.1 The parasitic cell division cycle as a drug target 
In mammalian cells the transition through the G1, S, G2 and M phases of the cell division 
cycle is highly regulated by CDKs, which in their active forms are composed of a catalytic 
unit (CDK) and a regulatory cyclin (Harmse et al., 2001; Doerig et al., 2002; Knockaert et al., 
2002). CDKs are serine/threonine kinases that, upon binding of a cyclin, shift into an active 
conformation, which then facilitates configuration of the active site and ATP positioning 
(Geyer et al., 2005). CDK/cyclin deregulation in diseases such as cancer has fuelled the 
search for kinase inhibitors to be evaluated for the treatment of neurological and 
cardiovascular disorders, as well as viral and parasitic infections (Harmse et al., 2001; 
Knockaert et al., 2002). 
The cell division cycle of P. falciparum differs greatly from that of mammalian cells in that 
during schizogony the parasite undergoes multiple rounds of division to produce 8-32 
merozoites, in contrast to the two daughter cells produced in mammalian cell division 
(Harmse et al., 2001; Geyer et al., 2005). In this regard, parasitic cell division is regulated 
differently to that of mammalian cells, with identified CDKs or CDK-related kinases 
exhibiting 40-60% homology to human CDKs (Knockaert et al., 2002; Geyer et al., 2005). 
Several genes encoding for CDKs and cyclins have been identified in P. falciparum and have 
shown to be inhibited by human CDK inhibitors (Doerig et al., 2002; Geyer et al., 2005). 
CDK-like sequences include; Plasmodium falciparum protein kinase 5, Pfmrk, Plasmodium 
falciparum protein kinase 6, and the Plasmodium falciparum cyclin-related kinases-1,-3,-4 
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and -5 (Doerig et al., 2002; Geyer et al., 2005). Plasmodium falciparum protein kinase 5 is 
related to the human CDK1 and CDK5; however unlike its mammalian counterparts, it 
possesses in vitro autophosphorylation activity (Doerig et al., 2002; Geyer et al., 2005). 
Pfmrk, expressed throughout the trophozoite- and schizont-stages, is related to the human 
CDK7, which in mammalian cells is responsible for activating other CDK/cyclin complexes 
(Doerig et al., 2002). Plasmodium falciparum protein kinase 6, also expressed in the 
trophozoite- and schizont-stages, exhibits limited homology to human CDK2 and the p38 
mitogen-activated protein kinase and interestingly, does not require activation by cyclins 
(Doerig et al., 2002; Geyer et al., 2005). Plasmodium falciparum cyclin-related kinase-1 is 
expressed mainly in the non-dividing gametocyte and exhibits homologies to a group of 
kinases mainly found to be involved in apoptosis induction and cellular differentiation. 
Plasmodium falciparum cyclin-related kinases-3 and -4 are expressed in both the asexual 
and gametocyte stages of the parasitic life cycle, with Plasmodium falciparum cyclin-related 
kinase-3 exhibiting homology to CDK1 and Plasmodium falciparum cyclin-related kinase-4 
exhibing homology to CDKs and p38 mitogen-activated protein kinases (Harmse et al., 
2001; Doerig et al., 2002; Geyer et al., 2005); whilst Plasmodium falciparum cyclin-related 
kinase -5 is predicted to be a CDK/p38 mitogen-activated protein kinase protein hybrid 
(Geyer et al., 2005). Purine analogues have shown strong CDK inhibitory effects, by 
competing with ATP for binding in the ATP-kinase binding site (Harmse et al., 2001; 
Knockaert et al., 2002; Geyer et al., 2005). 
It is evident that nucleoside phosphonates, phosphonic acids and purine/pyrimidine 
derivatives are a promising class of novel antimalarial agents and warrant further 
investigation. 
5.2 Materials and methods 
5.2.1 Test compounds 
A total of 90 nucleoside phosphonates, phosphonic acids, and purine/pyrimidine 
derivatives were received from Professors Ivan Rosenberg and Dominik Rejman of the 
Academy of Sciences of the Czech Republic, Prague, Czech Republic. The compounds were 
synthesised according to the methodology laid out by Roudeau et al. (2006), Suk et al. 
(2007), Rejman et al. (2009), and Vaněk et al. (2009), and grouped according to structural 
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similarities. The 90 compounds were classified into 11 structural groups, namely; 
Phosphonoxins (Table 5.1), Nucleoside Lipophosphonates (Table 5.2), Lipophosphonoxins 
(Table 5.3), PyrroPME (Table 5.4), Mickey Mouse (Table 5.5), Pyrrolidine nucleotides (Table 
5.6), Piperidine nucleosides and nucleotides (Table 5.7), and Aza sugars, U/T miscellaneous 
nucleosides and miscellaneous (Table 5.8). 
Table 5.1: The chemical names and codes of the Phosphonoxin group, as well as the 
(nucleo)base present. Chemical structures are represented in Table 5.17. 
Abbreviations: U, uracil; G, guanine. 
 
Table 5.2: The chemical names and codes of the Nucleoside Lipophosphonate group, as 
well as the (nucleo)base present. Chemical structures are represented in Table 
5.10. Abbreviations: A, adenine; U, uracil; G, guanine. 
Chemical  
Code 
Chemical name Base 
DR-3128 Uridin-5'-yl ([3R,4R]-3,4-dihydroxypyrrolidin-1-N-yl)methyl-phosphonate U 
DR-3129 Uridin-5'-yl ([3RS]-3-hydroxypyrrolidin-1-N-yl)thiocarbonyl-phosphonate U 
DR-3122 Uridin-5'-yl ([3RS]-3-hydroxypyrrolidin-1-N-yl)carbonylphosphonate U 
DR-3573 Uridin-5'-yl 2-([3R,4R]-3,4-dihydroxypyrrolidin-1-N-yl)ethyl-phosphonate U 
DR-3510 Uridin-5’-yl-2-([3S, 4S]-3,4-dihydroxypyrrolidin-1-N-yl)ethyl-phosphonate U 
DR-4066 Guanosin-5'-yl 2-([3S,4S]-3,4-dihydroxypyrrolidin-1-N-yl)ethyl-phosphonate G 
DR-4165 Guanosin-5'-yl 2-([3R,4R]-3,4-dihydroxypyrrolidin-1-N-yl)ethyl-phosphonate G 
DR-3095 Uridin-5'-yl 2-([3R,4R]-3,4-dihydroxy-2,5-dioxopyrrolidin-1-N-yl)ethyl-
phosphonate 
U 
DR-3096 Uridin-5'-yl 2-([3R,4R]-3,4-dihydroxy-2,5-dioxopyrrolidin-1-N-yl)ethyl-
phosphonate 
U 
DR-3111 Uridin-5'-yl 3-([3R,4R]-3,4-dihydroxypyrrolidin-1-N-yl)propyl-phosphonate U 
DR-3112 Uridin-5'-yl 2-([3R,4R]-3,4-dihydroxypyrrolidin-1-N-yl)ethoxymethyl-
phosphonate 
U 
DR-3502-C Uridin-5'-yl 2-([3RS]-3-hydroxypiperidin-1-N-yl)ethylphosphonate U 
DR-3679 Uridin-5'-yl 2-([3S,4R]-3,4-dihydroxypiperidin-1-N-yl)ethyl-phosphonate U 
DR-3707 Uridin-5'-yl 2-([3R,4S, 5S]-3,4,5-trihydroxypiperidin-1-N-yl)ethyl-
phosphonate 
U 
Chemical  
Code 
Chemical name Base 
DR-3641 Hexadecyloxypropyl (adenosin-5’-yl)methanphosphonate A 
DR-3621 Hexadecyloxypropyl (uridin-5’-yl)methanphosphonate U 
DR-3960 Hexadecyloxypropyl (guanosin-5’-yl)methanphosphonate G 
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Table 5.3: The chemical names and codes of the Lipophosphonoxin group, as well as the 
(nucleo)base present. Chemical structures are represented in Table 5.11. 
Abbreviations: U, uracil; G, guanine. 
Chemical  
Code 
Chemical name Base 
DR-4658 Ethyl uridin-5’-yl 2-([3R,4R]-3,4-dihydroxypyrrolidin-1-N-yl)ethyl-
phosphonate 
U 
DR-4695 2-Pivaloylthioethyl uridin-5’-yl 2-([3R,4R]-3,4-dihydroxypyrrolidin-1-N-
yl)ethylphosphonate 
U 
DR-4696 2-Pivaloylthioethyl uridin-5’-yl 2-([3R,4R]-3,4-dihydroxypyrrolidin-1-N-
yl)ethylphosphonate 
U 
DR-4137 Hexadecyloxypropyl uridin-5’-yl 2-([3R,4R]-3,4-dihydroxypyrrolidin-1-N-
yl)ethylphosphonate 
U 
DR-4878 Hexadecyloxypropyl cytidin-5’-yl 2-([3R,4R]-3,4-dihydroxypyrrolidin-1-N-
yl)ethylphosphonate 
C 
DR-4850 Under patent G 
DR-4914B Under patent G 
DR-4848 Hexadecyloxypropyl ((2R,3S,4R,5R)-5-(4-((3r,4s)-3,4-dihydroxypyrrolidin-1-
yl)-2-oxopyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl 
([3r,4s]-3,4-dihydroxypyrrolidin-1-N-yl)ethylphosphonate 
C 
DR-4463 Hexadecyloxypropyl uridin-5’-yl 2-([3S,4S]-3,4-dihydroxypyrrolidin-1-N-
yl)ethylphosphonate 
U 
DR-4458 Hexadecyloxypropyl uridin-5’-yl 2-([3R,5R]-3,4-dihydroxypiperidin-1-N-
yl)ethylphosphonate 
U 
DR-4459 Hexadecyloxypropyl uridin-5’-yl 2-([3R,4S,5S]-3,4-trihydroxypiperidin-1-N-
yl)ethylphosphonate 
U 
 
Table 5.4: The chemical names and codes of the PyrroPME group, as well as the 
(nucleo)base present. Chemical structures are represented in Table 5.12. 
Abbreviations: A, adenine; T, thymine; U, uracil; C, cytosine. 
Chemical  
Code 
Chemical name Base 
DR-3919 [3S,4R]-4-(Adenin-9-yl)-3-phosphonomethoxypyrrolidine A 
DR-3953 [3S,4R]-4-(Adenin-9-yl)-3-cyclohexyloxypropylphosphono-
methoxypyrrolidine 
A 
DR-3945 [3S,4R] 3-Phosphonomethoxy -4-(thymin-1-yl)- pyrrolidine T 
DR-3769 [3R,4S] 3-Phosphonomethoxy -4-(thymin-1-yl)- pyrrolidine T 
DR-4140 3-(Hexadecyloxy)propyl ((((3S,4R)-4-(5-methyl-2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)pyrrolidin-3-yl)oxy)methyl)phosphinate 
T 
DR-4001 [3S,4S] -3-Phosphonomethoxy-4-(uracil-1-yl)- pyrrolidine U 
DR-4255A [3R,4S]-4-(Cytosin-2-O-yl)- 3-phosphonomethoxypyrrolidine-1-
carbaldehyde 
C 
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Table 5.5: The chemical names and codes of the Mickey Mouse group, as well as the 
(nucleo)base present. Chemical structures are represented in Table 5.13. 
Abbreviations: Pu, purine ring structure; /, no (nucleo)base present. 
Chemical  
Code 
Chemical name Base 
Bn2NH.HCl Dibenzylamine hydrochloride / 
D1293-S N6,N6-Dibenzyl-9H-purine-2,6-diamine Pu 
DR-4461 2-Amino-6- dibenzylaminopurine Pu 
DR-4523 6-(N-Benzyl-N-3-trifluoromethylphenylmethylamino)purine Pu 
DR-4541 2-(6-(N-Benzyl-N-3-trifluoromethylphenylmethylamino)purin-9-
yl)ethyloxymethylphosphonic acid 
Pu 
DR-4651 2-(2-Amino-6- dibenzylaminopurin-9-yl)ethyloxymethyl-phosphonic 
acid 
Pu 
DR-3896 2-(6-Dibenzylaminopurin-9-yl)ethyloxymethylphosphonic acid Pu 
DR-4598A 3-(6-Dibenzylaminopurin-9-yl)propylphosphonic acid Pu 
DR-4640 4-(6-Dibenzylaminopurin-9-yl)butylphosphonic acid Pu 
DR-4599A 5-(6-Dibenzylaminopurin-9-yl)pentylphosphonic acid Pu 
DR-3892 4-((R)-3-(2-Amino-6-(dibenzylamino)-9H-purin-9-yl)pyrrolidin-1-yl)-2-
hydroxy-4-oxobutanoic acid 
Pu 
DR-3898 (R)-(2-(3-(2-Amino-6-(dibenzylamino)-9H-purin-9-yl)pyrrolidin-1-yl)-
2-oxoethyl)phosphonic acid 
Pu 
DR-4251 [3S,4R]-4-(6-N-Dibenzylaminopurin-9-yl)-3-phosphonomethoxy-
pyrrolidine-1-carbaldehyde 
Pu 
DR-4558 (2S,3S)-4-(3-(6-(Dibenzylamino)-9H-purin-9-yl)piperidin-1-yl)-2,3-
dihydroxy-4-oxobutanoic acid 
Pu 
 
Table 5.6: The chemical names and codes of the Pyrrolidine nucleotide group, as well as the 
(nucleo)base present. Chemical structures are represented in Table 5.14. 
Abbreviations: U, uracil; T, thymine; A, adenine; G, guanine. 
Chemical  
Code 
Chemical name Base 
K584 1-(Uracil-1-yl)-1,2,3-trideoxy-3-aza-4a-carba-α-L-glyceropentofuranos-3-
ylmethylphosphonic acid 
U 
K578 1-(Thymin-1-yl)-1,2,3-trideoxy-3-aza-4a-carba-α-L-glyceropento-furanos-3-
ylmethylphosphonic acid 
T 
DR-4028 [3S,4R]-[4-(4-Bromouracil-9-yl)-3-hydroxypyrrolidin-1-N-yl]carbonyl-
phosphonic acid 
U 
DR-3616 [3S,4R]-[4-(Adenin-9-yl)-3-hydroxypyrrolidin-1-N-yl]carbonyl-phosphonic 
acid 
A 
Pe141 [3S,4S]-[4-(Guanin-9-yl)-3-hydroxypyrrolidin-1-N-yl]carbonylphosphonic 
acid 
A 
DR-3876 Under patent G 
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Table 5.7: The chemical names and codes of the Piperidine nucleoside (K366-DR-4290B) 
and nucleotide (K423-K416) groups, as well as the (nucleo)base present. 
Chemical structures are represented in Table 5.15. Abbreviations: A, adenine; U, 
uracil; T, thymine; C, cytosine; G, guanine. 
Chemical  
Code 
Chemical name Base 
K366 4-(Adenin-9-yl)piperidine A 
DR-3994 (RS)-3-(Uracil-1-yl)piperidine U 
PipT 4-(Thymin-1-yl)piperidine T 
K349_B (RS)-3-(Adenin-9-yl)piperidine A 
K370_B (RS)-3-(Thymin-1-yl)piperidine T 
K351 (RS)-3-(Cytosin-2-O-yl)piperidine C 
K371_B (RS)-3-(Guanin-9-yl)piperidine G 
K523 (3S,5R)-5-Hydroxy-3-(uracil-1-yl)piperidine U 
K524 (3S,5R)-5-Hydroxy-3-(thymin-1-yl)piperidine T 
DR-4377 [3S,4R,5R]-1-(3,5-Dihydroxypiperidin-4-yl)uracil U 
DR-4380 [3S,4R,5S]-1-(4,5-Dihydroxypiperidin-5-yl)uracil U 
DR-4513 [3S,4R,5R]-9-(3,5-Dihydroxypiperidin-4-yl)adenine A 
DR-4290B [3S,4R,5R]-1-(4,5-Dihydroxypiperidin-5-yl)uracil U 
K423 (RS)-(3-(Thymine-1-yl)piperidin-1-yl)thiocarbonylphosphonic acid T 
K418 (RS)-(3-(Thymine-1-yl)piperidin-1-yl)methylphosphonic acid T 
K422 (RS)-(3-(Thymine-1-yl)piperidin-1-yl)ethylphosphonic acid T 
K414_A (RS)-(3-(Thymine-1-yl)piperidin-1-yl)carbonylphosphonic acid T 
K416 (RS)-(3-(Thymine-1-yl)piperidin-1-yl)carbonylmethylphosphonic acid T 
 
5.2.2 Pharmacological evaluation 
5.2.2.1 General methodology 
The methodology used was that as described in Sections 2.2, 2.3 and 2.4, with some 
modifications. Additional experimentation included the assessment of antimalarial activity 
over a double parasitic life cycle (Section 5.2.2.2), and combination studies with the 
nucleoside transport inhibitor, dipyridamole (Section 5.2.2.3). All compounds were 
assessed for antimalarial activity using the [3H]-hypoxanthine incorporation assay (Section 
2.2.2.1), as well as for toxicity against red blood cells (Section 2.4.2). From the results 
obtained, four compounds with IC50 values of less than 100 µM and twenty one inactive 
compounds (IC50 values > 100 µM), representative of all the chemical groups, were selected 
for flow cytometric analysis (Section 2.2.3.3). A lead compound was selected for a 
combination study with quinine (Section 2.2.2.3), as well as for stage sensitivity and 
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parasite morphology studies (Section 2.2.3.4). Due to the fact that only small amounts of 
the test compounds were received, some antimalarial mechanisms of action studies could 
not be completed on all of the active compounds, and in the case of combination, stage 
sensitivity and parasite morphology studies, the next most active compound was 
investigated. In order to examine the structure-activity relationships of the compounds, a 
selection of inactive compounds were also assessed for DPPH• free-radical scavenging 
(Section 2.3.2.1.2), iron chelating (Section 2.3.2.2.2) and β-haematin formation inhibitory 
activity (Section 2.3.1.2).  
Table 5.8: The chemical names and codes of the Aza sugars (K568 and K537), U/T 
miscellaneous nucleosides (K469-K545) and Miscellaneous (DR-3227-K580) 
groups, as well as the (nucleo)base present. Chemical structures are represented 
in Table 5.16. Abbreviations: T, thymine; U, uracil; G, guanine; Py, pyrimidine 
ring structure; /, no (nucleo)base present. 
Chemical 
 Code 
Chemical name Base 
K568 (3R,5R)-piperidine-3,5-diol / 
K537 (3R,5R)-1-benzylpiperidine-3,5-diol / 
K469 1-Cyclopropyluracil U 
DR-4034 1-Cyclopropylthymine T 
K470 1-(1-(Hydroxymethyl)cyclopentyl)uracil U 
DR-4031 1-(cis-2-Hydroxycyclopentyl)uracil U 
K479 1-Cyclohexyluracil U 
DR-4030 1-(trans-2-Hydroxycyclohexyl)uracil U 
DR-4037 1-(trans-4-Hydroxycyclohexyl)uracil U 
DR-4011 Methyl 2-(1-uracilyl)acetate U 
K480 1-(2,3-Dihydroxypropyl)uracil U 
K545 1-(2,3-Dihydroxypropyl)thymine T 
DR-3227 9-((3S,4R)-4-Hydroxypyrrolidin-3-yl)guanine G 
DR-3845 5-Methyl-1-((3R,4R,5S,6R)-2,3,5-trihydroxy-6-(hydroxymethyl)-
tetrahydro-2H-pyran-4-yl)pyrimidine-2,4(1H,3H) –dione 
Py 
DA-IX-158 Under patent A 
OP35 9-(Tetrahydrothiophen-3-yl)-adenine A 
K580 [3S,5S]-1-(5-(Hydroxymethyl)pyrrolidin-3-yl)uracil U 
 
5.2.2.2 Modified tritiated hypoxanthine incorporation assay 
A total of seven active and four inactive compounds were selected from the various 
chemical groups, with quinine included for comparison purposes, in order to assess 
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whether there was any improvement in the antimalarial activity of the compounds over 
two cycles of DNA synthesis and division, or two parasitic life cycles. Duplicate 96-well 
plates were prepared so that single (SC) and double cycle (DC) results could be compared. 
The methodology  was that as described in Section 2.2.2.1, with the exception of the 
double cycle plate to which the [3H]-hypoxanthine isotope was added after a 72 hour 
incubation period, as opposed to 24 hour incubation period as in the single cycle plate. The 
optimal gaseous atmosphere was maintained by re-lighting the candle within the glass 
dessicator on a 24 hourly basis and blood smears prepared at 48 and 96 hours to monitor 
parasite viability over the elongated incubation period. 
5.2.2.3 Combination studies with dipyridamole 
Dipyridamole is a highly lipophilic pyrimidopyrimidine analogue that interacts with the lipid 
phase of cell membranes, thereby modifying membrane lipids and membrane-bound 
proteins with the resultant inhibition of both human ENT1 and malarial PfENT1 (Gupte and 
Buolamwini, 2004; Lin and Buolamwini, 2007).  
Due to the fact that dipyridamole acts as a nucleoside transport inhibitor, and could 
interfere with the uptake of the [3H]-hypoxanthine isotope, combination studies were 
carried out using the flow cytometric methodology. Dipyridamole itself possesses 
fluorescent properties. However, its excitation and emission spectra (Ex = 280 nm, Em = 
490 nm) (Lin and Buolamwini, 2007) is different from that of dihydroethidium (Ex = 488 nm, 
Em = 610 nm), and would, therefore, not interfere with the detection of dihydroethidium in 
the FL2 channel of the BD FACSCalibur™. The antimalarial activity of dipyridamole and 
compounds DR-4463 and D1293-S were assessed utilising the flow cytometric methodology 
(Section 2.2.3.3); from which log sigmoid dose-response curves were constructed, and 
individual IC90, IC50 and IC10 values  obtained using Enzfitter® (version 1.05) software 
(Section 2.2.3.5). The test compounds and dipyridamole were prepared at concentrations 
20 times higher than the IC90, IC50 and IC10 values obtained, in order to account for the 
dilution factor of the experiment. Dipyridamole was combined with each test compound at 
different inhibitory concentration ratios (Table 5.9). Following a 24 hour incubation period, 
25 µl of incomplete culture media was added to each well, in the place of the [3H]-
hypoxanthine isotope, before the plates were re-incubated for a further 24 hours, under 
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optimal conditions. Flow cytometric analysis was then performed according to the 
methodology described in Section 2.2.3.3. 
Table 5.9: Ratios of dipyridamole to the test compounds used to determine 
pharmacological interactions in the combination study.  
 
 
 
 
 
 
 
 
 
Following acquisition of the % parasite growth for each sample, as described in Section 
2.2.3.3, relative ratios for each combination were calculated (Section 2.2.2.3). From the 
relative ratios obtained, isobolograms were constructed and the degree of the interaction 
determined (Section 2.2.2.3).  
5.3 Results 
5.3.1 In vitro antimalarial activity 
 Of the 90 compounds screened for antimalarial activity, 21.11% or 19 compounds inhibited 
parasite growth in a dose-dependent manner, with IC50 values below 100 µM (Figure 5.5); 
whilst the remaining compounds were incapable of inhibiting parasite growth below 100 
µM. Of the 19 compounds, 14 exhibited moderate antimalarial activity (10 µM ≤ IC50 value ≤ 
50 µM) and 5 exhibited low antimalarial activity (50 µM ≤ IC50 value ≤ 100 µM). Compounds 
DR-4850, DR-4878 and DR-4463 exhibited the most promising antimalarial activity (IC50 
values: 13.35 ± 0.38 µM, 17.76 ± 1.72 µM and 19.81 ± 0.80 µM, respectively); however they 
Dipyridamole Test compound(s) 
IC90 0 
IC50 0 
IC10 0 
IC90 IC90 
IC90 IC50 
IC90 IC10 
IC50 IC50 
IC50 IC90 
IC50 IC10 
IC10 IC10 
IC10 IC50 
IC10 IC90 
0 IC90 
0 IC50 
0 IC10 
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proved to be 89-, 118- and 132-fold less active than quinine (IC50 value: 0.15 ± 0.01 µM) 
(Table 5.11).  
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Figure 5.5: Antimalarial activity of compounds DR-4850 and DR-4463 compared to quinine. 
 
The Nucleoside Lipophosphonate, Lipophosphonoxin, PyrroPME, Mickey Mouse and 
Pyrrolidine nucleotide groups all produced active compounds (Tables 5.10, 5.11, 5.12, 5.13 
and 5.14). Whereas, the Piperidine nucleoside and nucleotide, Aza sugar, U/T 
Miscellaneous nucleoside and Miscellaneous, and Phosphonoxin structural groups 
produced no compounds with IC50 values < 100 µM (Tables 5.15-5.17).  
The three compounds comprising the Nucleoside Lipophosphonate group  were all active 
(Table 5.10), followed by the Lipophosphonoxin (Table 5.11), Mickey Mouse (Table 5.13), 
PyrroPME (Table 5.12) and Pyrrolidine nucleotide (Table 5.14) groups, of which 73%, 33%, 
25% and 17% of the compounds within each respective group were active. The base 
composition of the active compounds varied, 58% of the active compounds possessed a 
guanine or adenine base or the basic purine ring structure, whereas 42% of the active 
compounds possessed a cytosine, thymine or uracil base.   
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Table 5.10: The in vitro antimalarial (1% haematocrit, 0.5% parasitaemia) and haemolytic 
activity of the Nucleoside Lipophosphonate group of compounds (n = 4). 
Where: SC = single cycle; DC = double cycle 
Chemical  
Code 
Chemical structure 
Antimalarial 
activity 
Haemolytic 
activity 
IC50 value % 
µM ± s.d.  100 µM ± s.d. 
DR-3641 
N
N
N
N
NH2
O
O
O
OH
ONa
O
P
H33C16O
 
43.14 ± 1.67 0.61 ± 0.04 
DR-3621 
H
H
N
NH
O
O
O
P
OH
H41C20O
H
O
O
OHOH
H HNH3  
30.01 ± 1.65  
S.C. 
27.67 ± 2.21 
D.C. 
1.41 ± 0.85 
DR-3960 
C16H33
N
O
O
OH
N
NH
N
NH2
O
OH
O
O
O
PNa
O  
33.13 ± 2.10  
S.C. 
33.30 ± 1.69 
D.C. 
9.32 ± 3.50 
Quinine 
N
N
O
CH3
OH H
CH2 H
 
0.15 ± 0.01 
S.C. 
0.18 ± 0.00 
D.C. 
1.22 ± 0.98 
 
Table 5.11: The in vitro antimalarial (1% haematocrit, 0.5% parasitaemia) and haemolytic 
activity of the Lipophosphonoxin group of compounds. Values in parenthesis 
indicate the % inhibition of parasite growth at 100 µM (n = 4).  
Chemical 
 Code 
Chemical structure 
Antimalarial 
activity 
Haemolytic 
activity 
IC50 value % 
µM ± s.d.  100 µM ± s.d. 
DR-4658 
ClH
N
NH
O
ON
O
O
OH OH
P
O
OH
OH
O
CH3  
> 100 
(0.01 ± 2.61) 
0.38 ± 0.08 
DR-4695 
ClH
O
N
NH
O
O
N
O
O
OHOH
O
P
OH
OH O
SCH3
CH3
CH3  
> 100 
(0.01 ± 1.62) 
0.37 ± 0.12 
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Chemical 
 Code 
Chemical structure 
Antimalarial 
activity 
Haemolytic 
activity 
IC50 value % 
µM ± s.d.  100 µM ± s.d. 
DR-4696 
ClH
O
N
NH
O
ON
O
O
OHOH
O
P
OH
OH O
SCH3
CH3
CH3  
> 100 
(2.16 ± 1.61) 
0.39 ± 0.13 
DR-4137 
HH
N
O
NH
O
O
H33C16
O
O
O
P
N
OH
OH
H
OH OH
H
ClH
 
49.18 ± 0.79 4.56 ± 1.00 
DR-4878 
ClH
N
N
NH2
O
N
O
O
OHOH
O
P
OH
OH
O
OC16H33  
17.76 ± 1.72 5.17 ± 3.62 
DR-4850 
R
O
O
OHOH
O
PR
2
R
1
 
13.35 ± 0.38 9.25 ± 2.08 
DR-4914B 
R
O
O
OHOH
O
PR
2
R
1
 
21.05 ± 0.71 50.20 ± 3.35 
DR-4848 
ClH
N
N
NH
O
OHOH
N
O
O
OHOH
O
P
OH
OH
O
OC16H33  
30.46 ± 3.54 1.07 ± 0.34 
DR-4463 
OH
OH
N
O
HH
N
O
O
OH
O
O
P
NH
O
O
OH
H H
H33C16
ClH
 
19.81 ± 0.80  
S.C. 
6.04 ± 0.31 
 D.C. 
7.85 ± 1.41 
DR-4458 
ClH
H
N
H33C16 HH
N
O
O
OH
O
O
P
NH
O
O
OH
H
OH
OH
 
29.98 ± 0.70 6.32 ± 2.33 
DR-4459 
H33C16
N
O
O
OH
O
O
P
NH
O
O
OH
HH
N
OH
OH
OH
ClH
 
49.11 ± 4.11 1.14 ± 1.41 
Quinine 
N
N
O
CH3
OH H
CH2 H
 
0.15 ± 0.01 
S.C. 
0.18 ± 0.00 
D.C. 
1.22 ± 0.98 
   
144 
 
Table 5.12: The in vitro antimalarial (1% haematocrit, 0.5% parasitaemia) and haemolytic 
activity of the PyrroPME group of compounds. Values in parenthesis indicate 
the % inhibition of parasite growth at 100 µM (n = 4). 
Chemical  
Code 
Chemical structure 
Antimalarial 
activity 
Haemolytic 
activity 
IC50 value % 
µM ± s.d.  100 µM ± s.d. 
DR-3919 
Na
N
H
N
N
N
N
NH2
O
P
O
OH
O
 
> 100 
(0.01 ± 10.46) 
S.C. 
(0.01 ± 2.10) 
D.C. 
0.27 ± 0.10 
DR-3953 OC16H33
Na
N
H
O
P
O
O
O
N
N
N
N
NH2  
39.34 ± 2.77 5.64 ± 0.72 
DR-3945 N
H
O N
NH
O
O
P
OONa
OH
CH3  
> 100 
(0.01 ± 3.47) 
S.C. 
(2.20 ± 3.35) 
D.C. 
0.36 ± 0.15 
DR-3769 N
H
O
P
O
OH
ONa
N
NH
O
O
CH3
 
> 100 
(0.01 ± 5.17) 
0.44 ± 0.21 
DR-4140 N
H
O
O
O
O
PH
C3H6OC16H33
N
NH
O
O
CH3  
63.51 ± 5.60 0.93 ± 0.33 
DR-4001 
Na
N
H
O
P
O
OH
O
N
NH
O
O
 
> 100 
(2.26 ± 3.66) 
0.39 ± 0.19 
DR-4255A 
O
N
H
N
NH
NH2
OOP
O
O
ONa
Na
 
> 100 
(6.41 ± 2.78) 
0.39 ± 0.16 
Quinine 
N
N
O
CH3
OH H
CH2 H
 
0.15 ± 0.01 
S.C. 
0.18 ± 0.00 
D.C. 
1.22 ± 0.98 
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Table 5.13: The in vitro antimalarial (1% haematocrit, 0.5% parasitaemia) and haemolytic 
activity of the Mickey Mouse group of compounds. Values in parenthesis 
indicate the % inhibition of parasite growth at 100 µM (n = 5). 
Chemical 
 Code 
Chemical structure 
Antimalarial 
activity 
Haemolytic 
activity 
IC50 value % 
µM ± s.d.  100 µM ± s.d. 
Bn2NH.HCl ClH
NH
 
 
> 100 
(12.57 ± 4.88) 
 
0.31 ± 0.13 
D1293-S 
N
N
N
NH
N
NH2  
52.63 ± 3.79 0.39 ± 0.10 
DR-4461 
N
H
N
N
N
NH
N
NH2
cca  1  : 10  
 
> 100 
(33.87 ± 6.76) 
 
0.22 ± 0.05 
DR-4523 
N
N
NH
N
N
CF3
 
77.48 ± 8.57  
S.C. 
73.93 ± 1.03 
D.C. 
8.95 ± 5.70 
DR-4541 
F
F
O
N
N
N
N
N
F
P
O
OH
OH
 
> 100 
(14.26 ± 4.63) 
0.64 ± 0.31 
DR-4651 
O
N
N
NH
N
N
NH2
O
O
O P
Na
Na
 
79.66 ± 2.11 0.39 ± 0.15 
DR-3896 
O N
N
N
N
N
P
O
ONa
NaO
 
> 100 
(27.05 ± 10.99) 
0.51 ± 0.05 
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Chemical 
Code 
Chemical structure 
Antimalarial 
activity 
Haemolytic 
activity 
IC50 value % 
µM ± s.d.  100 µM ± s.d. 
DR-4598A 
Na
P
O
O
NaO
N
N
N
N
N
 
> 100 
(34.61 ± 3.17) 
0.46 ± 0.13 
DR-4640 
P
O
ONa
ONa
N
N
N
N
N
 
> 100 
(44.10 ± 3.07) 
0.47 ± 0.21 
DR-4599A 
Na
N
N
N
N
N
P
O
O
ONa
 
> 100 
(25.38 ± 6.03) 
0.44 ± 0.23 
DR-3892 OH
NaO
O
O
N
N
NH
N
N
NH2
N
 
57.11 ± 1.49 
S.C. 
47.73 ± 1.07 
D.C. 
0.38 ± 0.15 
DR-3898 
NaO
Na
P
O
O
O
N
N
N
N
N
NH2
N
 
> 100 
(2.50 ± 3.32) 
S.C. 
(0.01 ± 1.12) 
D.C. 
0.38 ± .17 
DR-4251 
Na
O
N
N
N
N
N
N
O
H
P
O
O
ONa
 
> 100 
(7.45 ± 5.10) 
0.40 ± 0.17 
DR-4558 OH
O
N
N N
N
N N
OH
O
OH
 
23.85 ± 1.76 
 S.C. 
16.71 ± 0.77 
D.C. 
0.32 ± 0.09 
Quinine 
N
N
O
CH3
OH H
CH2 H
 
0.15 ± 0.01 
S.C. 
0.18 ± 0.00 
D.C. 
1.22 ± 0.98 
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Table 5.14: The in vitro antimalarial (1% haematocrit, 0.5% parasitaemia) and haemolytic 
activity of the Pyrrolidine nucleotide group of compounds. Values in 
parenthesis indicate the % inhibition of parasite growth at 100 µM (n = 3). 
Chemical 
 Code 
Chemical structure 
Antimalarial 
activity 
Haemolytic 
activity 
IC50 value % 
µM ± s.d.  100 µM ± s.d. 
K584 
OH
N
P
O
NaO
OH
N
N
H
O
O
 
 
> 100 
(1.93 ± 0.76) 
 
0.41 ± 0.17 
K578 
OH
N
P
O
O
OH
Na
N
N
H
O
O CH3
 
> 100 
(7.60 ± 3.00) 
0.93 ± 1.24 
DR-4028 O
N
N
NH
O
O
Br
OH
P
O
OH
OH
 
 
> 100 
(0.64 ± 6.74) 
 
0.47 ± 0.24 
DR-3616 
P
O
ONaOH
N
OH
O
N
N
N
N
NH2
 
 
> 100 
(7.42 ± 8.39)  
 
0.31 ± 0.03 
Pe141 
Na
Na
O
N
P
O
O
O
OH N
N
N
N
NH2
 
> 100 
(0.01 ± 2.17) 
0.52 ± 0.16 
DR-3876 R
N
R
1
 
31.08 ± 2.33 
S.C. 
20.01 ± 0.88 
D.C. 
 
0.40 ± 0.11 
Quinine 
N
N
O
CH3
OH H
CH2 H
 
0.15 ± 0.01 
S.C. 
0.18 ± 0.00 
D.C. 
1.22 ± 0.98 
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Table 5.15: The in vitro antimalarial (1% haematocrit, 0.5% parasitaemia) and haemolytic 
activity of the Piperidine nucleoside (K366-DR-4290B) and nucleotide (K423-
K416) group of compounds. Values in parenthesis indicate the % inhibition of 
parasite growth at 100 µM (n = 3). 
Chemical 
 Code 
Chemical structure 
Antimalarial 
activity 
Haemolytic 
activity 
IC50 value % 
µM ± s.d.  100 µM ± s.d. 
K366 
N
N
N
N
NH2
NH
 
 
> 100 
(6.15 ± 1.22) 
 
0.41 ± 0.08 
DR-3994 
N NH
O
O
NH
 
> 100 
(0.01 ± 7.30) 
0.40 ± 0.17 
PipT 
N NH
O
O
CH3
NH
ClH  
> 100 
(5.04 ± 3.79) 
 
0.49 ± 0.21 
K349_B 
N
N
N
N
NH2
NH
 
> 100 
(13.55 ± 9.85)  
 
0.41 ± 0.25 
K370_B 
N
NH
O
O
CH3
NH
 
> 100 
(0.01 ± 0.07) 
0.39 ± 0.20 
K351 NH2N
N
O
NH
 
> 100 
(4.00 ± 9.78) 
0.33 ± 0.17 
K371_B 
N
NH
N
N
NH2
O
NH
 
> 100 
(19.40 ± 3.76) 
0.58 ± 0.31 
K523 
N
H
N
N
H
OO
OH
 
> 100 
(6.24 ± 0.12) 
0.30 ± 0.13 
K524 
N
H
N
N
H
OO
CH3
OH
 
> 100 
(0.01 ± 3.68) 
0.36 ± 0.18 
DR-4377 O
NH
NH
N O
OH
OH
 
> 100 
(0.01 ± 1.31) 
0.38 ± 0.18 
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Chemical 
 Code 
Chemical structure 
Antimalarial 
activity 
Haemolytic 
activity 
IC50 value % 
µM ± s.d.  100 µM ± s.d. 
DR-4380 
NH
N
N
H
OO
OH
OH
 
> 100 
(4.35 ± 1.80) 
0.35 ± 0.17 
DR-4513 
NH
N
N
N N
NH2OH
OH  
> 100 
(43.57 ± 0.48) 
0.49 ± 0.26 
DR-4290B N
H
N
N
H
O
O OH OH 
> 100 
(0.01 ± 4.84) 
0.39 ± 0.12 
K423 
S
N
N
P
O
ONaNaO
NH
O
O
CH3
 
> 100 
(0.01 ± 3.18) 
0.31 ± 0.13 
K418 
P
NaO
O
NaO
N
N
NH
O
O
CH3
 
> 100 
(0.01 ± 3.96) 
0.42 ± 0.22 
K422 
N
N
P
O
ONa
NaO
NH
O
O
CH3
 
> 100 
(0.01 ± 5.20) 
0.36 ± 0.14 
K414_A 
O
N
P
O
ONaNaO
N
NH
O
O
CH3
 
> 100 
(0.01 ± 10.66) 
0.27 ± 0.11 
K416 
N
N
P
O
O
O
Na
ONa
NH
O
O
CH3
 
> 100 
(2.19 ± 5.42) 
0.40 ± 0.21 
Quinine 
N
N
O
CH3
OH H
CH2 H
 
0.15 ± 0.01 
S.C. 
0.18 ± 0.00 
D.C. 
1.22 ± 0.98 
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Table 5.16: The in vitro antimalarial (1% haematocrit, 0.5% parasitaemia) and haemolytic 
activity of the Aza sugars (K568 and K537), U/T miscellaneous nucleosides 
(K469-K545) and Miscellaneous (DR-3227-K580) groups of compounds. Values 
in parenthesis indicate the % inhibition of parasite growth at 100 µM (n = 3). 
Chemical 
 Code 
Chemical structure 
Antimalarial 
activity 
Haemolytic 
activity 
IC50 value % 
µM ± s.d.  100 µM ± s.d. 
K568 
N
H
OHOH
 
 
> 100 
(2.57 ± 0.98) 
 
0.24 ± 0.18 
K537 
N
OHOH
 
> 100 
(5.87 ± 1.54) 
0.38 ± 0.16 
K469 
N
NH
O
O
 
 
> 100 
(0.01 ± 0.64) 
0.31 ± 0.15 
DR-4034 
N
NH
O
O
CH3
 
 
> 100 
(0.01 ± 7.21) 
0.42 ± 0.23 
K470 
N NH
O
O
OH  
> 100 
(4.81 ± 4.02) 
0.26 ± 0.13 
DR-4031 
N NH
O
O
OH  
> 100 
(0.85 ± 1.48) 
0.38 ± 0.24 
K479 
N NH
O
O  
> 100 
(4.75 ± 2.90) 
0.21 ± 0.12 
DR-4030 
N NH
O
O
OH
 
> 100 
(3.22 ± 3.15) 
0.28 ± 0.16 
   
151 
 
Chemical 
Code 
Chemical structure 
Antimalarial 
activity 
Haemolytic 
activity 
IC50 value % 
µM ± s.d.  100 µM ± s.d. 
DR-4037 
N NH
O
O
OH  
> 100 
(7.20 ± 3.10) 
0.41 ± 0.23 
DR-4011 O
N NH
O
O
OH
 
> 100 
(2.45 ± 16.76) 
0.55 ± 0.26 
K480 OH
OH N NH
O
O  
> 100 
(0.01 ± 8.49) 
0.25 ± 0.08 
K545 
OH
OH
N
N
H
O O
CH3  
> 100 
(5.13 ± 2.17) 
0.25 ± 0.14 
DR-3227 N
H
OH N
NH
N
N
NH2
O
ClH
 
> 100 
(5.36 ± 7.40) 
0.29 ± 0.18 
DR-3845 OH
O
OH
OH
N
NH
O
O
CH3
OH
 
> 100 
(5.77 ± 1.03) 
0.36 ± 0.16 
DA-IX-158 
N
N
N
N
NH2
R  
> 100 
(13.53 ± 8.97) 
0.25 ± 0.12 
OP 35 
N
N
N
N
NH2
S  
> 100 
(0.75 ± 4.67) 
0.39 ± 0.11 
K580 
OH
N
H
N
N
H
O
O
 
> 100 
(2.25 ± 3.81) 
0.42 ± 0.15 
Quinine 
N
N
O
CH3
OH H
CH2 H
 
0.15 ± 0.01 
S.C. 
0.18 ± 0.00 
D.C. 
1.22 ± 0.98 
   
152 
 
Table 5.17: The in vitro antimalarial (1% haematocrit, 0.5% parasitaemia) and haemolytic 
activity of the Phosphonoxin group of compounds. Values in parenthesis 
indicate the % inhibition of parasite growth at 100 µM (n = 3). 
Chemical  
Code 
Chemical structure 
Antimalarial 
activity 
Haemolytic 
activity 
IC50 value % 
µM ± s.d.  100 µM ± s.d. 
DR-3128 
N
O
O
OH
NH
O
O
OH
P
O
ONa
N
OH
OH
 
> 100 
(0.01 ± 4.03) 
0.31 ± 0.14 
DR-3129 
S
N
O
O
OH
NH
O
O
OH
ONa
O
PNOH
 
> 100 
(0.01 ± 1.20) 
0.37 ± 0.25 
DR-3122 
O
N
O
O
OH
NH
O
O
OH
ONa
O
PNOH
 
> 100 
(6.97 ± 0.18) 
0.36 ± 0.08 
DR-3573 
N
O
O
OH
NH
O
O
OH
P
O
ONa
N
OH
OH
 
> 100  
(12.54 ± 3.37) 
0.41 ± 0.23 
DR-3510 
N
O
O
OH
NH
O
O
OH
P
O
ONa
N
OH
OH
 
> 100  
(0.01 ± 2.52) 
0.39 ± 0.16 
DR-4066 
N
N
O
O
OH
ONa
O
P N
NH
N
NH2
O
HH
OH
OH
OH
 
> 100  
(36.84 ± 2.62) 
0.38 ± 0.09 
DR-4165 
N
O
O
OH
ONa
O
P N
NH
N
NH2
O
HH
OH
N
OH
OH
 
> 100  
(23.65 ± 8.24) 
0.39 ± 0.19 
DR-3095 
N
O
O
OH
OH
O
P
NH
O
O
OH
N
OH OH
O O
 
> 100  
(6.32 ± 2.41) 
0.43 ± 0.19 
DR-3096 
N
O
O
OH
OH
O
P
NH
O
O
OH
N
O O
OH OH  
> 100  
(10.15 ± 4.75) 
0.48 ± 0.21 
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Chemical 
Code 
Chemical structure 
Antimalarial 
activity 
Haemolytic 
activity 
IC50 value % 
µM ± s.d.  100 µM ± s.d. 
DR-3111 
N
O
O
OH
NH
O
O
OH
P
O
ONa
N
OH
OH
 
> 100  
(9.59 ± 4.45) 
0.29 ± 0.10 
DR-3112 
N
N
O
O
OH
NH
O
O
OH
P
O
ONa
O
OH
OH
 
> 100  
(3.54 ± 4.34) 
0.43 ± 0.14 
DR-3502-C 
N
O
O
OH
NH
O
O
OH
P
O
ONa
N
OH  
> 100  
(0.01 ± 4.81) 
0.40 ± 0.43 
DR-3679 
N
O
O
OH
NH
O
O
OH
P
O
ONa
N
OH
OH  
> 100 
(15.20 ± 0.26) 
S.C. 
 (0.01 ± 1.60) 
D.C. 
0.34 ± 0.20 
DR-3707 
N
O
O
OH
NH
O
O
OH
P
O
ONa
N
OH
OH
OH  
 
> 100 
(6.06 ± 2.21) 
 
0.35 ± 0.16 
Quinine 
N
N
O
CH3
OH H
CH2 H
 
0.15 ± 0.01 
S.C. 
0.18 ± 0.00 
D.C. 
1.22 ± 0.98 
 
5.3.1.1 Antimalarial activity over a double parasitic life cycle 
Of the seven active compounds assessed for improvement in antimalarial activity over a 
double parasitic life cycle, four exhibited statistically significant reductions (p < 0.05) in 
their IC50 values. 
 The greatest improvement was that of compound DR-4463, where a 3.3-fold reduction in 
its IC50 value occurred over a double cycle (Figure 5.6). A 1.6-, 1.4- and 1.2-fold decrease 
occurred in the IC50 values of compounds DR-3876, DR-4558 and DR-3892, respectively, 
over a double cycle (Figure 5.6). 
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Figure 5.6: The improved antimalarial activity of compounds DR-4463, DR-3876, DR-4558 
and DR-3892 over a double parasitic life cycle (n = 4).  
 
Compound DR-3960 showed no improvement in antimalarial activity over a double cycle 
(Table 5.10), and compounds DR-4523 (Table 5.13) and DR-3621 (Table 5.10) exhibited 
minimal reductions in their IC50 values. None of the four inactive compounds selected 
showed any improvement in antimalarial activity, with compound DR-3679 exhibiting a 
slight decrease in activity over a double cycle (Table 5.17). Similarly, quinine exhibited no 
statistically significant improvement in antimalarial activity over a double cycle, showing a 
slight increase in its IC50 value over a double cycle (IC50 value: 0.18 ± 0.00 µM) as opposed to 
a single cycle (IC50 value: 0.15 ± 0.01 µM).  
5.3.1.2 The effect of methodology on antimalarial evaluation 
Of the four active compounds selected for comparison in the two methodologies, only DR-
4878 showed a statistically significant difference (p < 0.05) in its IC50 value as determined by 
the tritiated hypoxanthine assay (24.77 ± 0.26 µM) and flow cytometric analysis (16.72 ± 
0.73 µM) (Table 5.18). Of the 21 inactive compounds selected from the various structural 
groups for re-screening using the flow cytometric methodology, six compounds, namely 
DR-4598A, DR-4066, DR-4461, DR-3227, OP 35 and DR-4034, showed discrepancies 
between the two methodologies (Table 5.18). 
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Table 5.18: A comparison of the IC50 values and % parasite growth inhibitions, at a 2% 
haematocrit and 2% parasitaemia, obtained from the [3H]-hypoxanthine 
incorporation assay and flow cytometry (n = 6). N.D. = not determined. 
Compound 
Antimalarial activity 
[3H]-hypoxanthine 
incorporation assay 
Flow cytometric analysis 
IC50 value 
 (µM) 
% Inhibition 
at 100µM 
IC50 value (µM) % Inhibition  
at 100µM 
DR-4878 24.77 ± 0.26  16.72 ± 0.73  
DR-4463 28.09 ± 3.26  20.49 ± 1.41  
DR-4850 30.04 ± 2.75  29.91 ± 1.88  
D1293-S 57.29 ± 2.84  57.72 ± 3.54  
DR-4598A > 100 30.58 ± 0.16 > 100 14.01 ± 9.70 
DR-4066 > 100 16.47 ± 4.04 > 100 0.01 ± 6.29 
DR-4461 > 100 12.16 ± 6.18 > 100 66.94 ± 4.35 
DR-3111 > 100 9.47 ± 3.71 > 100 9.20 ± 4.20 
DR-4695 > 100 9.39 ± 2.04 > 100 0.01 ± 3.47 
K414A > 100 8.61 ± 3.63 > 100 11.80 ± 3.52 
DR-4028 > 100 7.95 ± 1.53 > 100 11.02 ± 5.74 
K480 > 100 7.89 ± 3.02 > 100 6.93 ± 2.69 
K523 > 100 7.38 ± 3.31 > 100 4.32 ± 6.75 
DR-4255A > 100 7.34 ± 0.38 > 100 0.01 ± 3.82 
DR-3227 > 100 7.27 ± 4.92 > 100 28.33 ± 3.84 
DR-4034 > 100 7.17 ± 5.50 > 100 21.70 ± 4.80 
PipT > 100 6.82 ± 3.95 > 100 5.68 ± 0.20 
K545 > 100 6.33 ± 0.80 > 100 5.31 ± 4.45 
K580 > 100 5.52 ± 2.62 > 100 1.08 ± 3.27 
DR-3707 > 100 4.72 ± 2.79 > 100 9.99 ± 6.00 
Pe141 > 100 4.17 ± 2.17 > 100 6.89 ± 2.09 
OP 35 > 100 3.90 ± 6.25 > 100 23.44 ± 4.18 
DR-3919 > 100 3.60 ± 4.08 > 100 8.46 ± 6.16 
DR-4377 > 100 3.04 ± 2.49 > 100 4.48 ± 4.89 
DR-4001 > 100 2.63 ± 0.56 > 100 1.46 ± 4.35 
Chloroquine 0.012 ± 0.0013  0.014 ± 0.00068  
Quinine 0.15 ± 0.0014  0.058 ± 0.0026  
Dipyridamole N.D.  35.41 ± 7.31  
 
5.3.2 In vitro haemolytic activity 
The haemolytic activity of the compounds was generally low, with 78 compounds resulting 
in less than 1% haemolysis at 100 µM. Eleven compounds, namely  DR-4137, DR-4878, DR-
4850, DR-4848, DR-4463, DR-4458, DR-4459 (Table 5.11), DR-3621, DR-3960 (Table 5.10), 
DR-3953 (Table 5.12) and DR-4523 (Table 5.13), resulted in less than 10% haemolysis at 100 
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µM. Compound DR-4914B possessed the highest haemolytic activity of the compounds 
(50.20 ± 3.35% haemolysis at 100 µM) (Table 5.11). However, it did not appear to correlate 
with its antimalarial activity, as at a concentration of 50 µM, corresponding to the IC90 value 
of DR-4914B (51.67 ± 4.16 µM), the haemolytic activity was greatly reduced to 0.71 ± 
0.16%. 
5.3.3 Combination studies 
The isobolograms depict the variable pharmacological interactions between compound DR-
4463 in combination with quinine, as well as compounds DR-4463 and D1293-S in 
combination with the nucleoside transport inhibitor, dipyridamole (Figure 5.7).  
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Figure 5.7: Isobolograms depicting the pharmacological interactions of compound DR-4463 
in combination with quinine (a) (n = 3), as well as compounds DR-4463 (b) (n = 
4) and D1293-S (c) in combination with dipyridamole (n = 3).  
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The ΣFIC for each experiment was calculated from FIC values generated for each data point 
(Appendix E). Compound DR-4463, when combined with quinine, exhibited an additive 
interaction (ΣFIC = 0.89 ± 0.12) (Figure 5.7a), and when combined with dipyridamole 
exhibited an additive-antagonistic to antagonistic relationship (ΣFIC = 1.83 ± 0.17), with the 
greatest antagonism observed in combination ratios of dipyridamole to DR-4463 of 
IC50:IC90, IC50:IC10, as well as IC10:IC10 (Figure 5.7b). Similarly, combinations of compound 
D1293-S and dipyridamole also exhibited an additive-antagonistic to antagonistic 
interaction (ΣFIC = 1.87 ± 0.34), with the greatest antagonism observed at the ratios of 
IC50:IC90 , IC50:IC10, IC90:IC90, as well as IC10:IC10 (Figure 5.7c). 
5.3.4 Morphological and stage-specific effects of compound DR-4463 
The morphological and stage-specific effects of compound DR-4463 at its IC50 value (20 
µM), when compared to an untreated control, are depicted in Figures 5.8 and 5.9. No 
notable changes in parasite morphology occurred during the ring-stage, with the treated 
parasites progressing into the early trophozoite-stage (Figure 5.9A), where haemozoin 
crystals were evident (Figure 5.8A). Thereafter, treated parasites progressed through the 
mid to late trophozoite-stage (Figure 5.9B) with no distinct morphological changes (Figure 
5.8B). However, upon progression into the schizont-stage, development of the treated 
parasites appeared to be slightly stalled, with most parasites appearing to be in the late 
trophozoite- and early schizont-stages instead of the early to mid schizont-stage as in the 
untreated control (Figure 5.9C), and with no distinct merozoite formation as noted in the 
untreated control (Figure 5.8C).  
Thereafter, the untreated parasites progressed into the late schizont- and early ring-stages 
(Figure 5.9D), with 71% of parasites in the ring-stage and 29% of parasites in the late 
schizont-stage (Figure 5.8D), to produce an overall parasitaemia of 4.81%. In contrast, the 
total parasitaemia of the treated parasites was 2.4%, and appeared to be stalled 
predominantly in the late trophozoite- (40%) and mixed early to late schizont-stages (32%) 
(Figure 5.9D), with late trophozoite-staged parasites exhibiting signs of possible cytoplasmic 
vacuolation (Hamzah et al., 2004; Totino et al., 2008) (Figure 5.8D).  
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Figure 5.8: The effects of compound DR-4463 at the IC50 value (20µM) on parasite morphology 
and development. Red arrows indicate parasitic haemozoin (n = 1). 
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Figure 5.9: Flow cytometric analysis depicting the effects of compound DR-4463, at the 
IC50 value (20 µM), on parasite development. Where: FL2-H represents the 
maximum fluorescent intensity of dihydroethidium, the green line 
represents parasites treated with compound DR-4463 and the red line 
represents the parasite control (n = 1). 
 
Examination of the blood smears four hours post-invasion, or four hours into the next 
cycle showed the overall parasitaemia of the treated parasites to be 3.51%, as opposed 
to the parasitaemia of 7.45% of the untreated control. The majority of the parasites 
were in the ring-stage (73%), with the remainder in the schizont-stage (27%), as opposed 
to the untreated control, where 93% of parasites were in the ring-stage, and 7% were in 
the late schizont-stage (Figures 5.8E). Of the schizonts present in the treated parasite 
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sample, distinct merozoite formation was noticeable (Figure 5.8E), however the number 
of merozoites formed appeared to be greatly reduced from the untreated control of 
Figure 5.8D. The increase in the percentage of ring-staged parasites indicated that the 
schizonts (Figure 5.8D) had progressed through the cycle, and were capable of 
reinvading red blood cells.  
Parasites treated with compound DR-4463 at the IC25 value (10 µM) exhibited similar 
developmental abnormalities as those treated with compound DR-4463 at the IC50 value. 
However, an examination of blood smears prepared four hours post-invasion showed 
that the number of merozoites formed by treated parasites appeared similar to that of 
the parasite control of Figure 5.8D. 
5.3.5 Antimalarial mechanisms of action 
The effects of select compounds on β-haematin formation, as well as anti-oxidant and 
metal chelating activity were determined (Table 5.19). A total of 35 compounds were 
selected from the various structural groups, in order to examine structure-activity 
relationships. Of the 14 compounds possessing antimalarial activity, five were potent 
inhibitors of β-haematin formation, and showed significant differences (p < 0.05) in their 
activity when compared to chloroquine (IC50 value: 29.64 ± 3.35 µM) (Table 5.19). 
Compound DR-4137 proved to be the most potent (IC50 value: 8.29 ± 1.11 µM), and was 
3.6-fold more active than chloroquine. Compounds DR-4458, DR-4459, DR-4463 and DR-
3621 proved to be on average twice as active as chloroquine. Compounds DR-4523, DR-
4878 and DR-4914B were capable of inhibiting more than 75% of β-haematin formation 
at 400 µM; however their IC50 values were well above 100 µM (Table 5.19). The 
remaining six compounds inhibited β-haematin formation by between 13% and 53% at 
400 µM. Of the 21 compounds which lacked antimalarial activity, compound DR-4598A 
was noted to be a strong inhibitor of β-haematin formation (IC50 value: 9.19 ± 0.39 µM), 
and was 3.2-fold more potent than chloroquine. The remaining 20 compounds, as well 
as dipyridamole, were only capable of between 0.01% and 46% inhibitory activity at 400 
µM (Table 5.19). 
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Table 5.19: The β-haematin inhibitory, free-radical scavenging, and iron chelating 
activity of select compounds. Values in parenthesis indicate where IC50 
values (< 100 μM) were obtained (n = 5). N.D. = not determined.  
Compound 
% Inhibition of β-
haematin formation 
% DPPH• free-radical 
scavenging activity 
% Fe(II) chelation 
at 400 µM (± s.d.) at 240 µM (± s.d.) at 200 µM (± s.d.) 
DR-4137 (8.29 ± 1.11) 5.55 ± 2.30 N.D. 
DR-4598A (9.19 ± 0.39) 0.01 ± 2.16 12.00 ± 3.35 
DR-4458 (10.77 ± 1.12) 25.26 ± 3.16 1.51 ± 0.34 
DR-4459 (11.39 ± 1.71) 29.62 ± 2.47 N.D. 
DR-4463 (13.39 ± 2.16) 13.85 ± 1.03 N.D. 
DR-3621 (13.95 ± 0.65) 5.03 ± 1.95 4.67 ± 1.24 
DR-4523 97.30 ± 2.78 4.89 ± 2.53 0.01 ± 6.53 
DR-4878 75.74 ± 4.80 0.01 ± 4.53 1.33 ± 0.83 
DR-4914B 75.57 ± 7.68 23.43 ± 2.06 3.64 ± 2.90 
DR-4850 53.31 ± 9.15 31.60 ± 5.34 4.80 ± 1.05 
DR-3876 47.72 ± 7.27 N.D. N.D. 
DR-4461 46.10 ± 7.91 6.32 ± 1.72 2.43 ± 2.00 
DR-4001 42.70 ± 10.01 0.01 ± 4.25 6.72 ± 3.14 
DR-3919 38.42 ± 10.10 0.01 ± 2.13 3.69 ± 3.43 
DR-4848 34.43 ± 5.43 N.D. N.D. 
K414_A 31.99 ± 8.76 12.47 ± 1.64 34.86 ± 8.44 
DR-4558 27.27 ± 4.20 N.D. N.D. 
D1293-S 15.49 ± 5.17 N.D. N.D. 
DR-4028 14.38 ± 3.53 0.01 ± 4.51 7.19 ± 2.18 
DR-3641 13.22 ± 5.33 N.D. N.D. 
DR-3111 11.94 ± 2.62 0.01 ± 4.35 5.37 ± 2.62 
OP 35 11.81 ± 0.64 7.66 ± 5.78 1.02 ± 1.06 
DR-4695 10.50 ± 2.42 21.13 ± 2.76 3.77 ± 2.15 
K580 9.56 ± 2.86 0.01 ± 3.16 2.20 ± 1.52 
K545 6.93 ± 2.76 3.60 ± 1.09 2.36 ± 2.04 
PipT 6.75 ± 4.52 4.03 ± 2.69 2.40 ± 1.05 
K523 6.25 ± 4.06 0.01 ± 2.29 0.01 ± 1.71 
DR-3227 6.15 ± 2.43 11.07 ± 0.87 0.01 ± 4.30 
DR-4034 5.25 ± 4.89 3.48 ± 1.50 2.34 ± 0.94 
DR-3707 3.13 ± 2.14 0.01 ± 3.70 12.85 ± 2.69 
Pe141 1.17 ± 0.23 0.01 ± 4.04 2.20 ± 1.94 
DR-4377 0.01 ± 12.81 3.25 ± 0.80 1.35 ± 1.05 
DR-4255A 0.01 ± 10.54 9.35 ± 1.44 7.50 ± 3.03 
K480 0.01 ± 7.14 2.50 ± 1.09 0.01 ± 1.50 
DR-4066 0.01 ± 5.75 0.01 ± 3.59 3.01 ± 2.00 
Dipyridamole 21.75 ± 9.92 2.30 ± 0.75 0.01 ± 3.26 
Chloroquine (29.64 ± 3.35 μM) 0.31 ± 3.28 70.68 ± 0.97 
Quinine (63.00 ± 3.27 μM) 2.53 ± 1.17 0.01 ± 6.08 
EDTA N.D. N.D. (23.90 ± 1.83 μM) 
Ascorbic acid N.D. (19.31 ± 2.62 μM) N.D. 
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None of the 35 compounds, as well as dipyridamole, exhibited free-radical scavenging or 
iron chelating activity comparable to the respective controls, ascorbic acid (IC50 value: 
19.31 ± 2.62 µM) and EDTA (IC50 value: 23.90 ± 1.83 µM). With free-radical scavenging 
activity ranging from 0.01% to 32% at 240 µM and iron chelating activity ranging from 
0.01% and 35% at 200 µM (Table 5.19). 
5.4 Discussion 
The antimalarial activity of the nucleoside phosphonates, phosphonic acids and 
purine/pyrimidine derivatives tested in this study exhibited variable antimalarial activity, 
not only between the various structural groups, but also within the groups (Tables 5.10-
5.17; Figure 5.10).  
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Figure 5.10: Active antimalarial compounds of the Mickey Mouse, PyrroPME and 
pyrrolidine nucleotide groups. 
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When examining the general antimalarial activity of the various structural groups, it can 
be seen that the Lipophosphonoxin and Nucleoside lipophosphonate groups had the 
best antimalarial activity, producing 11 of the active compounds, with IC50 values ranging 
between 10 µM and 50 µM (Tables 5.13 and 5.14). Followed by the Mickey Mouse, 
PyrroPME, and Pyrrolidine nucleotide groups which had five, two, and one active 
compound(s), all producing one drug with an IC50 value of less than 50 µM (Figure 5.10).   
The Piperidine nucleoside and nucleotide, Aza sugar, U/T Miscellaneous, Miscellaneous, 
and Phosphonoxin  groups exhibited disappointing antimalarial activity; with compounds 
of these groups only capable of inhibiting parasite growth at 100 µM by a maximum of 
43.57 ± 0.48%, 2.19 ± 5.42%, 5.87 ± 1.54%, 7.20 ± 3.10%, 13.53 ± 8.97% and 36.84 ± 
2.62%,respectively (Tables 5.15-5.17). 
In contrast, an examination of the antiprotozoal effects of Phosphonoxins against 
Giardia, the protozoa responsible for the majority of reported waterborne-associated 
cases of diarrhoea in the United States, showed that compound DR-3510 was as active 
as existing therapeutics against the WB-6 strain of Giardia lamblia (Suk et al., 2007). The 
activity of this Phosphonoxin was attributed to the chelation of metal ions, most likely 
calcium, which are proposed to be at the active site of the cyst wall synthase enzyme, 
thereby inhibiting trophozoite cyst wall formation (Suk et al., 2007). The metal chelating 
activity was attributed to donor groups in the aminoalkylphosphonate moiety, 
speculating that the 2-carbon linker between the amino and phosphonate moieties 
allowed for the correct conformation for chelation of the metal ion (Suk et al., 2007). 
However, in this study, the linker between the amino and phosphonate moieties 
appeared to play no role in antimalarial activity, with compounds of the Phosphonoxin 
group possessing the 2C linker displaying no antimalarial activity (Table 5.17). 
Additionally, when tested for their ability to chelate Fe(II), none of the Phosphonoxins 
displayed any metal chelating activity (Table 5.19).     
What did appear to play a role in antimalarial activity was the attachment of a bulky 
(C16H33) aliphatic side chain to the phosphonate group, with a comparison of the 
Phosphonoxin (Table 5.17) and Lipophosphonoxin (Table 5.11) groups showing that they 
exhibited strong structural similarities, with the only difference lying in the addition of 
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this side chain. A study conducted by Rejman et al. (2011) showed that the addition of 
the aliphatic side chain to the Phosphonoxin group, to produce Lipophosphonoxins 
(Figure 5.11), resulted in substantially increased antibacterial activity (Rejman et al., 
2011). It was concluded that the negative charge of the phosphonate group of 
Phosphonoxins hampered cellular uptake, whilst the addition of the aliphatic side chain 
facilitated cellular uptake (Rejman et al., 2011).     
 
Figure 5.11: The general structure of the Lipophosphonoxin group of compounds 
(Rejman et al., 2011). 
 
This substitution appeared to confer antimalarial activity to the Lipophosphonoxin group 
of compounds, with IC50 values ranging from 13 µM to 49 µM, as when the side chain 
was shortened, or substituted with other moieties, the antimalarial activity was lost. This 
was observed with compounds DR-4658, DR-4695 and DR-4696 (0.01 ± 2.61%, 0.01 ± 
1.62% and 2.16 ± 1.61% inhibition of parasite growth at 100 µM, respectively) (Table 
5.11). Similarly, Rejman et al. (2011) found that when the aliphatic side chain was 
shortened, as was the case with compound DR-4658, antibacterial activity was 
abolished. They also found that compounds DR-4878 and DR-4463, both having the 
bulky side chain substitution, showed some of the most significant antibacterial activity, 
with these compounds also exhibiting some of the best antimalarial activity in this study.     
The heterocyclic substitution attached to the Phosphonate group appeared to not play a 
role in the antimalarial activity of the compounds, as the Nucleoside Lipophosphonoxin 
group (Table 5.10) lacked this substitution, yet still retained antimalarial activity similar 
to that of the Lipophosphonoxins. The substitution that did appear to play a role in 
antimalarial activity was the hydroxyl group on the heterocyclic ring. A comparison of 
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the structures of compounds DR-4458 and DR-4459 showed that the addition of an extra 
hydroxyl group on the heterocyclic ring resulted in a 1.6-fold decrease in the IC50 value 
(Table 5.11). The orientation of the hydroxyl groups also appeared to play a role, with 
compounds DR-4850 (IC50 value: 13.35 ± 0.38 µM) and DR-4914B (IC50 value: 21.07 ± 
0.71 µM) having identical chemical structures with the exception of the orientation of 
these groups on the heterocyclic ring (Table 5.11).  The bond orientation of the hydroxyl 
groups on the pyrrolidine ring also appeared to play a role in the haemolytic activity of 
the compounds, with compound DR-4850 exhibiting 9.25 ± 2.08% haemolysis at 100 µM 
compared to 50.20 ± 3.35% for compound DR-4914B (Table 5.11).  
The base composition of the compounds appeared to play a role in the antimalarial 
activity of the Lipophosphonoxins. Although the structures of compounds DR-4137 and 
DR-4850 were almost identical, the base attached to the ribose moiety was uracil in 
compound DR-4137 and guanine in compound DR-4850. This resulted in the 3.7-fold 
decrease in antimalarial activity observed in compound DR-4137 (Table 5.11). Similarly, 
the only difference between compounds DR-4914B and DR-4848 was that compound 
DR-4914B had a guanine base, and compound DR-4848 a modified cytosine base, 
resulting in compound DR-4914B being 1.5-fold more active than compound DR-4848 
(Table 5.11).  
Overall, the base composition of the compounds did not appear to be the determinant 
of antimalarial activity, with the three most active compounds (DR-4850, DR-4878 and 
DR-4463) having guanine, cytosine and uracil bases, respectively (Table 5.11). Similarly, 
the base composition of the Nucleoside Lipophosphonates was not a determinant of 
antimalarial activity, with compounds DR-3641, DR-3621 and DR-3960 having adenine, 
uracil and guanine bases, respectively (Table 5.10). When examining the structure of 
compound DR-3641, which had the highest IC50 value (43.14 ± 1.67 µM) of the three 
Nucleoside Lipophosphonates, the ribose moiety was dehydroxylated at the 3’ position 
of the ribose moiety (Table 5.10). 
An examination of the PyrroPME group showed that the only two active compounds in 
this group possessed the same bulky aliphatic side chain attachment to the phosphonate 
group (Figure 5.10; Table 5.12). The base composition did not play a role in the 
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antimalarial activity of the compounds in this group. Compounds DR-3919 and DR-3945 
were identical, except that DR-3919 had an adenine base and DR-3945 a thymine base, 
yet both displayed no antimalarial activity (Table 5.12). However, upon replacement of 
the hydroxyl group of compound DR-3919 with a bulky aliphatic side chain to produce 
compound DR-3953, the antimalarial activity was greatly improved (IC50 value: 39.34 ± 
2.77 µM). A similar trend was observed when comparing compound DR-3945 to 
compound DR-4140 (IC50 value: 63.51 ± 5.60 µM) (Table 5.12).  
Structural analysis of the Mickey Mouse group (Table 5.13) showed that the phosphonic 
acid derivatives exhibited no antimalarial activity; with the exception of compound DR-
4651, which exhibited poor antimalarial activity (IC50 value: 79.66 ± 2.11 µM) (Figure 
5.10; Table 5.13). When comparing the structures of compounds DR-4651, DR-4598A, 
DR-4640 and DR-4599A, all exhibit structural similarities, with the exception that 
compound DR-4651 had an amino group at the C2 position on the purine ring and 
contained an ethyloxymethyl linker between the purine ring and phosphonic acid 
moiety. Whereas compounds DR-4598A and DR-4640 contained propyl and butyl linkers, 
respectively (Table 5.13). A comparison of compounds DR-4541 and DR-4523 showed 
that the attachment of a trifluoromethyl group at the C3 position of the purine ring 
conferred weak antimalarial activity to compound DR-4523 (IC50 value: 77.48 ± 8.57 µM). 
However, upon addition of a phosphonic acid group via an ethyloxymethyl linker, the 
antimalarial activity was abolished, as observed in compound DR-4541 (14.26 ± 4.63% 
inhibition at 100 µM) (Table 5.13). A comparison of the chemical structures of 
compounds DR-3892 (IC50 value: 57.11 ± 1.49 µM) and DR-3898 (2.50 ± 3.32% inhibition 
at 100 µM), which were the same except DR-3892 was an oxobutanoic acid derivative 
and DR-3898 a phosphonic acid derivative. This indicates that the oxobutanoic acid 
moiety appeared to confer antimalarial activity, whereas the phosphonic acid moiety 
abolished it (Table 5.13).  
Compounds D1293-S, Bn2.NH.HCl and DR-4461 are closely related to each other, where 
compound DR-4461 is a composition of compounds D1293-S and Bn2.NH.HCl in a 1:10 
ratio. It can be seen that the dibenzylamine (Bn2.NH.HCl) component exhibits no 
antimalarial activity on its own (12.57 ± 4.88% inhibition of parasite growth at 100 µM); 
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whilst the addition of compound D1293-S to produce compound DR-4461 slightly 
increased the antimalarial activity (33.87 ± 6.76% inhibition of parasite growth at 100 
µM) (Table 5.13). Which was expected since compound D1293-S on its own exhibited 
moderate antimalarial activity (IC50 value: 52.63 ± 3.79 µM) (Table 5.13).  
Of the Pyrrolidine nucleotide group, only compound DR-3876 exhibited antimalarial 
activity (IC50 value: 31.08 ± 2.33 µM) (Figure 5.10). When comparing compounds DR-
3616, Pe141 and DR-3876, the latter differed from the other two in that it contained a 
guanine base, whilst the others contained an adenine base, with no hydroxyl group on 
the pyrrolidine ring, and it possessed a methyl linker between the phosphonic acid and 
carbonyl groups (Table 5.14). However, these structural modifications did not greatly 
improve its activity over a double parasitic life cycle, only contributing to a 1.6-fold 
decrease in the IC50 value (Figure 5.6). When tested for activity against human purine 
nucleoside phosphorylase, the enzyme responsible for catalysing the formation of 
hypoxanthine from inosine and the cleavage of guanine and hypoxanthine nucleosides 
to form the corresponding base and sugar phosphate, D. Rejman and co-workers found 
that two compounds were potent inhibitors of this enzyme, one of which was 
structurally similar to compound DR-3876 (D. Rejman; unpublished observations). In this 
respect, compound DR-3876 may have acted to inhibit human purine nucleoside 
phosphorylase present in the erythrocyte cytosol. However, inosine metabolism would 
still occur, following its transport into the parasite cytosol by PfENT1, and then via the P. 
falciparum purine nucleoside phosphorylase enzymes (Hyde, 2007; Downie et al., 2008; 
Riegelhaupt et al., 2010).     
When comparing compounds K584, K578 and DR-4028, the latter compound was 
hydroxylated on the pyrrolidine ring and contained a bromo-substitution on its uracil 
base (Table 5.14). However, the bromo-substitution did not improve antimalarial 
activity, with compound DR-4028 exhibiting a similar lack of antimalarial activity as seen 
for compounds K584 and K578 (Table 5.14). 
In contrast, the Piperidine nucleoside and nucleotide group produced no active 
compounds, regardless of the various structural differences between the compounds 
(Table 5.15). However, when comparing the Piperidine nucleosides, compounds DR-
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4377 and DR-4513, which are identical, except for the adenine base of compound DR-
4513 and uracil base of DR-4377. It was observed that compound DR-4513 exhibited 
slightly better inhibitory activity (43.57 ± 0.48 % growth inhibition at 100 µM) when 
compared to compound DR-4377 (0.01 ± 1.31% growth inhibition at 100 µM) (Table 
5.15). Similarly, the Aza sugar, U/T miscellaneous and Miscellaneous group of 
compounds displayed no antimalarial activity despite structural variations, such as the 
hydroxylation of piperidine/pyridine rings and attachment of sulphur-containing 
heterocyclic groups (Table 5.16). 
Derivatives of acyclic nucleoside phosphonates, prodrugs of the triphosphate inhibitors 
of DNA replication, have previously been shown to exhibit potent antimalarial activity. 
The most active of which, an adenine derivative, exhibited antimalarial activity in the 
low micromolar concentration range (IC50 value: 0.18 ± 0.07 µM) against the K1 strain of 
Plasmodium falciparum (Smeijsters et al., 1999). The antimalarial activity of these 
compounds was attributed to the inhibition of plasmodial DNA polymerases, thereby 
acting as DNA chain terminators (Smeijsters et al., 1999). It does not appear as if the 
compounds tested in this study acted in a similar manner, due to the fact that the 
activity of nucleoside phosphonate/phosphonic acid derivatives containing pyrimidine 
bases (Tables 5.10-5.15, 5.17) were comparable to those containing the purine ring 
structure (Table 5.13) or purine base (Tables 5.10-5.17). With Smeijsters et al. (1999)  
reporting that pyrimidine analogues of acyclic nucleoside phosphonates were inactive at 
concentrations exceeding 250 µM, which is validated by the fact that the parasite does 
not incorporate exogenous pyrimidines into its DNA (Parker et al., 2000; Hyde, 2007).  
Moreover, if the compounds acted by incorporation into parasitic DNA, a much lower 
IC50 value would be expected (< 1 µM), together with a greater difference between IC50 
values in the double versus single cycle of parasite growth (Figure 5.6). 
Select compounds from the Phosphonoxin, Piperidine nucleoside and nucleotide, Aza 
sugar, U/T Miscellaneous, Miscellaneous, Nucleoside Lipophosphonate, PyrroPME, 
Mickey Mouse and Pyrrolidine nucleotide groups (Table 5.20) were screened against the 
cancerous white blood cell lines, L1210 (murine lymphocytic leukaemia), HL60 (human 
acute promyelocytic leukaemia), CCRF-CEM (human acute lymphoblastic leukaemia); as 
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well as an epithelial cancer cell line HeLa S3 (human adenocarcinoma), by a collaborative 
laboratory.  
Table 5.20: The compounds tested for cytotoxicity (D. Rejman; personal 
communication). 
Group name Compounds 
Phosphonoxin DR-3573, DR 3679, DR3707 
Piperidine nucleoside and nucleotide DR-3994, PipT 
Aza sugars, U/T Miscellaneous and Miscellaneous 
K469, DR-4034, K470 
DR-4031, K479, DR-4030 
DR-4037, DR-4011, K480 
DR-3227, DR-3845 
Lipophosphonate DR-4696, DR-4878, DR-4463 
Nucleoside Lipophosphonate DR-3641, DR-3621, DR-3960 
PyrroPME DR-3953, DR-3919, DR-3945 
 DR-3769, DR-4001 
Mickey Mouse DR-3892, DR-3896, DR-3898 
Pyrrolidine Nucleotide DR-3876, DR-4028, DR-3616 
 
Of the compounds screened for cytotoxicity that possessed antimalarial activity (DR-
3641, DR-3621, DR-3960, DR-3953, DR-3892 and DR-3876), only compound DR-3621 
exhibited any cytotoxicity when screened at a concentration of 10 μM, inhibiting cell 
growth at IC50 values of 15.72 ± 0.87 µM, 14.10 ± 0.77 µM, 14.44 ± 0.14 µM and 13.90 ± 
0.19 µM against the L1210, HL60, CCRF-CEM and HeLa S3 cell lines, respectively (D. 
Rejman; personal communication).  
Similarly, none of the Lipophosphonates tested for cytotoxicity against erythroid 
progenitor cells (Table 5.20), derived from human umbilical cord blood, exhibited potent 
effects on cell viability, but did induce low levels of apoptosis (Rejman et al., 2011). The 
lack of appreciable anticancer activity or effects on cell viability on normal cells would 
then indicate that these compounds, with the possible exception of compound DR-3621, 
do not act to inhibit DNA replication even in mammalian cells. Unlike the triphosphate 
forms of 6-mercaptopurine and 6-thioguanine that are incorporated into RNA or DNA, 
thereby acting as chain terminators, that have IC50 values in the low micromolar range 
against the HEK293 (transformed human embryonic kidney) cell line (Wielinga et al., 
2002). However, none of the compounds, with the exception of compound DR-4914B 
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(50.20 ± 3.35 % haemolysis at 100 µM; Table 5.11), displayed toxicity against the host 
red blood cell (Tables 5.10-5.17). Possibly indicating that the activity of the compounds 
was as a result of a direct effect on the parasite by mechanisms other than inhibition of 
DNA polymerase enzymes. 
Thirteen (Tables 5.10-5.12) of the nineteen active compounds exhibited amphipathic 
properties and may have been capable of permeating cell membranes, in a similar 
manner to dipyridamole and amantadine. Amantadine is a primary amine used to treat 
and prevent Influenza A, but displays antimalarial activity in the micromolar 
concentration range against the chloroquine-resistant (FCR-3) strain of P. falciparum 
(Evans and Havlik, 1993).  
Whilst the remaining six active compounds (Tables 5.16 and 5.17) were modified purine 
bases, which may have inhibited nucleoside transport by PfENT1 in a manner similar to 
NBMPR, which inhibits human equilibrative nucleoside transporters in mammalian cells 
(Akaki et al., 2002; Lin and Buolamwini, 2007). In this respect, the mechanism of action 
of these compounds may lie in their ability to inhibit the transport of nucleosides. N6-
Diphenylethyl-5’-phenyl-carboxamidoadenosine (Figure 5.12a), a nucleoside derivative 
bearing a similar modified purine base to that of compound D1293-S (IC50 value: 52.63 ± 
3.79 µM; Table 5.13), has been shown to inhibit the growth of a chloroquine-resistant 
strain of P. falciparum (IC50 value: 1.8 µM), with its mechanism of action attributed to 
the inhibition of PfENT1 (Rodenko et al., 2006). However, the 25-fold difference in 
activity between N6-Diphenylethyl-5’-phenyl-carboxamidoadenosine and compound 
D1293-S pointed to the fact that D1293-S may not have acted to inhibit PfENT1. 
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Figure 5.12: The chemical structures of a) N6-diphenylethyl-5’-phenyl-
carboxamidoadenosine (Rodenko et al., 2006) and b) compound 
D1293-S.   
 
In order to determine whether compound D1293-S did in fact act to inhibit PfENT1, it 
was selected, together with the amphipathic uridine phosphonate derivative, compound 
DR-4463 (Table 5.11), for combination studies with dipyridamole, a known PfENT1 
inhibitor (Section 5.3.3). In both cases, an additive-antagonistic to antagonistic 
interaction was observed (Figure 5.7 b and c; Appendix E). An antagonistic interaction 
between two drugs may point to the fact that both drugs were competing for activity on 
the same target, or that binding of one drug to the transporter was inhibiting the uptake 
of the other (Bell, 2005).  
However, in this case, the noted antagonism did not appear to be due to compounds 
DR-4463 and D1293-S acting on the same target as dipyridamole. Examination of blood 
smears of parasites treated with compounds DR-4463 and D1293-S showed that parasite 
development was affected primarily in the schizont-stage, whereas examination of 
dipyridamole-treated parasites showed that parasite development was halted in the 
early trophozoite-stage, which is similar to parasites carrying a disrupted PfENT1 gene 
(El Bissati et al., 2006). This interference in stage progression by dipyridamole would be 
expected, since the gene expression of nucleoside transporters begins in the ring-stage 
with maximal expression at 32 hours into the parasitic cycle (Martin et al., 2005; El 
Bissati et al., 2006). The poor  antimalarial activity of compound D1293-S (IC50 value: 
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52.63 ± 3.79 µM) (Table 5.13) compared to that of N6-diphenylethyl-5’-phenyl-
carboxamidoadenosine  may  possibly have been due to the fact that Rodenko et al. 
(2006) attributed the PfENT1 inhibitory activity of the 5’-carboxamidoadenosine 
derivatives to a combination of the N6-diphenylethyl group on the adenine base and an 
aromatic residue on the 5’ position of the ribose moiety, with replacement of the 
aromatic residue with a methyl group resulting in IC50 values greater than 10 µM. 
In addition, if these compounds acted as PfENT1 inhibitors, a discrepancy between their 
IC50 values as determined by the [
3H]-hypoxanthine incorporation assay and flow 
cytometric analysis would have occurred, since they would have inhibited the uptake of 
the radiolabelled isotope (Table 5.18).  
However, some authors suggest that PfENT1 is insensitive to dipyridamole. Parker et al. 
(2000) cloned PfENT1 from the 3D7 strain of P. falciparum and expressed it in Xenopus 
oocytes and found that 10 µM dipyridamole had no effect on PfENT1-mediated 
transport of adenosine. In contrast,  Carter et al. (2000), reported that PfENT1  cloned 
form the 3D7 (chloroquine-sensitive) and W2 (chloroquine-resistant) strains and 
expressed in Xenopus oocytes, was sensitive to 10 µM dipyridamole which inhibited 
adenosine uptake by 85%.  
In this study, dipyridamole exhibited a direct effect on the parasite, inhibiting parasite 
growth in the micromolar concentration range (Table 5.18). However, the concentration 
of dipyridamole used in the combination study may have resulted in the inhibition of 
human ENT1, found in the red blood cell membrane. This could possibly result in the 
decreased transport of both purine and pyrimidine nucleosides and base analogues into 
the red blood cell, which may also be the cause of the noted antagonism (Figure 5.7) 
(Downie et al., 2008). There is also the possibility that compound D1293-S inhibited a 
non-PfENT1 purine nucleoside transporter (Figure 5.1), however in that case an additive 
or synergistic interaction with dipyridamole would be expected.   
Examination of the stage-specific and morphological effects of compound DR-4463 
showed some cytoplasmic vacuolisation in the late trophozoite-stage and a lag in 
schizont development and merozoite formation (Figure 5.8C,D and E). There was also a 
possible reduction in the number of merozoites formed or inability of merozoites to 
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invade red blood cells; with schizonts that had progressed through the cycle to form 
early rings only resulting in an increased parasitaemia of 3.51% (Section 5.3.4). In the 
latter case, it is possible that compound DR-4463 may have inhibited the sialic acid-
dependant binding of the merozoite to the red blood cell in a manner similar to that of 
polyanionic compounds, such as oligodeoxynucleotides (Ramasamy et al., 1996; 
Kanagaratnam et al., 1998).  
The process of merozoite invasion begins with the attachment of the merozoite to the 
red blood cell via merozoite membrane proteins, which potentially act as erythrocyte 
ligands (Figure 5.13A).  
 
Figure 5.13: The invasion of a red blood cell by a merozoite (Cowman et al., 2006). 
 
Following merozoite attachment, merozoite reorientation occurs (Figure 5.13B) so that 
the apical end of the merozoite is adjacent to the red blood cell; thereby facilitating the 
secretion of substances from merozoite organelles that are vital to the attachment of 
the apical end of the merozoite to the red blood cell and pit formation. Thereafter, the 
merozoite is propelled into the red blood cell (Figure 5.13C and D) by the action of the 
actin-myosin pump and finally, upon entry into the red blood cell, the merozoite protein 
surface coat is removed by parasitic proteases (Figure 5.13E) (Bozdech et al., 2003; Soni 
et al., 2005; Cowman et al., 2006). 
In addition, the amphipathic nature of compound DR-4463 may have facilitated its 
incorporation into the lipid bilayer of the red blood cell membrane, where it altered 
membrane shape and composition (Evans and Havlik, 1993; Ziegler et al., 2002). 
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Resulting in altered fluidity of the membrane and affecting parasite-induced 
modification of the red blood cell membrane, such as transport channels, exo- and 
endocytosis, as well as adhesion, making the membrane unfavourable for invasion by 
merozoites (Evans and Havlik, 1993; Ziegler et al., 2002). In addition, receptor-mediated 
processes may have been disrupted by compound DR-4463 resulting in the noted 
cytoplasmic vacuolisation, possibly due to the induction of autophagy (Evans and Havlik, 
1993; López et al., 2010). Amphiphiles have displayed growth inhibitory properties in the 
range of 7-28 µM in the 3D7 strain of P. falciparum, using [3H]-phenylalanine as a growth 
indicator. This activity was slightly lower than the IC50 value range observed with the 
amphiles in this study (13-64 µM) using [3H]-hypoxanthine as a growth indicator (Ziegler 
et al., 2002, 2004).  
Alternatively, the aliphatic side chains may have conferred the lipophilicity needed to 
facilitate the entry of the compounds into the red blood cell, and may have been cleaved 
off following entry. In this manner, the side chain may not have contributed to the 
inhibition of parasite growth. In all of the amphipathic compounds, the side chain was 
linked to the phosphonate/phosphonic acid group by a phosphoester bond (Table 5.10-
5.12), which is prone to attack by esterase enzymes present in the red blood cell cytosol 
(De Clercq, 2007; Vaněk et al., 2009). Similarly, nucleoside phosphonates and 
phosphonic acid derivatives containing a phosphoester linkage to the ribose moiety are 
also prone to attack by 5’-nucleotidases (Hyde, 2007; Mehrotra et al., 2010). 
Nucleotidases are capable of cleaving the phosphoester bond of both purine and 
pyrimidine nucleoside monophosphates to form the corresponding nucleoside, and are 
involved in the catabolism of ATP to form adenosine, providing a key source of 
hypoxanthine for the parasite (Hyde, 2007; Mehrotra et al., 2010). In contrast, a 
phosphate-carbon linkage between the ribose and phosphonate/phosphonic acid 
moieties provides metabolic stability against attack by catabolic enzymes (De Clercq, 
2007; Vaněk et al., 2009). However, it did not appear as if the possible cleavage of the 
phosphate group from the Lipophosphonoxin group of compounds (Table 5.11) had a 
detrimental effect on antimalarial activity. A comparison of the antimalarial activity of 
compounds which had a phosphoester linkage between the ribose and phosphonate 
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moieties, such as compound DR-4850 (IC50 value: 13.35 ± 0.38 µM; Table 5.11), and 
those with a phosphate-carbon linkage, such as compound DR-3960 (IC50 value: 33.13 ± 
2.10 µM; Table 5.10) highlights this. Following possible modification by enzymes in the 
red blood cell cytosol, the (nucleo)base derivatives and nucleoside analogues may then 
have been transported into the parasite by PfENT1 and in the case of some purine 
derivatives, possibly non-PfENT1 mechanisms (Downie et al., 2008; Riegelhaupt et al., 
2010).   
Following the entry of the pyrimidine (nucleo)base and nucleoside derivatives into the 
parasite, the lag in schizont development and possible reduction in merozoite formation 
may have been due to the  pyrimidine analogues and pyrimidine-containing nucleoside 
phosphonates/phosphonic acids acting as substrate analogues, thereby weakly inhibiting 
critical enzymes of DNA synthesis and division (Baragaña et al., 2011). One such enzyme 
is deoxyuridine 5’-triphosphate nucleotidohydrolase, and is responsible for catalysing 
the hydrolysis of deoxyuridine 5’-triphosphate (dUTP) to dUMP, thereby providing the 
dUMP necessary for dTTP synthesis in the thymidylate cycle. It is also responsible for the 
low dUTP:dTTP ratio necessary to prevent the inclusion of uracil into DNA by plasmodial 
DNA polymerases. The enzyme has been shown to be inhibited by both cyclic and acyclic 
deoxyuridine analogues, with some inhibiting enzyme activity at sub-micromolar 
concentrations (Kí range: 0.5-98 µM) (Baragaña et al., 2011).  
Similarly, orotidine-5’-monophosphate decarboxylase, responsible for the carboxylation 
of OMP to UMP (Figure 5.2), has been shown to be inhibited by pyrimidine nucleotide 
derivatives (Meza-Avina et al., 2010).  Enzyme inhibition results from the interaction of 
the phosphoribosyl moiety of the derivative with the enzyme, through hydrogen 
bonding of the hydroxyl and phosphoryl moieties (Meza-Avina et al., 2010). 
Furthermore, the plasticity of orotidine-5’-monophosphate decarboxylase enables it to 
accept various nucleotide derivatives as ligands, including purine derivatives (Meza-
Avina et al., 2010). Taking into account the low affinity transport of thymine and uracil 
bases and nucleosides derivatives, along with the relatively high IC50 values of the 
compounds (Tables 5.10-5.12), it seems unlikely that this enzyme was inhibited.  
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However, purine bases and nucleosides are transported by PfENT1 at a higher affinity 
than pyrimidine derivatives, due to the reliance of P. falciparum on purine salvage from 
the host (El Bissati et al., 2006; Downie et al., 2008; Riegelhaupt et al., 2010). The 
increased transport of purine base and nucleoside derivatives, together with the fact 
that PfENT1 is capable of accommodating a wide variety of alterations on natural 
substrates, makes purine metabolism an excellent drug target (Riegelhaupt et al., 2010). 
PfENT1 has been shown to transport tubercidin (Figure 5.14a), a 7-deazaadenosine 
analogue, and 9-deazahypoxanthine (Figure 5.14b), with an affinity similar to the natural 
substrates, adenosine and hypoxanthine, respectively. Indicating that alterations on the 
N7 and N9 positions on the purine ring did not inhibit substrate recognition. However, 
alteration of the ribose moiety in immucillins (Figure 5.14c), which are 9-deaza purines 
containing a cationic nitrogen in the place of oxygen in the ribose moiety, appeared to 
decrease or inhibit transportation of the nucleoside derivatives, possibly due to the 
altered charge of the moiety (Riegelhaupt et al., 2010). 
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Figure 5.14: The chemical structures of tubercidin (a) 9-deazahypoxanthine (b) and 
immucillin-H (c), showing where the base was modified (Riegelhaupt et al., 
2010).   
The metabolism of adenosine into inosine and then hypoxanthine by P. falciparum 
adenosine deaminase and P. falciparum purine nucleoside phosphorylase enzymes, 
respectively (Figure 5.1), maintains a low internal adenosine concentration which drives 
the uptake of adenosine into the parasite until equilibrium is reached (Riegelhaupt et al., 
2010). In addition, parasite-induced new permeation pathways within the red blood cell 
membrane are not saturable for concentrations in the millimolar range (Gero et al., 
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2003), possibly creating a situation where adenosine derivatives hyper-concentrate 
within the parasite, exerting toxic effects. 
P. falciparum has been shown to proliferate under conditions where adenine, 
adenosine, guanine, guanosine or xanthine was present as the sole purine source, at 
concentrations as low as 2 µM (Downie et al., 2008; El Bissati et al., 2008). It may then 
seem possible that the parasite utilised the adenine/guanine derivatives or nucleosides 
as an alternate purine source, incorporating them into its DNA, resulting in their 
antimalarial activity. However,  a lower IC50 value would be expected due to DNA chain 
termination, and IC50 results as obtained by the [
3H]-hypoxanthine assay and flow 
cytometric analysis would show large discrepancies due to the lack of incorporation of 
the hypoxanthine isotope into parasitic DNA, which was not the case (Table 5.18).  
Guanine/guanosine derivatives are also taken up via PfENT1, which may also result in a 
hyper-concentration of the derivatives within the parasite, with reports that guanine 
and guanosine are toxic to the parasite at concentrations above 50 µM (El Bissati et al., 
2008). Alternatively, both guanine and hypoxanthine are phosphoribosylated by the 
PfHGXPRT enzyme, which exhibits similar affinities for hypoxanthine and guanine (Km 
values = 0.46 µM and 0.30 µM, respectively). In this manner, the guanine/guanosine 
derivatives may have competed with hypoxanthine for phosphoribosylation, which 
ultimately would have lead to decreased ATP levels for nucleic acid synthesis and cell 
signalling (Downie et al., 2008). Alternatively, adenine nucleoside derivatives may act as 
structural analogues for enzyme substrates, and thereby inhibit enzymes involved in the 
sequential conversion of IMP to adenylsuccinate and finally to AMP (Bulusu et al., 2011). 
One such nucleoside derivative, 5-aminoimidazole-4-carboxamide ribonucleoside, has 
been shown to inhibit Plasmodium falciparum adenylosuccinate lyase, thereby inhibiting 
the conversion of adenylsuccinate to AMP. Although, it only exerted its antimalarial 
effect at very high concentrations (IC50 value: 167 ± 5µM) (Bulusu et al., 2011). 
Notwithstanding possible enzymatic inhibition, any minor disturbance of purine uptake, 
the salvage pathway, or purine nucleotide synthesis in P. falciparum would result in 
growth arrest in the schizont stage (Bulusu et al., 2011).          
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The structural diversity of the compounds and the presence of reactive functional 
groups’ on the side chains, could contribute to the compounds having mechanisms of 
action other than those proposed above. These could include inhibition of β-haematin 
formation, free-radical scavenging or metal chelation (Table 5.19).  
Aminoalkylphosphonates contain donor groups capable of chelating metals, thereby 
inactivating metalloenzymes (Kiss et al., 1994). However, none of the compounds in this 
study exhibited any Fe(II) chelating activity, with the Fe(II) chelating activity of the 27 
compounds tested  ranging from 0.01 ± 1.50% to 34.86 ± 8.44%  at 200 µM (Table 5.19). 
The lack of activity of the compounds could be due to the fact that a higher drug 
concentration was needed, with 2,2’-bipyridyl, a nitrogen-containing heterocyclic 
bidentate Fe(II) chelator, only capable of chelating iron in a ratio of 3:1 of drug to Fe(II) 
(Elandalloussi et al., 2003). Therefore, as is the case with 2,2’-bipyridyl, a 3:1 ratio of 
drug to Fe(II) may have been needed to chelate the free Fe(II) concentration of 200 µM 
used in this assay. 
 In a similar manner, none of the 30 compounds tested exhibited any DPPH• free-radical 
scavenging activity, with free-radical scavenging activity ranging from 0.01 ± 2.13% to 
31.60 ± 5.34% at 240 µM (Table 5.19). Despite the fact that the compounds contained 
amine groups and were hydroxylated; with these groups conferring anti-oxidant activity 
(Saito and Ishihara, 1997; von Gadow et al., 1997; Nishiyama et al., 2002). Spanou et al. 
(2007) also found that pyrano-nucleoside analogues of N4-benzoyl cytosine and N6-
benzoyl adenine did not exhibit any DPPH• free-radical scavenging activity, attributing 
their inactivity to the size of the analogues, resulting in steric hindrance and preventing 
their accessibility to the radical site of DPPH•. 
In contrast, of the 35 compounds screened for β-haematin formation inhibitory activity, 
six exhibited potent activity (Figure 5.15), with some compounds proving to be over 3.6-
fold more active than chloroquine. Of the six compounds, five belonged to the 
Lipophosphonoxin (Table 5.11) and Nucleoside Lipophosphonate groups (Table 5.10), 
whereas one belonged to the Mickey Mouse group (Table 5.13).  
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Figure 5.15: The inhibitory activities of compounds from the Lipophosphonate (DR-4137, 
DR-4458, DR-4459, DR-4463) Nucleoside Lipophosphonate (DR-3621) and 
Mickey Mouse groups (DR-4598A). 
 
The β-haematin inhibitory activity of the aliphatic side chain of the Lipophosphonoxin 
and Nucleoside Lipophosphonate groups appeared to parallel the antimalarial activity of 
the compounds. The Phosphonoxin, compound DR-3707 (Table 5.17) is similar to the 
Lipophosphonoxin, compound DR-4459 (Table 5.11), except for the aliphatic side chain. 
This structural difference resulted in an increase in β-haematin formation inhibitory 
activity from 3.13 ± 2.14% at 400 µM (compound DR-3707) to an IC50 value of 11.39 ± 
1.71 µM (compound DR-4459) (Table 5.19). The activity of the Lipophosphonoxins and 
Nucleoside Lipophosphonates may be attributed to the increased lipophilicity and 
affinity for haematin conferred by the aliphatic side chain, which itself may also have 
interacted with the porphyrin ring of the Fe(III)-protoporphyrin-IX (Egan et al., 2000). 
Similarly, the side chain may have provided the correct conformation for complexing of 
the heterocyclic moiety to the porphyrin ring, thereby preventing the interaction of a 
carboxylate group of one porphyrin ring to the Fe(III) of another porphyrin ring (Chemaly 
et al., 2007). Alternatively, it may have allowed for the hydroxyl groups present on the 
piperidine and pyrrolidine ring systems to interfere with hydrogen bonding between the 
dimers (Chemaly et al., 2007; Kouznetsov and Gomez-Barrio, 2009), thereby preventing 
dimerisation and/or chain formation.  
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Compound DR-4598A exhibited no antimalarial activity (34.61 ± 3.17% growth inhibition 
at 100 µM) (Table 5.13), however proved to be a potent inhibitor of β-haematin 
formation, being 3.2-fold more active than chloroquine (Figure 5.15; Table 5.19). The 
structure of DR-4598A (Table 5.13) is vastly different from those of the 
Lipophosphonoxins and Nucleoside Lipophosphonate inhibitors of β-haematin 
formation. It is not a nucleoside derivative and does not have an aliphatic side 
substitution; but rather contains a purine ring system substituted with dibenzylamino 
and propylphosphonic acid groups (Table 5.13). Compounds DR-4598A and DR-4523 
exhibit some structural similarities, with the exceptions that DR-4523 lacks the 
propylphosphonic acid substitution on the purine ring, and has a trifluoromethyl 
substitution on one of its benzene rings (Table 5.13). These differences accounted for a 
19-fold decrease in β-haematin inhibitory activity in compound DR-4523 (IC50 value: 
174.90 ± 4.28 µM). The trifluoro-methyl substitution of DR-4523 may have conferred 
weak β-haematin inhibitory activity and antimalarial activity in a similar fashion to the 7-
chloro group on the aminoquinolines (Egan et al., 2000). However, compound DR-4598A 
lacks this substitution and yet retains potent β-haematin inhibitory activity. Pointing to 
the propylphosphonic acid substitution as a contributing factor in its activity. Possibly by 
competing with the carboxylate of the propionic acid groups of a porphyrin ring for 
coordination to the Fe(III) of another porphyrin ring. The lack of antimalarial activity and 
strong β-haematin inhibitory activity of compound DR-4598A indicates that the 
phosphonic acid group contributed to its β-haematin inhibitory activity, but also 
hampered its ability to move through membranes. With most of the phosphonic acid 
derivatives tested in this study exhibiting no antimalarial activity (Tables 5.12-5.15).  
Although some of the analogues exhibited both antimalarial and β-haematin inhibitory 
activity, there appeared to be no correlation between the two activities (r2 = 0.43). This 
is highlighted by the fact that compound DR-4463 exhibited potent ex vivo β-haematin 
inhibitory activity (IC50 value: 13.39 ± 2.16 µM) (Table 5.19). However, haemozoin 
crystals were clearly visible when examining its effect on parasite morphology (Figure 
5.8A-D), indicating that perhaps the compound did not concentrate in the food vacuole 
or that inhibition of haemozoin formation is not its primary mechanism of action.  
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It can be concluded from the results that the compounds exhibit fairly poor specificity 
for DNA synthetic and replication processes of P. falciparum. However, certain structural 
modifications could greatly enhance the activity of the compounds. One such example is 
compound DA-IX-158, an adenine derivative which exhibited poor antimalarial activity 
(13.53 ± 8.97% inhibition at 100 µM) (Table 5.16). A study conducted by Hocková et al. 
(2009), found that an acyclic nucleoside phosphonate derivative with a similar structure 
to that of DA-IX-158 exhibited poor inhibition of the PfHGXPRT. However, upon 
modification of the base from an adenine to a guanine or hypoxanthine (Figure 5.16a), 
enzyme inhibition was greatly enhanced (Hocková et al., 2009). Similarly, DA-IX-158 
closely resembles (S)-(3-hydroxy-2-phosphonylmethoxy-propyl)adenine ((S)-HPMPA) 
(Figure 5.16b), but it lacks the 3’-hydroxyl moiety attributed to the antimalarial activity 
of ((S)-HPMPA) (0.18 ± 0.07 µM against the K1 chloroquine-resistant strain of P. 
falciparum) (Smeijsters et al., 1999). 
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Figure 5.16: Nucleoside phosphonic acids previously assessed for antimalarial activity. 
Where: a = phosphonoethoxyethyl hypoxanthine (Hocková et al., 2009) 
and b = 3-hydroxy-2-phosphonylmethoxypropyl adenine (HPMPA) 
(Smeijsters et al., 1999).    
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ANP derivatives provide an excellent drug scaffold in that they do not contain the classic 
glycosidic linkage, nor do they contain the phosphoester bond prone to hydrolysis. 
However, ANPs would need to be delivered in the form of a pro-drug due to their 
inability to cross membranes (Hocková et al., 2009).   
Similarly, ideal drug scaffolds have been proposed for CDK inhibitors of Pfmrk based on 
structure-activity relationships of Pfmrk inhibitors active in sub-micromolar 
concentrations; with these Pfmrk inhibitors also exhibiting no activity against human 
CDKs. In this manner, the ideal pharmacophore should contain two hydrogen bond 
acceptors and two hydrophobic sites, one of which should be an aromatic ring (Figure 
5.17) (Geyer et al., 2005). In addition, Harmse et al. (2001) found that substitution on 
the purine ring at C2 appeared to play a role in the ability of purine derivatives to inhibit 
parasite growth through the inhibition of plasmodial CDKs, with bulky aromatic rings in 
the R orientation abolishing antimalarial activity. 
 
Figure 5.17: The ideal pharmacophore for inhibition of Pfmrk (Geyer et al., 2005). 
 
Inhibition of the pyrimidine synthesis has typically involved inhibition of enzymes of the 
folate pathway, due to the necessity of folate cofactors in the conversion of dUMP to dTMP, 
making this pathway a susceptible antimalarial target (Hyde, 2007; Nzila, 2006). The parasite 
transports pyrimidines with a low affinity; however it readily takes up orotate derivatives 
(Baldwin et al., 2007; Hyde, 2007; Muregi et al., 2009). In this manner, orotic acid 
derivatives or active metabolites could be capable of inhibiting enzymes such as thymidylate 
synthase and would warrant further investigation. However, a pyrimidine such as uridine 
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would need to be co-administered to protect the host from toxicity (Baldwin et al., 2007; 
Hyde, 2007; Muregi et al., 2009). 
Alternatively, an ideal pharmacophore has been proposed as an inhibitor of the orotidine-
5’-monophosphate decarboxylase enzyme, that is required for conversion of OMP to UMP 
(Meza-Avina et al., 2010). The ideal pharmacophore has various components contributing to 
its activity (Figure 5.18). Component A is involved in the orientation of the nucleobase and 
substitutions of iodo, azido or nitrile on component B influence the inhibitory activity of the 
ligand. Whereas, component C, the phosphoribosyl moiety, forms hydrogen bonds with the 
enzyme via the 2’- and 3’-hydroxyl moieties of the ribose group, as well as the 5’ phosphoryl 
moiety (Meza-Avina et al., 2010). In addition, various modifications of the nitrogen-
containing heterocyclic are accommodated without affecting the inhibitory activity. These 
include the substitution of a pyrazole ring structure or even a purine base, with XMP also 
acting as a strong inhibitor of orotidine-5’-monophosphate decarboxylase. Additionally, the 
substitution of a purine base for a pyrimidine base may be beneficial in order to improve the 
transport of the inhibitor into the parasite (Meza-Avina et al., 2010). 
 
Figure 5.18: The ideal pharmacophore of an orotidine-5’-monophosphate decarboxylase 
inhibitor (Meza-Avina et al., 2010). 
 
When combined with quinine, compound DR-4463, a uridine phosphonate derivative, 
exhibited an additive interaction (Figure 5.7a; Appendix E), with the two compounds 
inhibiting parasite growth at different stages of the asexual life cycle. Although these 
nucleoside phosphonates, phosphonic acids and purine/pyrimidine derivatives did not 
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warrant further investigation, structural modifications to improve the lipophilicity and 
specificity of the compounds; whilst maintaining or improving the ability of the compounds 
to act in an additive or synergistic manner with quinine, may provide a new generation of 
derivatives worth investigating. 
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CHAPTER 6: CONCLUSIONS AND RECOMMENDATIONS 
6.1 Conclusions 
The metronidazole-thiosemicarbazone analogues were most active of the three classes of 
novel compounds tested, with six of the eight compounds possessing IC50 values below 10 
µM (Table 3.2).  The activity of this group of compounds appeared to be attributed to the 
presence of a thioamine moiety on the R-group, as when this moiety was replaced with a 
nitrogen-containing heterocyclic (compounds Y-5 and Y-6) (Figure 3.7) the antimalarial 
activity decreased to 51.91 ± 6.03% growth inhibition at 100 µM and an IC50 value of 71.07 ± 
8.97 µM, respectively (Table 3.2). Although, the presence of a quinoline ring structure at the 
R-group also conferred antimalarial activity, as observed in compound Y-7 (IC50 value: 3.79 ± 
0.72 µM; Table 3.2), which lacked the thioamine moiety. Metronidazole exhibited no 
antimalarial activity (22.94 ± 5.61% growth inhibition at 100 µM; Table 3.2), which may have 
been attributed to the lack of activation and subsequent accumulation of the drug in the 
parasite. In addition, the metronidazole moiety may have hindered the rotation of the 
compounds, resulting in their poor Fe(II) chelating activity (Table 3.4). 
In addition to the numerous mechanisms of action attributed to the thiosemicarbazone 
group, the set of analogues in this study were potent inhibitors of β-haematin formation 
(Figure 3.7), with a strong correlation (r2 = 0.87) noted between antimalarial and β-haematin 
inhibitory activity. Side chains wherein the R-group was a 2-chloro-benzyl amine (compound 
Y-3), a cyclooctyl amine (compound Y-1), or a 1,2,3,4-tetrahydroquinoline (compound Y-7) 
were the most potent inhibitors of β-haematin formation (Figure 3.7). The additive 
pharmacological interaction with quinine and dihydroartemisinin (Figure 3.4), the lack of 
toxicity towards the host red blood cells (Table 3.2), as well as the strong anti-oxidant 
activity (Table 3.4) of the compounds would all prove beneficial in the treatment of malaria. 
The antimalarial activity of the chloroquine-chalcones was disappointing when compared to 
chloroquine (IC50 value: 0.0065 ± 0.0002 µM) or quinine (IC50 value: 0.14 ± 0.0007 µM), with 
the most active, compound F-13, possessing an IC50 value of 31.31 ± 0.87 µM (Table 4.2). 
Hybridisation of the chloroquinoline and chalcone moieties abolished the strong β-haematin 
inhibitory activity of the chloroquinoline moiety, with compounds F-14, F-8 and F-3 
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inhibiting β-haematin formation by between 89% and 93% at 400 µM (2:1 ratio of 
drug:haem) (Table 4.3). However, at 100 µM they only inhibited β-haematin formation by 
between 10% and 23% (Section 4.3.4.1), which may have been attributed to the placement 
of the chloro- group on the C2 position and not the C7 position of the quinoline ring. 
Structure-activity relationships showed that compounds with a pyridine ring at R4 were the 
most active, possibly due to an interaction with the malarial protease, falcipain-2 (Mishra et 
al., 2008). In the case of the compounds which had a bromo- or chloro-substituted phenyl 
ring at R4, the positioning of the methyl and hydrogen substitutions at R1, R2 and R3 were the 
main determinant in antimalarial activity, and not the position of the chloro- or bromo- 
group (Table 4.2).  Chalcones have previously been shown to alkylate proteins, which would 
be a concern in that it may induce host cell toxicity, although, none of the compounds 
exhibited any haemolytic effects in this study. Despite this, future derivatives should be 
screened against a normal cell line for cytotoxicity. Compound F-13 exhibited a favourable 
interaction with quinine (Figure 4.5), which is promising for the development of second 
generation compounds as the WHO advocates the use of combination therapies for the 
treatment of malaria (WHO, 2010b).  
The antimalarial activity of the nucleoside phosphonates, phosphonic acids and 
purine/pyrimidine derivatives were weak, with only 19 of the 90 compounds tested 
exhibiting antimalarial activity below 100 µM, and no compounds exhibiting activity below 
10 µM (Tables 5.10-5.17). The compounds showed variable activity, not only between the 
11 structural groups, but also within each group. Overall, all compounds with an aliphatic 
side chain possessed antimalarial activity, with compounds DR-4850, DR-4878 and DR-4463 
possessing the best IC50 values of these compounds (IC50 values: 13.35 ± 0.38 µM, 17.76 ± 
1.72 µM, 19.81 ± 0.80 μM, respectively)  (Tables 5.11). This could possibly be attributed to 
the increased lipophilicity of the compounds, or the facilitation of the incorporation of these 
compounds into lipid membranes, where they could have acted to inhibit merozoite 
invasion of the red blood cell or disrupt transport channels in the membrane (Evans and 
Havlik, 1993; Ramasamy et al., 1996; Kanagaratnam et al., 1998). Some compounds lacking 
the aliphatic side chain substitution, such as compounds DR-4558 and DR-3876 (IC50 values: 
23.85 ± 1.76 µM, 31.08 ± 2.33 µM, respectively) (Tables 5.13-5.14) also displayed 
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antimalarial activity, which may have been due to weak inhibition of enzymes involved in 
DNA synthesis and division. However, no particular base appeared to confer antimalarial 
activity, nor did antimalarial activity significantly improve over a double parasitic life cycle 
(Section 5.3.1.1, Figure 5.6), indicating the lack of selectivity of the compounds for the 
inhibition of DNA/RNA synthesis and replication.  
Interestingly, some compounds such as compound DR-4137 exhibited strong β-haematin 
inhibitory activity (IC50 value: 8.29 ± 1.11 µM; Table 5.19), however, β-haematin inhibitory 
activity did not correspond to the antimalarial activity of the compounds. This was 
highlighted in morphological studies with compound DR-4463, which was a potent ex vivo 
inhibitor of β-haematin formation in the β-haematin inhibitory activity assay (IC50 value: 
13.39 ± 2.16 µM; Table 5.19), yet haemozoin crystals were clearly visible in vitro (Figure 5.8), 
indicating that these compounds work outside of the food vacuole or are incapable of 
entering the food vacuole. Generally the compounds caused no red blood cell lysis (Tables 
5.10-5.17), with the exception of compound DR-4914B (50.20 ± 3.35% haemolysis at 100 
µM; Table 5.11). When tested for cytotoxicity against cancer cell lines and erythroid 
progenitor cells, a selection of 33 compounds (Table 5.20) did not exhibit toxicity, with the 
exception of compound DR-3621 which inhibited growth of the cancer lines at IC50 values 
ranging from 14 µM to 16 µM.  
A comparison of the results obtained by the [3H]-hypoxanthine incorporation assay and flow 
cytometric analysis revealed some statistically significant differences (p < 0.05). Results 
obtained by flow cytometry correlated to blood smear analysis in which both non-viable and 
viable parasites were counted, indicating a lack of specificity for viable parasites only. The 
fluorochrome used in this study was selected due to the fact that it is oxidised into its DNA 
intercalating form in only viable parasites; however, it would appear as if the fluorochrome 
was spontaneous oxidised in non-viable parasites. The methodology provided a means in 
which the stage-specific activity of compounds could be quantitated, however due to the 
overlap in stages, the preparation of duplicate samples for assessment by blood smear 
analysis is crucial.  
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6.2 Recommendations 
6.2.1 Metronidazole-thiosemicarbazone analogues 
 Thiosemicarbazones have numerous proposed mechanisms of action, in this respect it 
would be worthwhile to further examine this class of compounds, such as testing their 
ability to chelate transition metals other than Fe(II), generate reactive oxygen species, 
and inhibit Plasmodial cysteine protease enzymes, from which additional structure-
activity data could be generated and a potent second generation of compounds 
synthesised.  
 In addition, replacement of the metronidazole moiety with other nitrogen-containing 
heterocyclics or an aliphatic amine side chain may facilitate the metal chelation activity 
of the compounds.   
  It would also be worthwhile to test the activity of the compounds against the sexual 
stages of the parasitic life cycle, as a compound that is active against both asexual and 
sexual stages would be highly beneficial as it would not only treat the disease, but also 
block transmission of the disease.   
6.2.2 Chloroquinoline-chalcones 
 The chalcone structure provides an ideal drug scaffold, thereby providing opportunities 
for structural improvements to increase the lipophilicity of the compounds, and facilitate 
the accumulation of the compounds in the food vacuole, via the substitution of 
nitrogen-containing groups at R4.  
 In addition, the chloroquinoline moiety can be modified to improve β-haematin 
inhibitory activity, whilst also circumventing drug resistance which is proposed to be 
conferred by the aminoalkyl side chain of chloroquine (Vangapandu et al., 2007; van 
Schalkwyk and Egan, 2006).  
 Further experimentation into the antimalarial mechanisms of action attributed to 
chalcones, such as an examination of their direct effect on the falcipain-2 enzyme, ability 
to form complexes with GSH, and inhibitory activities on parasite-induced new 
permeation pathways and plasmodial CDKs would be worthwhile examining, in order to 
provide structure-activity information for the further development of derivatives.  
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6.2.3 Nucleoside phosphonates, phosphonic acids and purine/pyrimidine derivatives 
 Derivatives of nucleosides and nucleobases to increase their specificity for parasitic 
enzymes of DNA synthesis would also be worthwhile investigating; such as, a series of 
acyclic nucleoside phosphonates, with a hypoxanthine or a guanine base and a 3’ 
hydroxyl moiety. However, these compounds would need to be delivered in the form of 
a pro-drug to facilitate their entry into the parasite.  
 Similarly, an orotic acid or orotidine derivative which may act to inhibit de novo 
pyrimidine synthesis or the conversion of orotidine monophosphate to uridine 
monophosphate would also be worth investigating.  
 Additionally, it would be interesting to examine other pyrimidine derivatives based on 
the structure and inhibitory activity of pyrimethamine against dihydrofolate reductase. 
6.2.4 Flow cytometry 
 The development of a double staining technique, wherein an RNA-specific fluorochrome 
is used together with dihydrethidium so that both DNA and RNA could be quantified 
would be beneficial, as it may provide a more accurate assessment of parasite viability 
and life cycle progression. However, fluorochromes are also costly, and dihydroethidium 
requires three washing steps, making the methodology time consuming and not 
necessarily suitable for IC50 value determination.  
 Additionally, any compound that could alter the intracellular pH, thereby affecting the 
binding of the probe to parasitic DNA, or result in fluorescent interference due to a 
similar emission spectra to that of the fluorochrome, or cause clumping of red blood 
cells would skew the results obtained using this methodology. In this respect, duplicate 
samples for microscopic analysis would need to be prepared to validate the results, 
negating this method as a high-throughput screening method. 
In the case of the metronidazole-thiosemicarbazone analogues the effects of the 
compounds on the parasitic targets examined were clear. The mechanisms of action of the 
chloroquinoline-chalcones and nucleoside phosphonates, phosphonic acids and 
purine/pyrimidine derivatives were not as evident. However, their effects on parasite 
morphology, parasitic life cycle progression and pharmacological interactions with standard 
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antimalarial drugs provided some insight into their antimalarial mechanisms of action. The 
results of the assays used in this study provided valuable structure-activity relationships for 
the rational drug design of second generations of the compounds. Priorority should be given 
to the further development of the metronidazole-thiosemicarbazone analogues since they 
were the most active class of compounds against P. falciparum, had additive 
pharmacological interactions when combined with standard antimalarials, and that phase I 
clinical trials of the thiosemicarbazone-derivative Triapine® showed that the drug was 
generally well-tolerated by patients (Giles et al., 2003).  
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Introduction: 
Ninety percent of malaria cases reported in sub-Saharan Africa are due to the Plasmodium 
falciparum parasite. For decades malaria chemotherapy has hinged on a limited range of 
drugs, with the parasite developing resistance to some. This has initiated an urgent search 
for novel compounds with unique mechanisms of action against plasmodia species. 
Metronidazole is commonly used against bacterial and protozoal infections by causing DNA 
damage through free-radical damage. Thiosemicarbazones are a small class of compounds 
which have shown to have profound antiviral, antifungal, antitumour and antimalarial 
effects. 
Aims: 
To examine the effects of a series of metronidazole-thiosemicarbazone analogues on the in 
vitro growth of P. falciparum, elucidate a possible mechanism of action, as well as assess the 
toxicity of these compounds. 
Methods: 
Metronidazole thiosemicarbazone analogues were synthesized wherein the thioamide 
moiety was substituted by different cyclic and aromatic amines. The P. falciparum 
chloroquine-sensitive strain (3D7) was maintained continuously in culture. For assessment 
of antimalarial activity, the tritiated hypoxanthine incorporation assay was employed. From 
the data generated the concentration required to inhibit parasite growth by 50% (IC50 value) 
was obtained. To determine a possible mechanism of action, the effects of the compounds 
on β-haematin formation was examined. To assess the toxicity of these compounds a red 
blood cell toxicity assay was performed. 
Results: 
The results obtained showed that all but one of the compounds inhibited parasite growth, 
with IC50 values below 10μM. Results from the β-haematin assay indicated that all but two 
of the compounds were able to completely inhibit β-haematin formation by an average of 
95% at a mole:mole ratio of less than one for drug:haemin. Some of the compounds 
inhibited β-haematin formation as effectively as quinine. Red blood cell toxicity results 
indicated negligible amounts of red blood cell lysis and were comparable to those of quinine 
and metronidazole alone. 
Overall, (1E)-1-(4-((E)-2-(1-(2-hydroxyethyl)-5-nitro-1H-imidazol-2-yl)vinyl)benzylidene)-4- 
cyclooctylthiosemicarbazide (Y1) and (1E)-4-(2-chlorobenzyl)-1-(4-((E)-2-(1-(2-hydroxyethyl)- 
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5-nitro-1H-imidazol-2-yl)vinyl)benzylidene)thiosemicarbazide (Y3) were the most active, 
with IC50 values of 2.99 ± 0.10μM and 2.89 ± 0.09μM respectively, as well as possessing the 
best safety profile. 
Conclusion: 
The above results indicate that these compounds show promising antimalarial activity, but 
require further attention to determine their combined interaction when used with classic 
antimalarials. 
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Appendix A2: (Poster presentation: WorldPharma 2010, the 16th World Congress of Basic 
and Clinical Pharmacology, Copenhagen, 2010) 
The Antimalarial Properties of Metronidazole Thiosemicarbazone 
Analogues 
Emma J. Moseley1, Robyn L. van Zyl1*, Mohammad Abid2, Ivan Havlik1, Amir Azam2 
1Pharmacology Division, Department of Pharmacy and Pharmacology, University of the 
Witwatersrand, Johannesburg, South Africa. 
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Ninety percent of malaria cases reported in sub-Saharan Africa are due to the Plasmodium 
falciparum parasite. For decades malaria chemotherapy has hinged on a limited range of 
drugs, with the parasite developing resistance to some. This has initiated a search for novel 
compounds with unique mechanisms of action against plasmodia species. 
Thiosemicarbazones are a small class of compounds with reported antifungal and 
antimalarial effects; while metronidazole is a commonly used broad spectrum antiprotozoal 
agent. The properties of these two groups of compounds were combined by synthesizing 
metronidazole thiosemicarbazone analogues, wherein the thioamide moiety of the 
thiosemicarbazone backbone was substituted by different cyclic and aromatic amines. The 
sensitivity of the chloroquine-sensitive P. falciparum strain (3D7) to the compounds was 
assessed using the tritiated hypoxanthine incorporation assay. The compounds were 
evaluated for their ability to inhibit β-haematin formation as well as their haemolytic 
properties. All but one of the compounds inhibited parasite growth, with IC50 values below 
10µM. Results from the β-haematin assay indicated that, with the exception of two 
compounds, all compounds inhibited β-haematin formation as effectively as quinine. Red 
blood cell toxicity results indicated negligible amounts of haemolysis and were comparable 
to those of quinine and metronidazole. Overall, (1E)-1-(4-((E)-2-(1-(2-hydroxyethyl)-5-nitro-
1Himidazol-2-yl)vinyl)benzylidene)-4-cyclooctylthiosemicarbazide (Y1) and (1E)-4-(2-
chlorobenzyl)-1-(4-((E)-2-(1-(2-hydroxyethyl)-5-nitro-1H-imidazol-2yl)vinyl)benzylidene)-
thiosemi-carbazide (Y3) were the mostactive, with IC50 values of 2.99±0.10µM and 
2.89±0.09µM respectively, as well as possessing the best safety profile. When combined 
with quinine Y3 exhibited an additive relationship. These results indicate that metronidazole 
thiosemicarbazones show promising antimalarial activity and necessatate further 
investigation. 
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The Antimalarial Properties of Metronidazole Thiosemicarbazone 
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Introduction:  
Ninety percent of malaria cases reported in sub-Saharan Africa are attributed to the 
Plasmodium falciparum parasite. For decades malaria chemotherapy has hinged on a 
limited range of drugs, with the parasite developing resistance to some. This has 
initiated an urgent search for novel compounds with unique mechanisms of action 
against plasmodia species. Thiosemicarbazones are a small class of compounds with 
reported antifungal and antimalarial effects; whilst metronidazole is a commonly used 
broad spectrum antiprotozoal agent. The properties of these two groups were combined 
by synthesizing metronidazole-thiosemicarbazone analogues, wherein the thioamide 
moiety of the thiosemicarbazone backbone was substituted with different cyclic and 
aromatic amines. These compounds were then tested against the in vitro growth of P. 
falciparum. Possible mechanisms of action and drug interactions were examined as well 
as the toxicity of these compounds. 
Methods:  
The P. falciparum chloroquine-sensitive strain (3D7) was maintained continuously in 
culture. For assessment of antimalarial activity and possible drug interactions the 
tritiated hypoxanthine incorporation assay was employed. From the data generated the 
concentration required to inhibit parasite growth by 50% (IC50 value) was obtained. To 
determine a possible mechanism of action, the effects of the compounds on β-haematin 
formation was examined. To assess the toxicity of these compounds a red blood cell lysis 
assay was performed. 
Results: 
The results obtained showed that all but one of the compounds inhibited parasite 
growth with IC50 values below 10μM. Results from the β-haematin assay indicated that, 
with the exception of two compounds, all compounds inhibited β-haematin formation as 
effectively as quinine. Red blood cell toxicity results indicated negligible amounts of red 
blood cell lysis and were comparable to those of quinine and metronidazole alone. 
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Overall, (1E)-1-(4-((E)-2-(1-(2-hydroxyethyl)-5-nitro-1H-imidazol-2-yl)vinyl)benzylidene)-
4-cyclooctylthiosemicarbazide (Y1) and (1E)-4-(2-chlorobenzyl)-1-(4-((E)-2-(1-(2-
hydroxyethyl)-5-nitro-1H-imidazol-2-yl)vinyl)benzylidene)thiosemicarbazide (Y3) were 
the most active, with IC50 values of 2.99 ± 0.10μM and 2.89 ± 0.09μM respectively, as 
well as possessing the best safety profile. In combined studies utilizing quinine and 
dihydroartemisinin Y3 exhibited an additive relationship. 
Conclusion: 
The above results indicate that these compounds show promising antimalarial activity 
combined with a good safety profile and necessitate further investigation 
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The Antimalarial Properties of Metronidazole Thiosemicarbazone 
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2
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1
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2
 
1Pharmacology Division, Department of Pharmacy and Pharmacology, Faculty of Health 
Sciences, University of the Witwatersrand, Johannesburg, South Africa. 2Department 
of Chemistry, Faculty of Natural Sciences, Jamia Millia Islamia, Delhi, India. 
*Corresponding author: Robyn.vanZyl@wits.ac.za 
Ninety percent of malaria cases reported in sub-Saharan Africa are due to the 
Plasmodium falciparum parasite. For decades malaria chemotherapy has hinged on a 
limited range of drugs, with the parasite developing resistance to some. This has 
initiated an urgent search for novel compounds with unique mechanisms of action 
against plasmodia species. Thiosemicarbazones are a small class of compounds with 
reported antifungal and antimalarial effects; while metronidazole is a commonly used 
broad spectrum antiprotozoal agent. The properties of these two groups of compounds 
were combined by synthesizing metronidazole-thiosemicarbazone analogues, wherein 
the thioamide moiety of the thiosemicarbazone backbone was substituted by different 
cyclic and aromatic amines. The sensitivity of the chloroquine-sensitive P. falciparum 
strain (3D7) to the compounds was assessed using the tritiated hypoxanthine 
incorporation assay. The compounds were evaluated for their ability to inhibit β-
haematin formation, as well as their haemolytic properties. All but one of the 
compounds inhibited parasite growth, with IC50 values below 10µM. Results from the β-
haematin assay indicated that, with the exception of two compounds, all compounds 
inhibited β-haematin formation as effectively as quinine. Red blood cell toxicity results 
indicated negligible amounts of haemolysis and were comparable to those of quinine 
and metronidazole. Overall, (1E)-1-(4-((E)-2-(1-(2-hydroxyethyl)-5-nitro-1H-imidazol-2-
yl)vinyl)benzylidene)-4-cyclooctylthiosemicarbazide (Y1) and (1E)-4-(2-chlorobenzyl)-1-
(4-((E)-2-(1-(2-hydroxyethyl)-5-nitro-1H-imidazol-2-yl)vinyl)benzylidene)thiosemi-
carbazide (Y3) were the most active, with IC50 values of 2.99 ± 0.10μM and   2.89 ± 
0.09μM respectively, as well as possessing the best safety profile. In combined studies 
utilizing quinine and dihydroartemisinin Y3 exhibited an additive relationship.These 
results indicate that metronidazole thiosemicarbazone show promising antimalarial 
activity and necessatate further investigation. 
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Appendix A5: (Publication: Antiprotozoal activity of chloroquinoline based chalcones) 
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APPENDIX B: BIOSAFETY AND ETHICAL CLEARANCES 
APPENDIX B1: 
PARASITE BIOSAFETY CLEARANCE 
 
 
***Ethical clearance was renewed in 2011 for a further five years. 
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APPENDIX B2: 
ETHICAL CLEARANCE FOR THE DRAWING OF BLOOD FROM VOLUNTEERS 
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APPENDIX C: SUM OF THE FRACTIONAL INHIBITORY CONCENTRATIONS (FIC50) FOR 
COMBINATION STUDIES WITH COMPOUNDS Y-3 AND Y-7 
 
Table C1: Sum of FIC50 values for compound Y-3 in combination with quinine. 
Experiment 1. 
 
 
Table C2: Sum of FIC50 values for compound Y-3 in combination with quinine. 
Experiment 2. 
 
Combination ratio’s IC50 values FIC50 values ΣFIC50 
values 
Y-3 Quinine Y-3 s.d. Quinine s.d. Y-3 Quinine  
10 0 3.14 0.26 0 - 1 0  
9 1 3.65 0.16 0.02 - 1.16 0.13 1.29 
8 2 3.16 0.04 0.04 - 1.01 0.26 1.27 
7 3 2.12 0.19 0.046 - 0.68 0.30 0.98 
6 4 1.83 0.10 0.06 - 0.58 0.41 0.99 
5 5 1.25 0.09 0.062 - 0.40 0.41 0.81 
4 6 1.39 0.20 0.10 - 0.44 0.69 1.13 
3 7 0.98 0.13 0.11 - 0.31 0.76 1.07 
2 8 0.55 0.19 0.11 - 0.18 0.73 0.91 
1 9 0.30 0.10 0.13 - 0.095 0.89 0.99 
0 10 0 - 0.15 0.033 0 1  
   SUM 9.44 AVE 1.05 s.d. 0.16 
Combination ratio’s IC50 values FIC50 values ΣFIC50 
values 
Y-3 Quinine Y-3 s.d. Quinine s.d. Y-3 Quinine  
10 0 1.33 0.10 0 - 1 0  
9 1 1.33 0.03 0.0074 - 1 0.13 1.13 
8 2 1.17 0.017 0.015 - 0.88 0.26 1.14 
7 3 0.88 0.02 0.019 - 0.67 0.34 1.01 
6 4 0.89 0.04 0.030 - 0.67 0.53 1.2 
5 5 0.69 0.03 0.034 - 0.52 0.61 1.13 
4 6 0.54 0.07 0.041 - 0.41 0.72 1.13 
3 7 0.39 0.02 0.046 - 0.29 0.81 1.1 
2 8 0.28 0.02 0.055 - 0.21 0.98 1.19 
1 9 0.14 0.01 0.062 - 0.10 1.10 1.2 
0 10 0 - 0.056 0.0046 0 1  
   SUM 10.23 AVE 1.14 s.d. 0.06 
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Table C3: Sum of FIC50 values for compound Y-3 in combination with quinine. 
Experiment 3. 
 
Table C4: Sum of FIC50 values for compound Y-7 in combination with quinine. 
Experiment 1. 
 
 
 
 
 
Combination 
ratio’s 
IC50 values FIC50 values ΣFIC50 
values 
Y-3 Quinine Y-3 s.d. Quinine s.d. Y-3 Quinine  
10 0 0.98 0.041 0 - 1 0  
9 1 0.83 0.013 0.0046 - 0.85 0.15 1 
8 2 0.81 0.015 0.010 - 0.82 0.33 1.15 
7 3 0.69 0.012 0.015 - 0.70 0.48 1.19 
6 4 0.62 0.016 0.021 - 0.64 0.68 1.32 
5 5 0.46 0.011 0.023 - 0.47 0.76 1.23 
4 6 0.37 0.035 0.028 - 0.37 0.90 1.27 
3 7 0.26 0.019 0.030 - 0.26 0.99 1.25 
2 8 0.17 0.013 0.033 - 0.17 1.08 1.25 
1 9 0.084 0.0074 0.038 - 0.09 1.23 1.31 
0 10 0 - 0.031 0.0018 0.00 1.00  
   SUM 10.98 AVE 1.22 s.d. 0.098 
Combination 
ratio’s 
IC50 values FIC50 values ΣFIC50 
values 
Y-7 Quinine Y-7 s.d. Quinine s.d. Y-7 Quinine  
10 0 4.44 0.46 0 - 1 0  
9 1 3.42 0.101 0.011 - 0.77 0.26 1.03 
8 2 2.69 0.057 0.017 - 0.61 0.41 1.02 
7 3 2.54 0.15 0.027 - 0.57 0.67 1.24 
6 4 1.99 0.075 0.033 - 0.45 0.82 1.27 
5 5 1.61 0.11 0.040 - 0.36 0.99 1.36 
4 6 0.92 0.14 0.034 - 0.21 0.85 1.05 
3 7 0.62 0.018 0.036 - 0.14 0.89 1.03 
2 8 0.45 0.031 0.045 - 0.10 1.11 1.22 
1 9 0.21 0.011 0.048 - 0.05 1.18 1.22 
0 10 0 - 0.0406 0.0027 0 1  
   SUM 10.44 AVE 1.16 s.d. 0.13 
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Table C5: Sum of FIC50 values for compound Y-7 in combination with quinine. 
Experiment 2. 
 
Table C6: Sum of FIC50 values for compound Y-7 in combination with quinine. 
Experiment 3. 
 
 
 
 
 
Combination 
ratio’s 
IC50 values FIC50 values ΣFIC50 
values 
Y-7 Quinine Y-7 s.d. Quinine s.d. Y-7 Quinine  
10 0 3.54 0.12 0 - 1 0  
9 1 3.33 0.095 0.0093 - 0.94 0.33 1.27 
8 2 2.90 0.14 0.018 - 0.82 0.64 1.47 
7 3 1.85 0.083 0.020 - 0.52 0.70 1.22 
6 4 1.45 0.065 0.024 - 0.41 0.86 1.27 
5 5 1.15 0.035 0.029 - 0.32 1.02 1.34 
4 6 0.83 0.051 0.031 - 0.24 1.11 1.35 
3 7 0.61 0.031 0.036 - 0.17 1.27 1.44 
2 8 0.39 0.021 0.039 - 0.11 1.40 1.51 
1 9 0.18 0.015 0.041 - 0.05 1.44 1.49 
0 10 0 - 0.028 0.00072 0 1  
   SUM 12.36 AVE 1.37 s.d. 0.11 
Combination 
ratio’s 
IC50 values FIC50 values ΣFIC50 
values 
Y-7 Quinine Y-7 s.d. Quinine s.d. Y-7 Quinine  
10 0 2.70 0.049 0 - 1 0  
9 1 2.33 0.50 0.0065 - 0.86 0.16 1.02 
8 2 2.28 0.031 0.014 - 0.84 0.34 1.19 
7 3 1.51 0.073 0.016 - 0.56 0.39 0.95 
6 4 1.29 0.057 0.022 - 0.48 0.52 1.00 
5 5 0.98 0.044 0.024 - 0.36 0.59 0.95 
4 6 0.88 0.074 0.033 - 0.32 0.80 1.12 
3 7 0.72 0.024 0.042 - 0.27 1.02 1.28 
2 8 0.43 0.02 0.043 - 0.16 1.05 1.21 
1 9 0.22 0.017 0.049 - 0.08 1.18 1.26 
0 10 0 - 0.041 0.0013 0 1  
   SUM 9.97 AVE 1.11 s.d. 0.13 
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Table C7: Sum of FIC50 values for compound Y-3 in combination with dihydroartemisinin 
(DA). Experiment 1. 
 
Table C8: Sum of FIC50 values for compound Y-3 in combination with dihydroartemisinin 
(DA). Experiment 2. 
 
 
 
 
 
Combination 
ratio’s 
IC50 values FIC50 values ΣFIC50 
values 
Y-3 DA Y-3 s.d. DA s.d. Y-3 DA  
10 0 1.62 0.05 0 - 1 0  
9 1 1.75 0.084 0.00013 - 1.08 0.19 1.27 
8 2 1.55 0.068 0.00026 - 0.96 0.37 1.33 
7 3 1.11 0.077 0.00032 - 0.69 0.46 1.14 
6 4 0.94 0.034 0.00042 - 0.58 0.61 1.19 
5 5 0.77 0.045 0.00051 - 0.48 0.74 1.22 
4 6 0.66 0.067 0.00066 - 0.41 0.96 1.36 
3 7 0.40 0.0073 0.00062 - 0.25 0.90 1.15 
2 8 0.24 0.012 0.00064 - 0.15 0.93 1.08 
1 9 0.12 0.011 0.00072 - 0.07 1.04 1.12 
0 10 0 - 0.00069 0.000033 0 1  
   SUM 10.86 AVE 1.21 s.d. 0.098 
Combination 
ratio’s 
IC50 values FIC50 values ΣFIC50 
values 
Y-3 DA Y-3 s.d. DA s.d. Y-3 DA  
10 0 3.51 0.1 0 - 1 0  
9 1 3.88 0.24 0.00029 - 1.11 0.18 1.29 
8 2 3.48 0.15 0.00058 - 0.99 0.37 1.36 
7 3 3.34 0.19 0.00095 - 0.95 0.61 1.56 
6 4 2.56 0.029 0.0011 - 0.73 0.73 1.46 
5 5 2.16 0.037 0.0014 - 0.62 0.92 1.54 
4 6 1.38 0.037 0.0014 - 0.39 0.88 1.28 
3 7 0.98 0.0046 0.0015 - 0.28 0.98 1.26 
2 8 0.67 0.019 0.0018 - 0.19 1.15 1.34 
1 9 0.29 0.0049 0.0017 - 0.08 1.12 1.20 
0 10 0 - 0.00156 0.021 0 1  
   SUM 12.28 AVE 1.36 s.d. 0.13 
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Table C9: Sum of FIC50 values for compound Y-3 in combination with dihydroartemisinin 
(DA). Experiment 3. 
 
Table C10: Sum of FIC50 values for compound Y-7 in combination with 
dihydroartemisinin (DA). Experiment 1. 
 
 
 
 
Combination 
ratio’s 
IC50 values FIC50 values ΣFIC50 
values 
Y-3 DA Y-3 s.d. DA s.d. Y-3 DA  
10 0 1.69 0.11 0 - 1 0  
9 1 1.96 0.055 0.00022 - 1.16 0.32 1.48 
8 2 1.34 0.06 0.00034 - 0.79 0.49 1.28 
7 3 1.07 0.042 0.00046 - 0.63 0.67 1.30 
6 4 0.86 0.028 0.00057 - 0.51 0.83 1.34 
5 5 0.59 0.034 0.00059 - 0.35 0.86 1.20 
4 6 0.47 0.0069 0.00071 - 0.28 1.03 1.31 
3 7 0.33 0.0052 0.00077 - 0.20 1.12 1.31 
2 8 0.20 0.0042 0.00079 - 0.12 1.14 1.26 
1 9 0.087 0.001 0.00078 - 0.05 1.13 1.19 
0 10 0 - 0.00069 0.000027 0 1  
   SUM 11.67 AVE 1.30 s.d. 0.084 
Combination 
ratio’s 
IC50 values FIC50 values ΣFIC50 
values 
Y-7 DA Y-7 s.d. DA s.d. Y-7 DA  
10 0 5.98 0.26 0 - 1 0  
9 1 8.68 0.48 0.00022 - 1.45 0.14 1.59 
8 2 5.85 0.18 0.00044 - 0.98 0.28 1.26 
7 3 5.35 0.17 0.00072 - 0.89 0.46 1.35 
6 4 3.68 0.14 0.00085 - 0.62 0.55 1.16 
5 5 2.5 0.052 0.0011 - 0.42 0.69 1.11 
4 6 2.15 0.074 0.0010 - 0.36 0.66 1.02 
3 7 1.53 0.027 0.0011 - 0.26 0.73 0.99 
2 8 0.96 0.004 0.0013 - 0.16 0.86 1.02 
1 9 0.4 0.005 0.0013 - 0.07 0.84 0.90 
0 10 0 - 0.00156 0.000049 0 1  
   SUM 10.41 AVE 1.16 s.d. 0.21 
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Table C11: Sum of FIC50 values for compound Y-7 in combination with 
dihydroartemisinin (DA). Experiment 2. 
 
Table C12: Sum of FIC50 values for compound Y-7 in combination with 
dihydroartemisinin (DA). Experiment 3. 
 
 
 
Combination 
ratio’s 
IC50 values FIC50 values ΣFIC50 
values 
Y-7 DA Y-7 s.d. DA s.d. Y-7 DA  
10 0 6.77 0.15 0 - 1 0  
9 1 5.93 0.091 0.00033 - 0.88 0.39 1.26 
8 2 4.04 0.018 0.00051 - 0.60 0.60 1.19 
7 3 2.96 0.049 0.00063 - 0.44 0.75 1.19 
6 4 2.1 0.066 0.0007 - 0.31 0.83 1.14 
5 5 1.47 0.059 0.00074 - 0.22 0.87 1.09 
4 6 0.94 0.052 0.00070 - 0.14 0.83 0.97 
3 7 0.61 0.0089 0.00071 - 0.09 0.84 0.93 
2 8 0.35 0.012 0.00069 - 0.05 0.82 0.87 
1 9 0.20 0.007 0.00088 - 0.03 1.04 1.07 
0 10 0 - 0.00085 0.000031 0 1  
   SUM 9.71 AVE 1.08 s.d. 0.13 
Combination 
ratio’s 
IC50 values FIC50 values ΣFIC50 
values 
Y-7 DA Y-7 s.d. DA s.d. Y-7 DA  
10 0 3.7 0.17 0 
 
- 1 0  
9 1 3.29 0.097 0.00018 - 0.89 0.30 1.19 
8 2 2.54 0.16 0.00032 - 0.69 0.52 1.21 
7 3 1.59 0.074 0.00034 - 0.43 0.56 0.99 
6 4 1.62 0.081 0.00054 - 0.44 0.89 1.32 
5 5 1.11 0.043 0.00056 - 0.30 0.91 1.21 
4 6 0.79 0.031 0.00059 - 0.21 0.97 1.19 
3 7 0.58 0.022 0.00068 - 0.16 1.11 1.27 
2 8 0.37 0.031 0.00074 - 0.10 1.21 1.31 
1 9 0.14 0.009 0.00063 - 0.04 1.03 1.07 
0 10 0 - 0.00061 0.000012 0 1  
   SUM 10.75 AVE 1.19 s.d. 0.11 
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APPENDIX D: SUM OF THE FRACTIONAL INHIBITORY CONCENTRATIONS (FIC50) FOR 
COMBINATION STUDIES WITH COMPOUND F-13 AND QUININE 
-------------------------------------------------------------------------------------------------------------------------- 
Table D1: Sum of FIC50 values for compound F-13 in combination with quinine. 
Experiment 1. 
 
Table D2: Sum of FIC50 values for compound F-13 in combination with quinine. 
Experiment 2. 
 
Combination 
ratio’s 
IC50 values FIC50 values ΣFIC50 
values 
F-13 Quinine F-13 s.d. Quinine s.d. F-13 Quinine  
10 0 37.12 1.71 0 - 1 0  
9 1 42.78 2.48 0.014 - 1.15 0.22 1.37 
8 2 35.03 1.2 0.027 - 0.94 0.40 1.34 
7 3 27.55 1.72 0.036 - 0.74 0.53 1.28 
6 4 21.7 1.03 0.044 - 0.58 0.65 1.24 
5 5 13.23 1.55 0.040 - 0.36 0.60 0.96 
4 6 12.78 1.43 0.058 - 0.34 0.87 1.21 
3 7 10.21 1.49 0.072 -- 0.28 1.08 1.35 
2 8 6.49 1.17 0.079 - 0.17 1.18 1.35 
1 9 3.49 0.73 0.095 - 0.09 1.42 1.52 
0 10 0 - 0.067 0.011 0 1  
   SUM 11.61 AVE 1.29 s.d. 0.15 
Combination 
ratio’s 
IC50 values FIC50 values ΣFIC50 
values 
F-13 Quinine F-13 s.d. Quinine s.d. F-13 Quinine  
10 0 33.91 4.38 0 - 1 0  
9 1        
8 2 43.89 3.83 0.033 - 1.29 0.50 1.80 
7 3 34.73 1.66 0.045 - 1.02 0.68 1.71 
6 4 26.33 0.93 0.053 - 0.78 0.80 1.58 
5 5 18.39 1.48 0.056 - 0.54 0.84 1.38 
4 6 12.98 2.41 0.059 - 0.38 0.89 1.27 
3 7 10.53 2.62 0.074 - 0.31 1.13 1.44 
2 8 5.64 1.64 0.068 - 0.17 1.03 1.20 
1 9 2.77 0.72 0.076 - 0.08 1.14 1.22 
0 10 0 - 0.066 0.013 0 1  
   SUM 11.60 AVE 1.45 s.d. 0.22 
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Table D3: Sum of FIC50 values for compound F-13 in combination with quinine. 
Experiment 3. 
 
Table D4: Sum of FIC50 values for compound F-13 in combination with quinine. 
Experiment 4. 
 
 
 
 
 
Combination 
ratio’s 
IC50 values FIC50 values ΣFIC50 
values 
F-13 Quinine F-13 s.d. Quinine s.d. F-13 Quinine  
10 0 67.87 2.53 0 - 1 0  
9 1 82.20 2.55 0.028 - 1.21 0.46 1.67 
8 2 65.77 1.93 0.050 - 0.97 0.83 1.80 
7 3 43.58 2.71 0.057 - 0.64 0.94 1.59 
6 4 32.75 2.85 0.066 - 0.48 1.10 1.59 
5 5 18.74 2.37 0.057 - 0.28 0.95 1.22 
4 6 7.60 3.90 0.035 - 0.11 0.58 0.69 
3 7 4.76 1.53 0.034 - 0.07 0.56 0.63 
2 8 3.92 1.38 0.048 - 0.06 0.79 0.85 
1 9 1.97 0.59 0.054 - 0.03 0.90 0.92 
0 10 0 - 0.060 0.0063 0 1  
   SUM 10.96 AVE 1.22 s.d. 0.46 
Combination 
ratio’s 
IC50 values FIC50 values ΣFIC50 
values 
F-13 Quinine F-13 s.d. Quinine s.d. F-13 Quinine  
10 0 46.85 15.87 0 - 1 0  
9 1 36.57 1.82 0.012 - 0.78 0.20 0.98 
8 2 40.31 1.49 0.031 - 0.86 0.51 1.37 
7 3 25.43 1.44 0.033 - 0.54 0.55 1.09 
6 4 20.23 1.05 0.041 - 0.43 0.68 1.11 
5 5 15.65 0.88 0.047 - 0.33 0.79 1.12 
4 6 19.64 2.06 0.089 - 0.42 1.48 1.90 
3 7 15.40 1.93 0.11 - 0.33 1.80 2.13 
2 8 8 1.03 0.097 - 0.17 1.61 1.78 
1 9 2.82 0.54 0.077 - 0.06 1.27 1.33 
0 10 0 - 0.060 0.0088 0 1  
   SUM 12.80 AVE 1.42 s.d. 0.41 
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APPENDIX E: SUM OF THE FRACTIONAL INHIBITORY CONCENTRATIONS (FIC50) FOR 
COMBINATION STUDIES WITH COMPOUNDS DR-4463 AND D1293-S 
 
Table E1: Sum of FIC50 values for compound DR-4463 in combination with quinine. 
Experiment 1. 
 
Table E2: Sum of FIC50 values for compound DR-4463 in combination with quinine. 
Experiment 2. 
 
Combination ratio’s IC50 values FIC50 values ΣFIC50 
values 
DR-4463 Quinine DR-4463 s.d. Quinin
e 
s.d. DR-4463 Quinine  
10 0 33.76 1.45 0 - 1 0  
9 1 25.92 0.18 0.014 - 0.77 0.26 1.03 
8 2 19.18 0.38 0.024 - 0.57 0.43 1.00 
7 3 13.60 0.44 0.029 - 0.40 0.52 0.93 
6 4 11.38 0.37 0.038 - 0.34 0.68 1.02 
5 5 8.33 0.40 0.042 - 0.25 0.75 0.99 
4 6 5.68 0.24 0.043 - 0.17 0.77 0.93 
3 7 3.76 0.19 0.044 - 0.11 0.79 0.90 
2 8 2.57 0.18 0.051 - 0.08 0.92 1.00 
1 9 1.27 0.12 0.057 - 0.04 1.03 1.06 
0 10 0 - 0.056 0.0053 0 1  
   SUM 8.86 AVE 0.98 s.d. 0.054 
Combination 
ratio’s 
IC50 values FIC50 values ΣFIC50 
values 
DR-4463 Quinine DR-4463 s.d. Quinine s.d. DR-4463 Quinine  
10 0 34.67 2.32 0 - 1 0  
9 1 28.59 1.14 0.016 - 0.82 0.10 0.93 
8 2 22.08 0.74 0.028 - 0.64 0.18 0.82 
7 3 14.15 0.79 0.030 - 0.41 0.20 0.61 
6 4 13.27 0.65 0.044 - 0.38 0.29 0.67 
5 5 10.63 0.36 0.053 - 0.31 0.35 0.65 
4 6 9.36 0.70 0.070 - 0.27 0.46 0.73 
3 7 6.66 0.24 0.078 - 0.19 0.51 0.70 
2 8 5.30 0.27 0.11 - 0.15 0.69 0.85 
1 9 2.87 0.25 0.13 - 0.08 0.85 0.93 
0 10 0 - 0.15 0.014 0 1  
   SUM 6.88 AVE 0.76 s.d. 0.12 
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Table E3: Sum of FIC50 values for compound DR-4463 in combination with quinine. 
Experiment 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Combination ratio’s IC50 values FIC50 values ΣFIC50 
values 
DR-4463 Quinine DR-4463 s.d. Quinine s.d. DR-4463 Quinine  
10 0 33.04 2.11 0 - 1 0  
9 1 25.57 0.8 0.014 - 0.77 0.15 0.93 
8 2 20.10 0.29 0.025 - 0.61 0.27 0.88 
7 3 15.63 0.92 0.033 - 0.47 0.36 0.83 
6 4 13.01 0.33 0.043 - 0.39 0.46 0.86 
5 5 10.61 0.41 0.053 - 0.32 0.57 0.89 
4 6 8.35 0.42 0.063 - 0.25 0.67 0.92 
3 7 6.15 0.16 0.072 - 0.19 0.77 0.96 
2 8 4.23 0.18 0.085 - 0.13 0.91 1.04 
1 9 2.27 0.16 0.10 - 0.07 1.10 1.16 
0 10 0 - 0.093 0.0075 0 1  
   SUM 8.46 AVE 0.94 s.d. 0.10 
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Table E4: Sum of FIC50 values for compound DR-4463 in combination studies with 
dipyridamole. Experiment 1. 
 
Table E5: Sum of FIC50 values for compound DR-4463 in combination studies with 
dipyridamole. Experiment 2. 
 
Concentration ratio’s FIC values ΣFIC  
DR-4463 Dipyridamole DR-4463 Dipyridamole DR-4463 Dipyridamole Values 
IC90 - 125 µM - 1 0  
IC50 - 20 µM - 1 0  
IC10 - 4 µM - 1 0  
IC90 IC90   1.07 0.51 1.58 
IC50 IC90   0.46 1.14 1.60 
IC10 IC90   0.22 0.97 1.19 
IC90 IC50   0.79 0.27 1.06 
IC50 IC50   1.70 2.96 4.66 
IC10 IC50   0.90 2.73 3.63 
IC90 IC10   0.85 0.13 0.98 
IC50 IC10   1.25 0.97 2.22 
IC10 IC10   0.42 0.56 0.98 
- IC90 - 130 µM 0 1  
- IC50 - 35 µM 0 1  
- IC10 - 7 µM 0 1  
 SUM 17.90 AVE 1.99 s.d. 1.31 
Concentration ratio’s FIC values ΣFIC 
values DR-4463 Dipyridamole DR-4463 Dipyridamole DR-4463 Dipyridamole V
IC90 - 125 µM - 1 0  
IC50 - 20 µM - 1 0  
IC10 - 4 µM - 1 0  
IC90 IC90   1.04 0.47 1.51 
IC50 IC90   0.40 1.12 1.52 
IC10 IC90   0.31 1.21 1.52 
IC90 IC50   1.73 0.39 2.12 
IC50 IC50   0.56 0.79 1.35 
IC10 IC50   0.64 1.26 1.90 
IC90 IC10   1.37 0.21 1.58 
IC50 IC10   0.84 0.79 1.63 
IC10 IC10   0.78 1.01 1.79 
- IC90 - 130 µM 0 1  
- IC50 - 35 µM 0 1  
- IC10 - 7 µM 0 1  
 SUM 14.92 AVE 1.66 s.d. 0.24 
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Table E6: Sum of FIC50 values for compound DR-4463 in combination studies with 
dipyridamole. Experiment 3. 
 
Table E7: Sum of FIC50 values for compound DR-4463 in combination with dipyridamole. 
Experiment 4. 
Concentration ratio’s FIC values ΣFIC 
values DR-4463 Dipyridamole DR-4463 Dipyridamole DR-4463 Dipyridamole V
IC90 - 125 µM - 1 0  
IC50 - 20 µM - 1 0  
IC10 - 4 µM - 1 0  
IC90 IC90   2.92 1.41 4.33 
IC50 IC90   0.27 1.42 1.69 
IC10 IC90   0.17 1.31 1.48 
IC90 IC50   3.35 0.46 3.81 
IC50 IC50   1.22 1.86 3.08 
IC10 IC50   1.10 2.43 3.53 
IC90 IC10   1.66 0.63 2.29 
IC50 IC10   1.01 0.09 1.10 
IC10 IC10   1.07 0.98 2.05 
- IC90 - 130 µM 0 1  
- IC50 - 35 µM 0 1  
- IC10 - 7 µM 0 1  
 SUM 23.36 AVE 2.60 s.d. 1.13 
Concentration ratio’s FIC values ΣFIC 
values DR-4463 Dipyridamole DR-4463 Dipyridamole DR-4463 Dipyridamole V
IC90 - 125 µM - 1 0  
IC50 - 20 µM - 1 0  
IC10 - 4 µM - 1 0  
IC90 IC90   1.95 0.49 2.44 
IC50 IC90   0.75 1.06 1.81 
IC10 IC90   0.37 1.05 1.42 
IC90 IC50   1.99 0.16 2.15 
IC50 IC50   0.90 0.40 1.30 
IC10 IC50   1.09 0.97 2.06 
IC90 IC10   1.55 0.11 1.66 
IC50 IC10   1.21 0.49 1.70 
IC10 IC10   1.13 0.90 2.03 
- IC90 - 130 µM 0 1  
- IC50 - 35 µM 0 1  
- IC10 - 7 µM 0 1  
 SUM 16.57 AVE 1.84 s.d. 0.36 
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Table E8: Sum of FIC50 values for compound D1293-S in combination studies with 
dipyridamole. Experiment 1. 
 
Table E9: Sum of FIC50 values for compound D1293-S in combination studies with 
dipyridamole. Experiment 2. 
Concentration ratio’s FIC values ΣFIC 
values D1293-S Dipyridamole D1293-S Dipyridamole D1293-S Dipyridamole V
IC90 - 135 µM - 1 0  
IC50 - 58 µM - 1 0  
IC10 - 13 µM - 1 0  
IC90 IC90   0.83 0.73 1.56 
IC50 IC90   0.41 1.07 1.48 
IC10 IC90   0.28 1.28 1.56 
IC90 IC50   0.73 0.46 1.19 
IC50 IC50   0.49 0.88 1.37 
IC10 IC50   0.42 1.37 1.79 
IC90 IC10   0.76 0.21 0.97 
IC50 IC10   0.74 0.60 1.34 
IC10 IC10   0.83 1.19 2.02 
- IC90 - 130 µM 0 1  
- IC50 - 35 µM 0 1  
- IC10 - 7 µM 0 1  
 SUM 13.28 AVE 1.48 s.d. 0.31 
Concentration ratio’s FIC values ΣFIC 
values D1293-S Dipyridamole D1293-S Dipyridamole D1293-S Dipyridamole V
IC90 - 135 µM - 1 0  
IC50 - 58 µM - 1 0  
IC10 - 13 µM - 1 0  
IC90 IC90   1.07 0.86 1.93 
IC50 IC90   0.65 1.16 1.81 
IC10 IC90   0.34 1.04 1.38 
IC90 IC50   1.15 0.47 1.62 
IC50 IC50   0.82 0.74 1.56 
IC10 IC50   0.75 1.15 1.9 
IC90 IC10   4.29 1.14 5.43 
IC50 IC10   1.01 0.60 1.61 
IC10 IC10   0.95 0.96 1.91 
- IC90 - 130 µM 0 1  
- IC50 - 35 µM 0 1  
- IC10 - 7 µM 0 1  
 SUM 19.15 AVE 2.13 s.d. 1.25 
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Table E11: Sum of FIC50 values for compound D1293-S in combination studies with 
dipyridamole. Experiment 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Concentration ratio’s FIC values ΣFIC  
D1293-S Dipyridamole D1293-S Dipyridamole D1293-
S 
Dipyridamole Values 
IC90 - 135 µM - 1 0  
IC50 - 58 µM - 1 0  
IC10 - 13 µM - 1 0  
IC90 IC90   1.33 0.92 2.25 
 
IC50 IC90   0.22 1.08 1.30 
IC10 IC90   0.14 1.21 1.35 
IC90 IC50   1.89 0.38 2.27 
IC50 IC50   1.07 1.52 2.59 
IC10 IC50   0.97 2.35 3.32 
IC90 IC10   1.20 0.10 1.30 
IC50 IC10   1.04 0.61 1.65 
IC10 IC10   0.92 0.92 1.84 
- IC90 - 130 µM 0 1  
- IC50 - 35 µM 0 1  
- IC10 - 7 µM 0 1  
 SUM 17.87 AVE 1.99 s.d. 0.69 
